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ABSTRACT  
Introduction 
Patients with HIV infection frequently encounter oral candidiasis, caused by Candida 
species. However, factors responsible for Candida colonisation and development of 
oral candidiasis in these patients are controversial. This study investigated the effect 
of social and clinical factors on oral Candida colonisation in HIV positive women. In 
addition, virulence of these organisms during clinical infection, the role of non-
albicans Candida and reinfections with C. albicans were investigated. 
Methods 
After ethical clearance, 197 HIV positive women were recruited at the Charlotte 
Maxeke Hospital, Johannesburg. Oral rinse samples were collected, and quantitative 
and qualitative analyses of Candida were performed. A detailed questionnaire was 
used to collect data on oral and personal hygiene and habits, HIV treatment and 
coinfections. CD4 count and HIV viral load were either determined or obtained from 
the clinical records. A logistic regression model was used to determine the risk factors 
for colonisation. Candida carriers were followed up for 6 months at 3 months 
intervals. Oral examinations were performed to detect the presence of clinical oral 
candidiasis, CD4 counts were noted and Candida was isolated and identified from the 
oral rinse samples at each visit. The production of proteinase and phospholipase by 
Candida isolates were measured using Bovine serum albumin agar and Egg Yolk 
media. The adherence ability of Candida species were also measured using buccal 
epithelial cells. Candida counts, virulence factors and CD4 counts were compared in 
patients with and without oral candidiasis using non parametric tests. Antifungal 
susceptibility was performed on all the C. albicans isolates using broth microdilution 
 
vi 
minimum inhibitory concentration system described by Clinical Laboratory Standards 
Institute. Isolates of C. albicans from 17 patients that attended regularly over a period 
of 6 months and carried C. albicans at all the visits were subjected to ABC typing and 
Multilocus sequence typing (MLST) technique. The Unweighted Pair Group Method 
with Arithmetic Mean dendrogram (UPGMA) using cluster analysis was generated to 
measure genotypic similarities between the C. albicans strains. 
Results 
Candida carriage rate was 59.4% with Candida albicans being the predominant 
species. The presence of tuberculosis, diabetes mellitus (p=0.06), oral prostheses 
(p=0.02), caries (p=0.02), low CD4 counts (p=0.02) and absence of antiretroviral 
treatment (p<0.01) significantly increased the colonization rate. In addition, Candida 
counts were significantly higher in patients with low CD4 counts (p<0.01).  
The virulence characteristics of C. albicans such as adherence to buccal epithelial 
cells, proteinase and phospholipase fluctuated over time but it was not significantly 
correlated with the CD4 count. Although the virulence factors were not significantly 
different in patients with and without oral candidiasis, the Candida counts were 
higher in symptomatic patients (p<0.01). When isolates of C. albicans and non-
albicans Candida were compared, C. albicans produced more proteinase and 
phospholipase compared to non-albicans Candida isolated from patients with and 
without candidiasis (p<0.01). However, non-albicans Candida isolated from 
symptomatic women produced significantly high amount of phospholipase (p=0.02) 
than the controls. Nevertheless, resistance to antifungal drugs was low in C. albicans 
isolates (0.8 to 1.7%).  
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Although ABC genotyping showed that the same strains were carried by the majority 
of patients (94.1%), the more discriminatory MLST technique showed evidence of 
recolonisation with new strains of C. albicans (64.7 %) that produced significantly 
high amounts of proteinase. MLST also showed that microevolution occurred in the 
original existing oral strains. In addition, 28 previously undocumented strains of C. 
albicans that were unique to this region were identified thus expanding the MLST C. 
albicans database. 
Conclusions 
The findings of this study have important implications regarding C. albicans 
colonization and infection in HIV positive patients on ARV. In addition, HIV 
treatment maintains high CD4 counts that would reduce C. albicans counts and the 
likelihood of developing oral candidiasis. Furthermore, a decrease in Candida counts 
would collectively reduce hydrolytic enzymes that cause tissue damage.  However, 
recolonisation by new virulent strains of C. albicans could occur, thus increasing the 
chance of candidiasis. Therefore, ARV treatment, personal hygiene and regular oral 
hygiene measures using antifungal compounds could reduce the risk of developing 
oral candidiasis. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
Introduction 
In HIV infection, oral candidiasis is the most prevalent opportunistic fungal infection, 
affecting up to 90% of subjects.  When the infection is active it creates a significant 
amount of discomfort, inhibits eating, negatively impacts on quality of life and 
threatens the general wellbeing of HIV positive individuals (Samaranayake et al., 
2009).  
 
With the introduction of Highly Active Antiretroviral Therapy (HAART), the 
frequency of oral candidiasis and other opportunistic oral infections have been 
reduced in HIV positive patients (Ceballos-Salobrena et al., 2000). However, in Sub 
Saharan Africa, only a third of HIV positive individuals have access to HAART. 
Furthermore, oral candidiasis may occur in HIV patients on antiretroviral therapy 
because of poor compliance and sustenance of therapy (Thompson et al., 2010). 
Although oral candidiasis can be controlled with azole antifungal agents, resistance to 
therapy is a growing concern (Fekete-Forgacs et al., 2000; Posteraro et al., 2006) and 
morbidity from candidemia is still being reported (Gautam et al., 2010). In addition, 
the mechanism how HAART affects asymptomatic colonisation, clinical and social 
variables in the long term are not fully understood. 
 
Factors that determine colonisation and virulence of Candida species and the 
development of clinical infection have been studied in HIV positive patients 
(Calderone and Fonzi, 2001; Cannon and Chaffin, 2001). With HIV infection, yeasts 
were more virulent and had greater genotypic diversity than yeasts in HIV negative 
individuals (Ollert et al., 1995; Sweet et al., 1995). However, it is not clear weather 
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yeast counts or the virulence of these organisms that predisposes to oral candidiasis. 
Furthermore, it is not clear whether patients carry the same strain of Candida or are 
they constantly being reinfected with new strains of C. albicans. In addition, the role 
of non-albicans Candida in initiating oral candidiasis is not fully elucidated (Cannon 
and Chaffin, 2001; Cannon et al., 1995; Samaranayake et al., 2003).  
 
1 Literature Review  
1.1    Oral candidiasis and HIV 
Oral candidiasis is the clinical manifestation of infection of the oral mucosa by 
Candida species. The plural form for candidiasis is candidiases. Similar exchangeable 
terms are candidosis and candidoses for the singular and the plural form.  
 
1.1.1 Epidemiology 
In recent times, infection by pathogenic or opportunistic fungal pathogens, including 
Candida species has escalated. This may be attributed to widespread antibiotic use 
and immune suppression from disease or the result of therapy related to organ/ tissue 
transplantation (Williams et al., 2011). In colonised people, Candida species are 
opportunistic pathogens that may cause infection when there is local or systemic 
compromise in the immune status. Candida infection has thus been appropriately 
dubbed “the disease of the diseased” (Williams et al., 2011). The occurrence of 
candidiasis varies with the local or systemic condition. Candida associated stomatitis 
is present in about half of all denture wearers (Figueiral et al., 2007) and 7.2% to 52% 
of all cancer patients yet to resume therapy (Schelenz et al., 2011).  
Colonisation with Candida species in the oral cavity varies widely according to age, 
geographic location and other local factors such as denture wearing and the systemic 
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health of the individuals. In presumably healthy adults, prevalence may be as low as 
15.2% or as high as 75% (Odds, 1988; Yang et al., 2011). Colonisation rates are 
higher in individuals immunocompromised due to diabetes mellitus, cancer, cancer 
chemotherapy, organ transplantation and HIV infection (Schelenz et al., 2011). This 
pattern is supported by the work of Patel and colleagues who observed 81% 
prevalence in HIV positive individuals in contrast to 53% in their HIV negative 
counterparts (Patel et al., 2006). A similar study in South Africa among HIV positive 
children who were institutionalized and not receiving antiretroviral therapy had a 
prevalence of yeast colonisation from 37.5% to 53.3%. (Blignaut, 2007). 
 
In HIV infected patients, 5.8% to 93% will develop an acute Candida infection during 
the course of the illness (Egusa et al., 2008). Table 1.1 shows the global prevalence of 
oral candidiasis in HIV infection that varies from 6% to 98% depending on the region 
and HIV treatment. 
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Table 1.1 Prevalence of oral candidiasis in HIV infection from various studies 
worldwide [source: Egusa et al, 2008]. 
 
Oral candidiasis is also a fairly reliable predictor of progression to AIDS. Patients 
with infection have a 2.5 times greater risk of progression compared with those 
without infection (Sharma et al., 2006). While the introduction of HAART has 
dramatically reduced the prevalence of oral candidiasis, the effect on oral yeast 
colonisation is less obvious and may be influenced by other factors (Yang et al., 
2006). Furthermore, oral candidiasis is still prevalent in the era of HAART in 
communities without access to HAART, patients on HAART whose immune systems 
do not recover or become resistant to HIV drugs. In addition, some researchers have 
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observed a high frequency of oral candidiasis and persistent oral colonisation with 
Candida among HIV patients on HAART (Tami-Maury et al., 2011; Traeder et al., 
2008). As the HIV infection progresses to AIDS, the prevalence of colonisation tends 
to remain as high as 81% even with HAART (Thompson et al., 2010).  
 
Oral candidiasis may be clinically classified as primary or secondary. It is termed 
primary when the disease is found only in the oral and perioral structures and 
secondary when it manifests in the mouth as part of systemic disease. There are also 
lesions where oral candidiasis is present but C. albicans is not the sole aetiological 
agent. These are referred to as Candida associated lesions. They usually occur in 
patients with oral prostheses not necessarily associated with HIV infection. 
 
1.1.2 Primary candidiasis 
Three distinct forms of the primary candidiasis exist based on the peculiar clinical 
presentations (Marsh and Martin, 2009; Samaranayake et al., 2009). 
Pseudomembranous candidiasis presents as a characteristic white or cream coloured 
plaques on the oral mucosa. Most frequent areas affected are the tongue, labial and 
buccal mucous membrane and hard and soft palate. The plaques can usually be 
scraped off leaving a red and inflamed underlying mucosa. This is usually considered 
diagnostic. The scraped off plaques can be stained to reveal the fungal elements and 
desquamated cells, blastospores, bacteria, inflammatory cells and fibrin. The patients 
may have problems with swallowing and a burning sensation in the mouth. 
Pseudomembranous and erythematous candidiases are usually acute conditions and 
may often be present at the same time (Samaranayake et al., 2009) (Figure 1.1).  
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Erythematous candidiasis is the most common type found in HIV infection. However, 
this candidiasis may also be associated with broad-spectrum antibiotic or 
corticosteroid inhaler therapy, a condition called “antibiotic sore mouth”. It presents 
clinically with painful red patches on any part of the mucosa but chiefly on the 
dorsum of the tongue and palate. These lesions may be described as “kissing” when 
both sites are simultaneously affected. Erythematous candidiasis in HIV infection 
may go unnoticed because it may be asymptomatic. However, in typical antibiotic 
sore mouth, there is soreness and burning which may be associated with the loss of 
filiform papillae on the tongue (Samaranayake et al., 2009). 
 
Hyperplastic candidiasis also known as Candida leukoplakia is the least commonly 
encountered form of primary candidiasis. It is a chronic disease that presents as white 
plaques of varying sizes that cannot be rubbed off unlike the lesion of the 
pseudomembranous variety. The lesions are usually rough and nodular on palpation 
and may sometimes present with red spots that are termed “speckled”. The lesions 
usually occur at the lip commissures or the inner surface of any or both cheeks at the 
commissural areas and less commonly on the lateral surfaces of the tongue. 
Hyperplastic candidiasis is a potentially premalignant lesion and up to 15% may later 
undergo malignant change. A biopsy is usually performed to rule out change and to 
monitor the lesion. Histology reveals inflammatory exudate and Candida hyphae 
within the hyperplastic epithelium.  
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Figure 1.1 Pseudomembranous and erythematous candidiasis in the same patient 
[Source: Photograph by the investigator] 
 
1.1.3 Candida associated lesions 
Candida-associated denture stomatitis is also known as chronic atrophic candidiasis 
or denture sore mouth. Apart from the commensal Candida organisms, other bacterial 
organisms, mechanical irritation and possibly allergic reaction from the denture may 
be involved during the initiation stage of the infection. The causative factors lead to 
an overgrowth of oral Candida organisms in the niche between the denture surface 
and the palate where the saliva flow is limited. This condition may occur without 
symptoms or as burning sensation in the affected area. Inflammation around the 
commissure of the lips (angular cheilitis) may be present. Three subtypes or stages of 
denture sore mouth are described depending upon the severity and chronicity of the 
lesion. This is Newton’s classification (Newton, 1962; Samaranayake et al., 2009) i.e. 
Type I, Patchy areas of inflammation and redness, Type II, Diffuse areas of 
inflammation and redness restricted to the denture bearing area and Type III, granular 
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inflammation with the development of papillary lesions in the palate (Figure 1.2). 
 
Figure 1.2 Advanced (Type III) Candida-associated denture stomatitis  
Source: http://www.dentalcare.co.uk/dental-professional-
education/oralmucosal.aspx?ModuleName=coursecontent&PartID=2&SectionID=-1 
 
 
 
In angular cheilitis, the angle of the mouth or the lip commissure is affected. The 
typical lesion presents as redness and fissuring in the affected area, which is painful 
with movement. It is similar to denture sore mouth with bacterial organisms 
especially Staphylococcus aureus being involved. Other associated factors are vitamin 
deficiency (mainly Vitamin B12), iron deficiency anaemia and excessive folding in 
the area due to ill-fitting dentures and loss of facial height in old age (Samaranayake 
et al., 2009). 
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In Median rhomboid glossitis, this previously enigmatic lesion on the dorsum of the 
tongue was recently associated with oral Candida infection even though other 
bacterial organisms may be involved. The usual lesion is found on the dorsum of the 
tongue anterior to the circumvallate papillae. It is associated with an area of 
depapillation that is elliptical or rhomboid in shape but may sometimes be lobulated 
or hyperplastic (Samaranayake et al., 2009). 
 
Secondary Candida lesions occur from an early age and are usually associated with an 
underlying immune defect. In addition to the oral lesions, sites distant from the oral 
cavity such as the skin, nail and genitalia may be involved. The immunological defect 
may be related to systemic conditions for example HIV infection, cytotoxic therapy, 
haematological malignancies or may have a familial origin. Typical secondary 
candidiasis conditions are chronic mucocutaneous candidiasis (CMC) Syndromes. 
Researchers have postulated that deficient cell mediated immunity may be responsible 
for CMC, particularly a deranged Th2 response to yeast invasion (Puel et al., 2011). 
Additionally, interleukin-2, may be low or absent, gamma interferon production may 
be absent or increased whereas the IgG2/ IgG4 ratio is reduced in these patients (Lilic 
et al., 1996). Recent reports have indicated that inherited errors of interleukin-17 (IL-
17) may be important in the aetiology of CMC. IL-17 is a proinflammatory cytokine 
that helps to recruit neutrophils and monocytes and is similar to the action of gamma 
interferon (Puel et al., 2011). The principal clinical feature of CMC is persistent oral 
candidiasis that may last for years and responds poorly to topical antifungal therapy. 
The white patches in the oral cavity which cannot be scraped off are hyperplastic and 
nodular. The lesions have a predilection for the palate and dorsum of the tongue. The 
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nails are usually thickened and grey and the skin may present with desquamating 
erythematous patches (Eyerich et al., 2010) 
 
1.1.4   Causative organisms 
Candida organisms are among the most frequently encountered fungal pathogens in 
human disease (Table 1.2). The term Candida comes from the word “candid” in 
Latin, which means white. The genus Candida belongs to the family 
Saccharomycetaceae with more than 350 species (Marsh and Martin, 2009). Although 
not many species cause disease in man, it is believed that there are many 
undiscovered species that includes two-thirds of Candida species incapable of 
growing at 37
0
C (Schulze and Sonnenborn, 2009). While C. albicans is the most 
common aetiological agent in oral candidiasis, other Candida species such as C. 
glabrata, C. parapsilosis and C. dubliniensis have been frequently isolated from 
patients with candidiasis (Thompson et al., 2010). The increasing isolation of non-
albicans Candida species may be due to increased diagnostic methods available for 
these organisms or their resistance to conventional antifungal agents that leads to their 
persistence (Gonzalez et al., 2008).  
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Table 1.2 Candida species and similar fungi implicated in human infection [Source: 
Marsh and Martin, 2009] 
Candida species Other uncommon fungal species 
Candida albicans  
Candida dubliniensis  
Candida parapsilosis  
Candida tropicalis  
Candida glabrata  
Candida kefyr (pseudotropicalis) 
Candida lusitaniae  
Candida krusei 
Candida guilliermondii  
Candida utilis  
Candida lipolytica  
Candida famata  
Candida haemulonii  
Candida rugosa 
Saccharomyces spp 
Cryptococcus neoformans 
Histoplasma capsulatum 
Geotrichum spp 
Aspergillus spp 
Paracoccidiodes brasiliensis 
Mucor spp 
 
1.1.5 Candida carriage 
Oral colonisation (carriage) involves acquisition and persistence of a stable 
population at a particular site without clinical disease (Cannon and Chaffin, 1999). 
The interplay between acquisition, multiplication and the ability of the immune 
system to eliminate the organism determines whether an individual remains colonised 
(Cannon and Chaffin, 2001). Usually, about a third of healthy subjects are colonised 
by Candida species (van der Meer et al., 2010).  
Colonizing Candida organisms do not exist alone in the oral cavity but live in 
biofilms with bacteria (Rautemaa and Ramage, 2011). This bacterial fungal 
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relationship determines the eventual survival and proliferation of different species. 
For instance, non-pathogenic commensals provide a barrier against exogenous 
pathogens and inhibit the transition of colonizing Candida to the pathogenic state 
(Mukherjee et al., 2005). On the other hand, the interaction of colonizing Candida 
with certain Streptococcus and Pseudomonas species may increase the resistance of 
the yeasts and bacteria (Wargo and Hogan, 2006). The commensal behaviour of C. 
albicans in the oral cavity is still poorly understood. It is not clear how it adapts to the 
changing physical and chemical conditions of the mouth such as pH and how it 
acquires iron from ferritin stores in the oral epithelium while other microbes do not 
have this ability (Martin et al., 2011). 
 
The prevalence of yeast colonisation in the mouth varies with age, location and the 
immune status of the population sampled. In HIV positive patients, Candida carriage 
is higher than in HIV negative individuals (Table 1.3). For example, 80% carriage 
prevalence was found in HIV positive children and 57.5% of their sero-negative 
siblings (Cerqueira et al., 2010). Furthermore, a South African study showed a 
prevalence of 81.3 % in HIV positive adults compared to 63% in their HIV negative 
counterparts (Patel et al., 2006). The introduction of HAART has reduced the rate of 
oral candidiasis (Hood et al., 1998; Revankar et al., 1998) and probably the rate of 
colonisation as well (Cerqueira et al., 2010). However, oral candidiasis is still a major 
problem in patients with advanced HIV disease and those who carry strains of C. 
albicans that are resistant to antifungal drugs. Similarly, patients with non-albicans 
Candida strains who live in resource poor areas where ARVs are not available and are 
still vulnerable (Thompson et al., 2010). Although Wu et al. (2012) showed that the 
initiation of HAART reduced the rate of oral Candida colonisation (Wu et al., 2012), 
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Yang et al, (2006) showed no changes in the colonisation.  They suggested that 
prolonged HAART might be more beneficial in reducing opportunistic yeast 
infections rather than yeast colonisation (Yang et al., 2006).  
 
Table 1.3 Reports of Candida carriage rate in HIV-positive and HIV-negative 
subjects in Asia, Europe and Africa [Source: Patel et al., 2006]. 
 
 
1.1.5.1 Source of carriage 
The gastrointestinal tract (GIT) is the chief source of Candida organisms colonizing 
the mouth. The GIT and the vagina to a lesser extent, serve as a pool that regularly 
seeds the oral cavity (Cannon and Chaffin, 2001). Other body sites that are frequently 
colonised by Candida organisms include the vagina and the skin, especially the 
axillary folds, the groin and the perineum (van der Meer et al., 2010).  
 
The GIT is sterile at birth, but by the end of the first month of life, an indigenous 
intestinal microflora (including Candida organisms) is detectable. This flora becomes 
established by the age of 3 to 5 years and is peculiar to each individual based on 
compatibility with their immune system (Schulze and Sonnenborn, 2009).  
Oral Candida may also be derived from exogenous sources such as contaminated 
food and contaminated hands and equipment of health workers. Other sources are 
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kissing or similar activities between close contacts where there is direct saliva-to-
saliva contact (Cannon and Chaffin, 2001). 
 
1.1.5.2 Sites of colonisation 
In intraoral sites, Candida organisms are most commonly found on the dorsum of the 
tongue. The cheeks and other intraoral sites also harbour the organism and 
distribution is influenced by the availability of ligands that provide adhesion (Cannon 
and Chaffin, 1999). The presence and population size of colonizing Candida are 
determined by several factors. These include presence of other colonizing bacteria, 
use of antibiotics, presence of diabetes mellitus and oestrogens (van der Meer et al., 
2010).  
 
Other bacteria may compete for available nutrients or produce substances such as 
lactic acid and hydrogen peroxide that inhibit Candida spp. Broad-spectrum 
antibiotics may destroy local bacteria flora thereby provoking Candida overgrowth. 
Similarly, the high glucose content of tissues and immune deficiency in diabetics 
enhance yeast colonisation while oestrogens boost the glycogen content of epithelial 
cells thereby provide ample nutrition for yeasts to thrive (Dennerstein and Ellis, 
2001).  
1.1.5.3 Colonisation in other sites and invasive Candida infections  
Candida organisms are found in other parts of the body apart from the mouth. In these 
sites, they behave as commensals as long as the site specific microbial populations are 
intact and innate immunity is not compromised (Schulze and Sonnenborn, 2009). 
The vagina is the other major reservoir apart from the gut and up to 50% of women 
are colonised with Candida species (Mahmoudi Rad et al., 2011). The danger with 
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colonisation is the possibility of developing fungaemia and invasive candidiasis if 
there are overt risk factors. Colonisation itself is a known independent risk factor for 
fungaemia and invasive candidiasis (IC) and the number of colonised sites and 
intensity of colonisation are strongly predictive of IC (Magill et al., 2006; Pelz et al., 
2001). Furthermore, the site of colonisation has been associated with the risk of 
invasive candidiasis. In a study that related the anatomic site of colonisation with the 
risk of IC, patients with urinary, respiratory and rectal colonisation appeared to be at 
the greatest risk (Magill et al., 2006). This is possible because yeasts colonizing 
epithelial surfaces can germinate and form hyphae which they use to invade the 
tissues (van der Meer et al., 2010). 
 
C. albicans is the dominant species found at different body sites. However, the 
prevalence of other non-albicans Candida species has increased. Consequently, azole 
resistant C. glabrata is only second to C. albicans in the causation of IC (44%) 
followed by C. tropicalis (6%) and C. parapsilosis (5%). Other less commonly 
encountered yeasts include Cryptococcus spp, Geotrichum spp, Rhodotorula spp, 
Saccharomyces spp and Trichosporon species (Miceli et al., 2011). 
 
1.1.6 Factors influencing Candida carriage  
Several factors have been associated with oral colonisation with Candida organisms. 
These vary due to the differences in study locations and populations, sampling 
techniques, use and type of antiretroviral therapy and several other factors (Cerqueira 
et al., 2010). In addition, other associated factors are age, race, poor nutritional status, 
reduced salivary flow, use of antibiotics, wearing a dental prosthesis and poor oral 
hygiene. Underlying systemic diseases such as diabetes mellitus and disseminated 
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malignancy have been implicated as well as cancer chemotherapy and radiotherapy.  
 
The extremes of age have long been associated with increased predisposition to yeast 
colonisation and infection. These age groups have a compromised immunity and 
reduced capacity to eliminate colonizing yeast organisms (Jabra-Rizk et al., 2001).  In 
the elderly, the reasons for an increased rate of colonisation are multifactorial, i.e. 
compromised immunity, reduced salivary flow, nutritional deficiency and increased 
tendency to wear prosthesis (Darwazeh et al., 2010; Shay et al., 1997). Wearing 
prostheses such as dentures provide a means of adherence for Candida while 
precluding the area covered from the protective effects of saliva (Fanello et al., 2006).   
 
Malignant conditions and their treatment with cytotoxic chemotherapy or 
radiotherapy, compromise cellular mediated host immunity that is needed to control 
fungal infections (Schelenz et al., 2011). In addition, malignant conditions and their 
therapy reduce the protective effects of saliva by inducing hyposalivation. The 
induction of mucositis from radiotherapy further compromises saliva flow and 
function (Suryawanshi et al., 2012). With a variable prevalence of 10.8% to 58% 
Candida colonisation in head and neck cancer, predisposition to colonisation may be 
a function of the type of cancer. Generally, head and neck cancers have the highest 
level of prevalence as radiotherapy and chemotherapy are targeted at vulnerable saliva 
producing tissues (Schelenz et al., 2011). In addition, the high glucose content in the 
tissues and impaired cellular mediated immunity in diabetics are contributing factors 
for yeast colonisation (van der Meer et al., 2010). Similarly, broad-spectrum 
antibiotics have been implicated due to destruction of the oral microbial ecosystem 
(Fanello et al., 2006). However, several authors did not show a statistically significant 
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relationship between antibiotic use and oral colonisation by yeasts (Davies et al., 
2006; Schelenz et al., 2011). 
 
Poor oral hygiene is regarded as a risk factor for oral yeast colonisation due to 
increased plaque accumulation that creates the ideal niche for Candida and other 
organisms. In a study among elderly hospitalised patients, poor oral hygiene was 
implicated after adjusting for other risk factors (Fanello et al., 2006). Conversely, 
healthy dentate patients did not demonstrate any significant association between poor 
oral hygiene (using plaque and gingival indices) and oral Candida colonisation. 
However, adults who were not flossing on a regular basis had higher colonisation 
rates (Darwazeh et al., 2010b).  
 
Carious lesions serve as reservoirs for yeasts and therefore constitute risk factors in 
oral colonisation (Cerqueira et al., 2010).  Furthermore, studies in adults and children 
showed that low CD4 count and high viral load were significantly associated with 
carriage and development of oral Candida infection (Duggal et al., 2010; Sharma et 
al., 2010). On the other hand, no relationship was found between carriage rates and 
CD4 count thus suggesting that other factors may influence yeast carriage and 
development of symptomatic infection (Barchiesi et al., 2002; Sanchez-Vargas et al., 
2005b). Viral load has been independently associated with oral Candida infection and 
the association was more significant than CD4 count (Mercante et al., 2006). 
However, a similar study did not detect a relationship between viral load and oral 
colonisation with yeasts (Erkose and Erturan, 2007). In short, contributory factors for 
oral colonisation appear to be many and variable. 
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1.1.7   Treatment of oral candidiasis 
Treatment of oral candidiasis involves a combination of procedures and therapy. 
Detailed clinical and laboratory assessments are required to identify predisposing 
factors and to prevent ineffective treatment and recurrence of infection. Effective oral 
hygiene practices must be instituted to remove Candida biofilms from the mouth and 
prosthetic appliances. Therefore, adequate attention must be paid to proper nutrition 
and the cessation of smoking advised in smokers. Likewise, patients on steroid 
inhalers must be advised to rinse their mouth with water after using the inhaler to 
prevent oral candidiasis. When the mouth is dry, efforts should be made to rehydrate 
the mouth using artificial saliva, frequent sips of water and drugs that stimulate 
salivary flow. The treatment of oral candidiasis includes topical or systemic drugs or a 
combination of both. The treatment regimen depends on factors such as the type and 
severity of infection, the presence of systemic illness and previous antifungal therapy. 
A general guide for treatment adopted from (Williams et al., 2011) is provided in 
Table 1.4. 
 
1.1.7.1   Antifungal agents and their mode of action 
New antifungal medications have been developed in the last decade after a long 
period of relative inactivity. These became imperative due to rising incidence of 
invasive candidiasis, infection by non-albicans Candida, development of resistant 
strains and the toxicity of the existing drugs. A wide array of antifungal therapies 
exists but no single agent is ideal for all the patients. Antifungal therapy is usually 
individualised depending on the site of the infection, other existing comorbidities and 
concurrent drug therapies. Drug hypersensitivity and the immune status of the patients 
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are other factors to consider in order to arrive at patient specific antifungal regimens 
(Lewis, 2011). 
Six classes of antifungal drugs are available namely Polyenes, Azoles, Echinocandins, 
Allylamines, Pyrimidine analogues and Mitotic inhibitors. They are classified 
according to their mode of action (Figure 1.3). Only some of these drugs are used 
routinely to treat oral candidiasis (Table 1.4). 
 
Figure 1.3 Mechanism of action of antifungal drugs  [Source: Lewis RE, 2011] 
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Table 1.4 Treatment guidelines for oral candidiasis [Source: Williams et al, 2011] 
 PMC AEC CEC CHC Adult Dose 
Topical application      
 
 
         Nystatin 
  


 
 1 lozenge- of 100,000 units q.i.d. 
for 7–14 days 
Suspension: 500,000 units by rinse 
and swallow q.i.d. for 7–14 days 
 
         
        Amphotericin 
  
 
 1 lozenge (10 mg) q.i.d. for 10–15 
days 
 
        
        Miconazole 
  
 
 Oral gel (24mg⁄ml); 5–10 ml q.i.d. 
for 7–14 days 
 
         
        Clotrimazole 
  
 
 1 lozenge (10 mg) five times per 
day for 7–14 days 
 
 
     
Systemic administration      
       Ketoconazole     200–400 mg ⁄ day for 7–14 days 
 
       Fluconazole     100 mg ⁄ day for 7–14 days 
 
       Itraconazole     200 mg (20 ml) suspension by 
rinse and swallow without food 
q.i.d. for 7–14 days 200 mg ⁄day 
(capsules taken with food) for 2– 
4 weeks 
PMC- Pseudomembranous candidiasis, AEC- Acute erythematous candidiasis, CEC- 
Chronic erythematous candidiasis, CHC- Chronic hyperplastic candidiasis  
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Nystatin and Amphotericin B belong to polyenes class. Amphotericin B was 
synthesised in 1958, and was very effective and remained the mainstay of antifungal 
therapy for many decades. However, toxicity to the kidneys led to the development of 
less toxic formulations of the same drug, namely amphotericin B lipid complex, 
amphotericin B colloidal dispersion and liposomal amphotericin B (Proia, 2006). 
Amphotericin B can be used parenterally unlike nystatin which is used topically. The 
polyenes act by bind to ergosterol in the cell membrane of pathogenic fungi. This 
causes leakage of the cell contents and death of the cell (Lewis, 2011).  
 
Azoles belong to 2 classes: the imidazoles and the triazoles. Miconazole and 
ketoconazole belong to the imidazoles class of azole antifungals. They are effective 
against Candida and Aspergillus species although like the polyenes they are also 
nephrotoxic. On the other hand, triazoles have three nitrogen atoms in the azole ring 
that confer a greater affinity for cytochrome P450 in the yeast rather than the host 
cells. Therefore the triazoles have reduced toxicity unlike the imidazole and polyenes. 
Fluconazole (a triazole) was introduced in 1990 and showed greater efficacy and 
higher concentration in the tissues than the imidazoles that were already in clinical 
use with less side effects. However, fluconazole was not effective against Aspergillus, 
Mucorales and non-albicans Candida. Sensitive organisms also rapidly developed 
resistant strains to fluconazole and this prompted the development of the other azoles. 
Itraconazole, introduced in 1992, was effective against Aspergillus but fell into 
disrepute due to severe gastrointestinal (GI) side effects and unreliable absorption 
from the gut following oral administration. Subsequently, voriconazole was approved 
in 2002 for clinical use and showed better tolerability and efficacy than itraconazole. 
It also had excellent GI absorption following oral administration. The broad-spectrum 
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activity of voriconazole has an advantage as well as a disadvantage. The wide 
spectrum of activity led to an increase in interaction with other medication. The 
azoles posaconazole and isavuconazole were developed much later. Their advantage 
is they have much less drug interactions. Nonetheless, voriconazole is still the first 
line therapy in disseminated candidiasis. The azoles also act on the yeast cell 
membrane by inhibiting lanosterol demethylase, a cytochrome P450 dependent 
enzyme necessary for ergosterol synthesis (Lewis, 2011).  
 
The introduction of semi-synthetic lipopeptides called echinocandins heralded a new 
phase in antifungal therapy. With a unique action on fungal cell wall, which 
mammalian cells do not possess, the collateral damage to host cells was reduced to a 
minimum. Echinocandins target the β-1,3-D-glucan synthase enzyme used for cell 
wall synthesis in yeast cells. With a defective cell wall, the yeast pathogens are prone 
to osmotic lysis and subsequent death. Capsofungin was the first to be introduced 
with anidulafungin and micafungin coming later. They are effective against non-
albicans Candida and azole resistant Candida albicans. With few side effects and 
drug interactions coupled with a long half-life necessitating a once daily regimen, 
they appear well tolerated. Echinocandins have not showed any cross-resistance with 
azoles or polyenes and are useful alternatives when resistance to the other antifungals 
has developed (Lewis, 2011). 
 
Terbinafine and naftifine belong to the allylamines class. These drugs target squalene 
monooxygenase, an enzyme necessary for ergosterol synthesis in the yeast cell 
membrane. Terbinafine concentrates selectively in the skin and nails after oral 
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administration and therefore has very few side effects. However, it is not effective for 
disseminated fungal infection due to the selective accumulation in the skin and nails. 
Pyrimidine analogues such as flucytosine are similar to cancer chemotherapeutic 
drugs because they target intracellular processes in fungal cells. However, they are 
often ineffective as a single therapy for systemic fungal infections. The yeast enzymes 
cytosine permease and cytosine deaminase convert flucytosin to 5-fluorouracil which 
then inhibits thymidylate synthase activity and leads to miscoding of RNA. 
Furthermore, serious side effects such as bone marrow suppression, diarrhoea and 
vomiting have been reported with flucytosine therapy (Lewis, 2011). 
Mitotic inhibitors, including griseofulvin act intracellularly like the pyrimidine 
analogues. They bind to tubulin thereby inhibiting microtubular formation in the yeast 
cell but they are only useful for dermatophyte infection due to selective concentration 
in the keratinocytes (Lewis, 2011).  
 
1.1.7.2  Antifungal drug resistance 
Antifungal resistance may be viewed from either the microbiological or clinical 
perspective. Microbiologic resistance is evident when the antimicrobial concentration 
required to inhibit the growth of an infecting organism is higher than the 
concentration needed to inhibit the growth of wild-type strains. On contrast, clinical 
resistance occurs when the inhibitory antifungal dose exceeds the normal range that 
can be safely administered to the patient (Turnidge and Paterson, 2007).  
 
Resistance to conventional and newer antifungal medications is on the increase 
among hospitalised and immunocompromised patients. Different species of Candida 
exhibit different levels of resistance. For example Candida glabrata is resistant to 
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fluconazole and cross resistant to other azoles (Pfaller and Diekema, 2010) whereas 
C. glabrata may display multidrug resistance and several mutations in the same 
individual (Chapeland-Leclerc et al., 2010). The pattern of resistance and the 
predominant resistant organism may vary between countries and the region of studies. 
For example, multidrug resistant Aspergillus fumigus, a filamentous fungus not 
associated with oral candidiasis has been reported. Azole resistance was present 
without prior exposure to antifungal therapy which suggests that agriculturally used 
azoles are the likely cause of the resistant strains (Mortensen et al., 2010).   
 
Antifungal resistance may occur through a primary or secondary mechanism, i.e. 
pathogenic yeasts may hinder the antifungal capacity of the drug through innate or 
acquired characteristics. Resistant strains from other sources may also replace 
sensitive indigenous flora (Pfaller, 2012).  Resistance to azoles is more prevalent than 
any other categories of antifungal drugs. Furthermore Candida and other pathogenic 
yeasts organisms may exhibit more than one method of resistance to azole 
antifungals. One mechanism is the upregulation of efflux pumps that reduce the 
availability of the drug within the target structures (Kanafani and Perfect, 2008).  As a 
result, the drug is not able to inhibit the enzyme lanosterol demethylase which the 
fungi use to synthesise cell membrane ergosterol. The CDR or MDR gene in C. 
albicans encodes the upregulation of efflux pumps and this mechanism of resistance 
is common to all azole drugs. Candida species may also become resistant to azoles 
due to point mutations in the ERG11 gene that codes for the target enzyme. Alteration 
in the target enzymes thus inhibits their binding capacity to azoles. Furthermore, the 
altered target enzyme may be upregulated or the yeasts may develop alternate 
pathways whereby the drug is unable to interact and destroy the yeast membrane. In 
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addition, the ERG3 gene is responsible for the alternative pathways (Pfaller, 2012).  
Resistant strains of Candida species have also been reported for the relatively recently 
developed echinocandins. Their efficacy is reduced by mutations in the gene encoding 
for the cell wall enzyme 1,3-β-D-glucan synthase complex targeted by the drugs 
(Pfaller, 2012). For these reasons, antifungal resistance raises the MICs of the drugs 
and worsens the prognosis of fungal infections. These observations have resulted in 
an increase in antifungal susceptibility testing. 
In vitro susceptibility testing has helped to identify antifungal agents that may likely 
control an infection and have also identified agents that may not work.  There are 
several new products that are used for susceptibility testing i.e. the Etest® and the 
Vitek 2® yeast susceptibility test (both bioMerieux, Inc., Marcy l’ Etoile, France 
products) and the Sensititre YeastOne® colorimetric plate (TREK Diagnostic 
Systems, Inc., Cleveland, OH, USA).  
 
1.1.7.3 Antifungal drug resistance and HIV  
Antifungal drug resistance is a major clinical challenge, particularly in HIV infection 
where recurrent oral candidiasis may necessitate the prescription of antifungal drugs. 
Although azole antifungals such as fluconazole have been the predominant agents in 
antifungal therapy in HIV infection, azole resistance has compromised therapy. Up to 
9.8% of C. albicans strains demonstrate resistance to fluconazole even without 
previous therapy and resistance could increase to 44.7% following antifungal therapy 
(Pfaller, 2012). Itraconazole also shows a similar pattern of resistance (Magaldi et al., 
2001). In a longitudinal study of HIV positive and negative individuals, most of the 
resistant strains were C. albicans or C. glabrata isolated from the HIV positive group 
(Sanchez-Vargas et al., 2005b). 
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Azole antifungals are able to precipitate the growth of less susceptible strains and 
non-albicans Candida especially with prophylactic use when the CD4 count is low 
(Badiee et al., 2010). Non-albicans Candida species such as C. krusei and C. glabrata 
demonstrate a high levels of fluconazole resistance and are also resistant to other 
agents due to cross resistance (Mokaddas et al., 2007). Antifungal agents with low 
MICs and high activity against Candida species have been recommended for 
empirical therapy or following fluconazole resistance in HIV infection. Badiee and 
co-workers recommended the use of voriconazole, Amphotericin B and capsofungin 
due to low MICs values observed (Badiee et al., 2010). The prevention of oral 
candidiasis in HIV infection using mouthrinses such as triclosan/fluoride has also 
been suggested. These agents keep the yeast count low and stimulate salivary flow in 
the colonised, thereby preventing the development of clinical infection (Patel et al., 
2008). 
 
1.2 Candida albicans  
The Candida genus belongs to the family Saccharomycetaceae of which Candida 
albicans is the most common species (Shi et al., 2007). C. albicans, a diploid 
polymorphic yeast with eight chromosomes is the most common pathogenic yeast in 
humans (Kim and Sudbery, 2011; Schulze and Sonnenborn, 2009). The genome of C. 
albicans is 13.3-13.4 Mb encoding between 6,100 to 6,200 genes. C. albicans can 
exist in at least three distinct morphological forms- the yeast, the pseudohyphae and 
the hyphae forms (Figure 1.4). The pseudohyphae and hyphae are often collectively 
referred to as filamentous. Other forms may even occur during phenotypic switching. 
The filamentous forms are invasive and the ability to switch between different 
morphologic forms is an indication of their virulence. This virulence is enhanced by 
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the disseminative ability of the yeast form and the capacity of the hyphal form to 
invade tissues (Sudbery et al., 2004).  
 
The morphologic differences between the yeast, the pseudohyphae and hyphae have 
been described (Sudbery et al., 2004). The pseudohyphae are produced from 
incomplete separation after the cell cycle leading to yeast cells that demonstrate 
polarised growth. The pseudohyphae also differ from the hyphae forms in the 
diameter of the filament that is not constant along the length. The pseudohyphae is 
constricted at the ends and wider at the centre in contrast to the hyphae that has a 
constant filament width. 
 
Macroscopically, Candida spp. form colonies that have a cream colour and a yeasty 
smell following aerobic incubation at a temperature range of 20°-38°C. The pH range 
for growth is 2.5 to 7.5, which can be seen after 48 to 72 hours. Growth at 37°C helps 
to identify yeasts from clinical specimens as most pathogenic species grow readily at 
temperatures between 25°C and 37°C. Microscopically, Candida yeasts are almost 
identical and stain Gram-positive.  However, the shape of the blastospores can vary 
from spherical to ovoid or elongated forms. Candida albicans is a dimorphic yeast, 
meaning that it can switch from blastospores (ovoid and budding yeast cells) to 
parallel-sided hyphae (Webb et al., 1998).  
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Figure 1.4 Morphologic forms of Candida albicans  [Source: Kim and Sudbery, 
2011] 
 
 
1.2.1 Pathogenicity of Candida albicans 
C. albicans has the ability to live as a commensal or transform to an active pathogen. 
The physical barrier provided by the oral epithelium, the presence of other inhibitory 
bacteria and an intact immune system help to maintain the commensal status of the 
yeast. Although some known factors aid the switch to a pathogen, the molecular 
mechanisms underlying yeast attachment, invasion, destruction and dissemination are 
not fully understood (Dalle et al., 2010).  
The known pathogenic characteristics involve a change in morphology from the yeast 
to the hyphal forms (dimorphism), phenotypic switching and the elaboration of 
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certain hydrolytic enzymes (Figure 1.5). These enzymes hydrolyse large substrates 
into smaller units for easier movement into the cell for nutritional purposes and break 
down host targets for colonisation and invasion. The most vigorously described are 
the phospholipases and proteinases (Chaffin, 2008) whereas lipases have been studied 
to a lesser extent (Naglik et al., 2003). Furthermore, C. albicans is able to haemolyse 
red blood cells and release haemoglobin and iron for its nutrition. This haemolytic 
capacity is proportional to the virulence of the yeast (Baboni et al., 2009). 
 
Other pathogenic characteristics include the expression of factors that aid adherence, 
directed growth/thigmotropism, adaptation to stress and metabolic flexibility 
(Wachtler et al., 2011). Recent findings show that the mechanisms of invading the 
host epithelial cells by Candida include the active penetration and the induction of 
endocytosis (Dalle et al., 2010).  With all that is known so far, it is certain that the 
interplay of both host and yeast factors ultimately enhance pathogenicity and the 
development of oral candidiasis (Martin et al., 2011). 
 
 
 
 
 
 
 
 
 
30 
Figure 1.5 Stages and pathogenic characteristics of Candida albicans  
[Source: Naglik et al., 2003]
 
It is known that C. albicans isolated from HIV positive subjects produce more 
secreted aspartyl protease and are more adherent than isolates from health controls, 
which suggest they are more virulent (De Bernardis et al., 1996; Ollert et al., 1995; 
Sweet et al., 1995). 
 
1.2.1.1     Adherence 
The ability of Candida albicans to adhere to host cells, other oral bacteria and/or 
medical devices is the first stage in the process of infection. C. albicans adheres to 
itself by flocculation and to other organisms by coaggregation. Adherence can be 
specific or non-specific and enables the yeast to resists clearance from the mouth by 
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the cleansing action of saliva and swallowing. Specific adherence involves the 
interaction of cell surface proteins with specific ligands or receptors in the oral cavity.  
This interaction may occur between proteins or protein-sugar interactions. In contrast, 
non-specific adherence involves physical entrapment due to hydrophobic and 
electrostatic interactions with biotic and abiotic surfaces (Chaffin, 2008; Marsh and 
Martin, 2009). 
 
Once the yeast makes contact with the epithelial cells, rapid formation of the hyphae 
and the expression of genes that mediate adherence are stimulated (Wachtler et al., 
2011). The presence of specific cell wall proteins called adhesins in Candida species 
correlates with the adherence ability of the yeasts. Specific genes in the Candida 
genome code for adhesins and several types of adhesins have been described (Chaffin, 
2008).  The adhesins and the ligands or receptors on the host that aid adherence have 
been reviewed extensively (Chaffin, 2008; Chaffin et al., 1998).  
 
Adhesins or agglutinin like proteins assists C. albicans to attach and form biofilms. 
They are glycophosphatidylinositol cell wall proteins consisting of three domains. 
The variable central portion of the adhesins is used to classify them into different 
subgroups. At least 8 genes that encode for these proteins have been described. The 
members of the agglutinin like sequence (ALS) gene family, ALS1, ALS2, ALS3 are 
the most commonly expressed. These genes are expressed variably in different strains 
and clinical samples. However, upregulation of these genes have been demonstrated 
in patients with oral candidiasis (Zakikhany et al., 2007). Hwp1p adhesin is found on 
the hyphal surface and forms a covalent attachment to the host cell. Unlike the 
Hwp1p, Ywp1p adhesin it is a glycophosphatidylinositol cell wall protein commonly 
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expressed on the surface of the yeast cell. Expression is greatest towards the end of 
the exponential growth phase of the yeast. 
 
Mannans and mannoproteins form part of the cell wall of the C. albicans and they 
interact with host proteins. Cell surface hydrophobicity in C. albicans is possible due 
to the existence of several proteins. These proteins enhance adherence to extracellular 
matrix, epithelial and endothelial cells and plastic materials in catheters and other 
medical devices. Several cell wall proteins and mannoproteins such as mp58 
fibrinogen binding mannoprotein prove to be hydrophobic (Zakikhany et al., 2007). A 
similar gene CSH1 encodes 38kDa protein that has hydrophobic properties (Singleton 
et al., 2001). 
 
Filamentous, thin and long appendages on the surface of C. albicans called fimbriae 
mediate adhesive interactions with host receptors. The major component of the 
fimbria is a 66kDa glycoprotein which binds to glycosphingolipids on the surface of 
human buccal epithelial cells. The proteins in the fimbriae also have strong affinity 
for collagen. Epithelial binding lectin-like protein (EBLP) also contribute to the 
adherence of C. albicans to epithelial cells. The sap Protein family also called 
secreted aspartyl proteinases are hydrolytic enzymes implicated in C. albicans 
virulence. Apart from acting as proteinases, they also contribute to adherence (Naglik 
et al., 2003). 
 
In an intact epithelium or endothelium which covers the basement membrane, the 
underlying connective tissue containing the extracellular matrix host proteins is 
inaccessible to colonizing yeasts. When this protective layer is compromised, yeasts 
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are able to escape into the vascular system and penetrate the deeper layers where they 
bind to components of the extracellular matrix. Extracellular matrix is ubiquitous and 
increases the potential of binding via protein-protein and protein-carbohydrate 
interactions (Chaffin, 2008). C. albicans can adhere to type I collagen, gelatin (which 
is denatured type I collagen) and type IV collagen. A 75kDa glycoprotein called 
vitronectin found in the vascular wall and serum provides a ligand for germ tubes at a 
greater capacity than for yeast cells. Tenascin-C is a hexameric 200 kDa protein. Like 
vitronectin, it also binds more readily to germ tubes than yeast cells. The entry of C. 
albicans into the blood stream via catheters or by translocation provides an avenue for 
the yeast to interact with proteins and other blood constituents. Proteins in serum, 
particularly complement fragments C3d and iC3b can bind to yeasts. Fibrinogen, C4b 
binding protein, factors H and FHL-1, haemoglobin and plasminogen are other serum 
ligands with varying degree of activity. Surfaces in the oral cavity are covered by 
pellicle that contains salivary components. Recently, research has shown that binding 
of salivary components to yeast cells is more crucial for adherence than binding to 
epithelial surfaces. The major salivary binding components are proline rich proteins 
(PRPs), which are predominantly salivary polypeptides.  Statherin is another salivary 
polypeptide that may contribute to adherence. In contrast, salivary IgA inhibits 
adherence (Chaffin, 2008). 
 
Studies have found that C. albicans isolated from HIV positive patients adheres more 
readily to oral epithelial cells than isolates from HIV negative individuals (Jain et al., 
2010; Mane et al., 2012). This could be one of the reasons for the increase in 
colonisation and carrier rate among HIV positive patients. 
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 1.2.1.2 Secreted aspartyl proteinases 
The secreted aspartyl proteinases (SAPs) and their role in C. albicans virulence have 
been studied more comprehensively than other extracellular hydrolytic enzymes 
produced by C. albicans (Kwon-Chung et al., 1985). Ten SAP genes (SAP 1-10) that 
code for the protein have been identified. These genes are not peculiar to C. albicans, 
and are found in other pathogenic Candida species, particularly C. dubliniensis, C. 
tropicalis and C. parapsilosis (Fotedar and Al-Hedaithy, 2005).  
 
The SAP family is divided into 4 subfamilies based on sequence homology of the SAP 
isoenzyme family. They are proteins that range from 35-50 kDa that are produced 
with changes in pH. This versatility allows the yeast to remain virulent in different 
ecological niches, for example the vagina and other mucosal surfaces, the skin and the 
internal organs. This virulence and capacity to cause infection is due to the ability of 
these enzymes to source nutrition for yeast cells, aid invasion and penetration of host 
tissues while evading the immune response (Naglik et al., 2003). SAPs contribute to 
penetration by degrading E-cadherin, an interepithelial junction protein through 
proteolysis (Zhu and Filler, 2010). 
 
In human Candida infection, SAP9 is the most commonly expressed SAP gene in wild 
type cells.  Furthermore, there is usually an upregulation of the SAP5 gene in active 
oral or vaginal infection, (Naglik et al., 2008). In addition, C. albicans SAP 
production was more intense in HIV positive individuals with oral Candida infection 
than asymptomatic HIV positive or HIV negative subjects (Mane et al., 2012). Similar 
high SAP production was detected in C. albicans infections in the vagina of HIV 
positive women (de Bernardis et al., 1999; Tosun et al., 2005). This infection 
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progresses with the advance of HIV disease and is probably induced by the HIV 
envelope (GP160) or other viral proteins such as Tat (Gruber et al., 2001). SAPs also 
induce inflammation via the induction of monocytes that produce proinflammatory 
cytokines IL-1b, IL-6 and TNFα. This pathway is totally independent of their 
proteolytic abilities and forms an independent pathway of interaction with host 
(Pietrella et al., 2010). 
 
1.2.1.3 Phospholipases 
Phospholipases are extracellular hydrolytic enzymes that enhance Candida species 
virulence. They also contribute to the pathogenesis of other fungal and non fungal 
organisms such as Aspergillus fumigatus, Rhodotorula rubra, Cryptococcus 
neoformans, Toxoplasma gondii and Rickettsia rickettsii (Niewerth and Korting, 
2001). 
 
C. albicans shows greater phospholipase activity compared to other non-albicans 
Candida species. This may be as high as 53.8% of all C. albicans isolates (Oksuz et 
al., 2007). The site of the yeast and immune status of the host influences the degree of 
production. Samples taken from different anatomic sites show that phospholipase 
production was most prominent in the mouth (59%) and faecal (42%) samples (Oksuz 
et al., 2007). Similarly, Price and colleagues isolated phospholipase from 55% of C. 
albicans samples from the blood, 50% from wound infection and 30% from urine 
samples (Price et al., 1982).  
 
Six types of phospholipases have been described, phospholipase A, B, C and D, 
lysophospholipase, and lysophospholipase-transacylase. Phospholipases hydrolyse 
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phospholipids into fatty acids and contributes to the damage of the host cell 
membrane. The hydrolysed phospholipids are important cell membrane components, 
which are necessary for structure and function. Furthermore, phospholipases enhance 
adherence of yeast cells by exposing cell surface ligands and production is 
proportional to the degree of pathogenicity (Niewerth and Korting, 2001). 
 
Phospholipase expression by Candida species is highly variable due to differences in 
the type, stage and site of infection in addition to the host response (Mane et al., 
2011). While phospholipase production may be present in HIV infection, it may not 
be associated with other virulence attributes (Samaranayake et al., 2005). A study in 
children found slightly higher but not significantly different enzyme production in 
children with AIDS compared to their negative counterparts (Bosco et al., 2003). 
Mane et al, (2012) showed that C. albicans isolates from HIV positive patients with 
oral candidiasis produced larger amount of phospholipase compared to the isolates 
from HIV negative patients.  
 
1.2.1.4 Biofilm formation  
In a biofilm, yeasts and bacteria are enclosed in a matrix of polysaccharides and 
glycoproteins produced by the microorganisms.  Mixed biofilms in the oral cavity are 
involved in binding of C. albicans to several oral microbes such as Streptococcus 
oralis, Streptococcus sanguinis and Streptococcus gordnii resulting in co-aggregation. 
The cell wall polysaccharides and proteins of the bacteria and specific Candida 
adhesins directly mediate these interactions. Indirect interactions are due to metabolic 
by-products and signalling molecules (ten Cate et al., 2009). Some of the extracellular 
signalling molecules that have been studied extensively include quorum sensing 
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molecules such as farnesol and tyrosol. These molecules regulate behaviour for 
example biofilm formation, production of virulence factors, competence and 
bioluminescence (Albuquerque and Casadevall, 2012).  
 
The formation and attachment of biofilms to biotic and abiotic surfaces enable 
Candida organisms to survive and proliferate in the oral cavity.  In addition, Candida 
organisms in biofilms are more resistant to antifungal agents than the planktonic 
forms. The molecular mechanisms mediating this resistance are yet to be fully 
elucidated. In vitro studies suggest that multidrug efflux pumps and cell wall 
components of Candida such as β-1,3-glucan are responsible for the resistance 
(Mukherjee et al., 2005). Biofilms have gained prominence in the last decade due to 
their role in infections of indwelling medical devices implanted in the body ie central 
venous and urinary catheters and joint prostheses. These infections respond poorly to 
established antifungal therapy, are associated with higher mortality rates and health 
care, costing more that $11 billion annually (Mukherjee et al., 2005).  
 
The higher prevalence of Candida carriage in HIV infected individuals may be partly 
responsible for enhanced biofilm formation ability. However, a recent study did not 
show any significant difference in the biofilm forming ability of yeasts from HIV 
positive and HIV negative individuals (Jin et al., 2003). This was attributed to the 
possible differences between the in vivo situation where host immunity and other 
factors may play a role rather than the laboratory environment. Furthermore, higher 
carriage rates in HIV infection may be due to other virulence factors and host 
immunity rather than biofilm formation capacity (Jin et al., 2003). In addition, oral 
Candida species from patients with HIV infection had similar biofilm forming ability 
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to isolates from invasive Candida infections (Junqueira et al., 2012). This indicates 
that oral strains may be equally virulent if they invade the systemic circulation. 
  
 
1.2.1.5 Cell surface hydrophobicity (CSH) 
Hydrophobicity is a complex phenomenon that is a function of the host and the yeast 
characteristics. Several yeast cell surface proteins may be responsible for the 
hydrophobic characteristics, which include a group of low molecular weight proteins 
of less than 65 kDa (Chaffin et al., 1998). These hydrophobic components are more 
abundant in germ tubes than yeast cells.  
 
Hydrophobic interactions aid the adherence of Candida organisms and biofilm 
formation and CSH is directly related to virulence. In view of the many adhesins in 
the armamentarium of C. albicans, CSH is not as prominent as in the non-biofilm 
forming Candida that depend more on CSH for attachment (Borghi et al., 2011). CSH 
differs across species with C. dubliniensis showing greater CSH than C. albicans 
(Borecka-Melkusova and Bujdakova, 2008). Even in C. albicans strains, the smooth 
phenotypes are associated with greater CSH compared with the wrinkled, star or ring 
morphologic types (Antony et al., 2007). 
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1.2.1.6 Phenotypic switching  
Phenotypic switching, a virulence attribute in oral Candida that usually occurs due to 
the response of the yeast to environmental stresses. Such stresses induce 
genotypic/phenotypic changes that are reflected as differences in colony morphology. 
The changes occur spontaneously, reversibly and may underly the expression of other 
virulence attributes such as cell surface hydrophobicity, proteinase production and 
adherence (Antony et al., 2007).  
 
In HIV infection, C. albicans strains exhibited high level phenotypic switching even 
before the first episode of a clinical thrush infection. This switching is also associated 
with a higher propensity for antifungal resistance and expression of other virulence 
factors (Vargas et al., 2000). The wrinkled morphology is associated with higher 
proteinase production compared with other morphologic types whereas the smooth 
variety is associated with greater CSH (Antony et al., 2007). 
 
1.3 Oral candidiasis, HIV infection and immune response 
Oropharyngeal Candida infection is the most common opportunistic infection in 
individuals with HIV infection. The severity varies from asymptomatic carrier state to 
disseminated and potentially fatal candidemia. The likelihood of infection is higher 
when the CD4 count falls below 200 cell/mm
3
 or when the viral load exceeds 10,000 
copies/mL (Delgado et al., 2009).  Although the prevalence of oropharyngeal 
Candida infection dropped with the advent of antiretroviral therapy, infections still 
occur. Such infections are due to episodes of depressed immunity, non-compliance 
with antiretroviral therapy and the development of azole antifungal resistant strains as 
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well as other factors. This justifies the need for constant monitoring of HIV positive 
individuals for episodes of oropharyngeal Candida infection (Patel et al., 2012). 
The immune response to C. albicans is a complex phenomenon. Although the body is 
able to distinguish between harmless colonizing strains and exogenous pathogenic 
strains, the exact mechanisms are not fully understood. Pattern recognition receptors 
on the host interact with molecules on the surface of the yeasts known as pathogen 
associated molecular patterns (PAMPs) (van der Meer et al., 2010). Examples of these 
pattern recognition receptors are C-type lectin receptors, toll like receptors, 
nucleotide-binding domain leucine-rich repeat-containing receptors and the retinoic 
acid-inducible gene I receptors (Takeuchi and Akira, 2010). 
 
The pathogen associated molecular patterns (PAMPs) form part of the components of 
the cell wall of Candida species (Figure 1.6). Cell wall components of Candida 
organisms that are recognised as PAMPs include chitin, the β-glucans (β-1,3 glucan 
and β-1,6 glucan), mannans and mannoproteins. Mannoproteins are recognized by the 
mannose receptors and dectin-2 whereas dectin-1 recognizes the β-glucans. The β-
glucans and mannans PAMPs along with complement factor C5a induce the 
differentiation of T helper (Th) lymphocytes into the Th17 subset. The Th17 initiate a 
proinflammatory cytokine response mainly involving IL-17 and IL-22, which then 
initiates the production of β defensins by the epithelial cells. β defensins are 
antimicrobial peptides with antifungal properties that are able to restrict the growth of 
Candida organisms (van der Meer et al., 2010). Failure to recognize C. albicans 
PAMPs and initiate the appropriate cytokine response due to dectin-1 deficiency is 
responsible for some cases of recurrent candidiasis (Ferwerda et al., 2009). 
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HIV infection has also revealed fresh insights into the immune response to oral 
Candida infections. The primary defence against Candida organisms are CD4 plus T 
cells. When CD4
 
cells are deficient as occurs in HIV infection, secondary defence 
mechanisms are deployed. These include CD8
+
 T-cells, proinflammatory protective 
cytokines in the saliva and the defence mechanisms that are based in oral epithelial 
cells (Fidel, 2006). An increased understanding of these mechanisms may lead to the 
development of immunotherapeutic methods of curtailing infections in susceptible 
individuals. These individuals have a poor prognosis even in the advent of more 
effective antifungal therapy (Fidel, 2006; van der Meer et al., 2010). 
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Figure 1.6 Major pathogen associated molecular patterns on the cell wall of C. 
albicans [Source: van der Meer et al., 2010] 
 
 
1.4 Genotyping of C. albicans 
Genotyping uses differences in the DNA sequences of yeast isolates to generate strain 
or clone specific datasets. This helps to identify organisms at strain level i.e. below 
the species level. Genotyping is more accurate than phenotyping due to the poor 
discriminatory power, technical complexity and poor reproducibility of phenotyping 
methods (van Belkum et al., 2007). Phenotypes are therefore not reliable as 
epidemiologic markers because they do not truly reflect the genotype of an organism. 
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Furthermore, genotyping methods help to monitor the population and spread of yeasts 
in clinical and environmental settings which leads to better infection control 
measures. Genotyping also assist in studying colonisation patterns in individuals to 
determine whether the same strains or different strains are present at different times. 
This information makes it possible to determine risk factors for colonisation, the 
virulence characteristics of the strains and the evolution and relationships between 
strains. Such knowledge provides a basis for informed clinical decisions (Vanhee et 
al., 2010). The ideal genotyping method should be affordable, reproducible, easy to 
use and interpret. In addition, it should posses a high discriminatory power and yield 
rapid results. 
 
1.4.1 Genotyping techniques 
Genotyping of fungal organisms is more challenging compared to bacteria. The 
diploid nature of some yeasts make interpretation difficult as variable sites may show 
the presence of two bases. Genotyping methods for Candida albicans include Pulsed-
field gel electrophoresis (PFGE), Restriction fragment length polymorphism (RFLP), 
Polymerase chain reaction-Restriction fragment length polymorphism (PCR-RFLP) 
and Amplified fragment length polymorphism (AFLP). Other available methods are 
Random amplified polymorphic DNA (RAPD), Retrotransposon insertion-site context 
(RISC), Sequence-specific DNA primer (SSDP), Repetitive-sequence-based PCR 
(rep-PCR), Variable number of short tandem repeat (VNTR), Electronic 
karyotyping/Microsatellite markers, ABC genotyping and Multilocus sequence typing 
(MLST). Theses different methods (Table 1.6) have their strengths and drawbacks 
(Boriollo et al., 2010; Garcia-Hermoso et al., 2010). 
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Table 1.5 Comparison of genotyping methods [Source: Vanhee et al., 2010] 
Method Reproducibility Portability Discriminatory 
Power 
Ease of 
Use 
Ease of 
Interpretation 
Set up 
cost 
Cost/isolate Time 
to 
result 
(days) 
AFLP High Poor High Moderate Difficult High Moderate 2 
MLST Very high Excellent Moderate Moderate Moderate High High 2 
PFGE High Poor High Moderate Moderate Moderate Moderate 3 
RAPD Moderate Poor Limited Easy Moderate Moderate Low 1 
RFLP High Poor Moderate Easy Moderate Moderate Low 1 
rep-
PCR 
High Poor Moderate Easy Moderate Moderate Low 1 
SSDP Very high Good Limited Easy Easy Moderate Low 1 
VNTR High Good HIgh Moderate Moderate High Moderate 2 
 
Restriction fragment length polymorphism (RFLP) also known as restriction enzyme 
analysis (REA) involves the breakdown of DNA with restriction enzymes. The 
restriction fragments are then analysed using gel electrophoresis. The advantages are 
low cost, ease of use and rapidity of obtaining results. The main drawback is the 
modest discrimination, which can be improved when combined with hybridization 
(Vanhee et al., 2010).  
 
Ca3 probing combines Southern blot hybridisation with the use of specific probes 
such as Ca3, 27a and CARE2. These probes hybridise to repetitive sequences 
scattered throughout the genome to identify variability among isolates wherever such 
diverse loci are found. The probes will also hybridise to less variable sequences 
thereby showing allelic polymorphism. This overcomes the problem of homoplasy, 
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which is a disadvantage with some genotyping techniques. They also hybridise to 
hypervariable sequences that show microevolutionary changes within a strain thus the 
relatedness of isolates can de demonstrated (Soll, 2000). 
 
In Amplified fragment length polymorphism (AFLP), DNA is digested using 
restriction enzymes and specific adapters are joined to selected restriction sites. This 
is followed by 2 PCRs on the restricted template to amplify a subset of the restriction 
fragments. Thereafter the PCR products are separated by gel electrophoresis and 
banding patterns are analysed with software. It is a highly discriminatory technique. 
The main disadvantages are poor portability i.e. results vary with the laboratories and 
difficult interpretation. (Vanhee et al., 2010). 
 
In contrast, Random amplified polymorphic DNA (RAPD), amplicons are targeted 
and amplified throughout the genome. Thereafter, agarose gel is used to separate the 
amplified products, and thereafter stained with ethidium bromide (Soll, 2000). The 
technique is more discriminatory than RFLP but shares the same disadvantage 
because it is not able to distinguish between homologous and heterozygous 
genotypes. This phenomenon is termed homoplasy where equal bands of 
electrophoretic activity may not be homologous. The other disadvantage of RAPD is 
low portability and low reproducibility (Vanhee et al., 2010).  
 
Sequence-specific DNA primer (SSDP) is more stringent and overcomes the 
drawbacks of RFLP and RAPD. The discriminatory power is limited however it is 
cheap and easy to interpret. 
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Microsatellite length polymorphism detects the pattern of microsatellites (nucleotide 
sequences of short fragments on the genome of 6-10 nucleotides), which tends to 
repeat several times on the genome. The main disadvantage is homoplasy. 
Electronic karyotyping uses chromosome length polymorphism that is common in 
fungi. However, the disadvantage is that homoplasy may yield results that appear 
similar without being ancestrally related (Vanhee et al., 2010).  
 
In multilocus enzyme electrophoresis (MEE), the polymorphisms of housekeeping 
enzymes (isoenzymes) are evaluated. These enzymes are generally conserved through 
evolution. It has a high discriminatory power but because it is an indirect assay of 
genotype (using enzymes), nucleotide variation may go undetected. It is also 
expensive, time consuming because at least 10 enzymes must be evaluated. 
 
In ABC genotyping, cellular DNA is digested with EcoRI enzyme. The PCR products 
of the V3 region of the 25S rRNA gene (rDNA) can be separated into 3 types based 
on the size of the fragments on gel electrophoresis. The predominant fragment size is 
then used to type the strain. The product for Genotype A is 450bp, Genotype B is 
840bd whereas both fragments (450bp and 840bp) are present in Genotype C 
(McCullough et al., 1999).  
1.4.2 Multilocus sequence typing (MLST) 
This genotyping technique was introduced in 1998 to provide accurate and portable 
data on the biology of pathogens and to study their evolution. Originally developed 
for prokaryotic bacteria, it is now widely used to characterise eukaryotic organisms 
including Candida species. The differentiation of strains is based on polymorphism of 
the internal fragments of selected housekeeping genes. For each housekeeping locus, 
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the different sequences found in a bacterial or fungal species are recorgnised as 
distinct alleles. The alleles at each of the sequenced loci help to define an allelic 
profile or sequence type for each isolate. The unique sequences of a locus are 
assigned an allele number (Urwin and Maiden, 2003). The advantages of MLST are 
high discriminatory ability and easy comparison between laboratories as it allows the 
exchange of molecular typing data via the Internet for global epidemiology. In 
addition, it is reproducible and can be used to study extracted DNA or clinical 
specimen (Bougnoux et al., 2002). 
 
Furthermore, MLST is a useful tool for the characterisation of C. albicans because it 
yields results that are unambiguous and is the most reliable method for differentiating 
C. albicans strains (Odds et al., 2006). In addition, it also detects slight variations in 
the sequences of related isolates. After extensive work on candidate housekeeping 
genes, MLST was used to study Candida organisms in 2002 and as a result, a 
consensus was reached using the seven most discriminatory housekeeping genes i.e. 
AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13, and ZWF1b. The MLST international 
standard for C. albicans is based on these genes and a central Internet database has 
been set up (http://calbicans.mlst.net). Thus C. albicans data from any country world 
wide can be deposited and analysed using this site (Bougnoux et al., 2003). 
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CHAPTER 2: STUDY DESIGN 
2.1 Introduction 
The factors responsible for the development of symptomatic oral candidiasis in HIV 
infection are controversial. Some studies reported that a decline in cellular immunity, 
especially CD4 counts below 200 cells/mm
3
 and high viral load were associated with 
colonisation and candidiasis, whereas others found no relationship (Duggal et al., 
2010; Erkose and Erturan, 2007; Sanchez-Vargas et al., 2005a; Sharma et al., 2010). 
These conflicting findings suggest that other factors may influence yeast carriage and 
development of symptomatic infection. Factors that may foster the development of 
symptomatic disease include the type and virulence of the fungi as well as antifungal 
resistance due to previous treatment with azoles (Loreto et al., 2010). In addition, 
antiretroviral treatment with protease inhibitors (PI) was associated with a decrease in 
opportunistic oral Candida infection (Diz Dios et al., 2001). On the other hand, the 
use of protease inhibitors did not influence Candida carriage despite the in vitro 
observation that PI inhibited the adherence of Candida (Delgado et al., 2009). Yeast 
counts and the expression of virulence factors tend to increase in patients with oral 
candidiasis. However, it is not clear whether increased yeast count or the virulence of 
the organism that predisposes to the development of oral candidiasis.  
 
The persistence of the same strain in yeast colonised individuals is still contentious.  
While some authors identified a unique persistent strain, (Cross et al., 2004), others 
described multiple colonizing strain (Samaranayake et al., 2003). As a result, it is not 
clear whether patients colonised with Candida carry the same strain or get reinfected 
with other strains. It has been proposed that C. albicans isolates are highly diverse 
genetically in colonised individuals due to gene conversion, recombination or a 
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change in chromosomal ploidy. Conditions under which this occurs is poorly 
understood (Odds et al., 2006). To date, no longitudinal study has been undertaken to 
monitor strain maintenance and the acquisition of new strains of C. albicans in an 
African population. 
2.2 Aim and objectives 
2.2.1 Aim 
The aim of this study was to investigate the effect of social and clinical factors on the 
Candida carriage in HIV positive women. In addition, the role of Candida counts, 
virulence, presence of non-albicans Candida and reinfections in the development of 
oral candidiasis was studied. 
2.2.2 Objectives 
a. To examine the carrier rate of Candida among HIV-positive women: 
prevalence, types and quantities of Candida, influence of oral hygiene, social 
and clinical factors.  
b. To determine the virulence of C. albicans during the study period and the 
influence of quantity and/or virulence of C. albicans on the development of 
oral candidiasis.  
c. To examine the occurrence and role of non-C. albicans yeasts in the 
development of  candidiasis. 
d. To study the antifungal sensitivity of C. albicans isolated from HIV positive 
women. 
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e. To determine and compare the genotypes of C. albicans in those colonised 
women at intervals during the follow up period.  
 
2.3 Study outline 
Figure 2.1 is a flow diagram depicting the study design and the layout of the thesis.  
a. To examine the carrier rate of Candida among HIV-positive women: 
prevalence, types and quantities of Candida, Influence of oral hygiene, 
social and clinical factors.  
Briefly, oral rinses from 197 HIV positive women were collected, cultured on 
selective media that support the growth of Candida. Thereafter, the isolates 
were analysed quantitatively and qualitatively. A detailed questionnaire was 
administered in order to collect data about oral and personal hygiene and 
habits, HIV treatment and coinfections. CD4 count and HIV viral load were 
performed or obtained from the clinical records. Descriptive statistics was 
applied to determine the prevalence, type and quantities of Candida in the 
study group. Chi squared statistics was used to compare proportions. The t-test 
or the non-parametric equivalent was used for continuous variables. A logistic 
regression model was fitted to determine the risk factors for colonisation. 
Results of this section of study are described in Chapter 3. 
b. To determine the virulence of C. albicans during the study period and the 
influence of quantity and/or virulence of C. albicans on the development 
of oral candidiasis.  
One hundred and seventeen women who carried C. albicans in their oral 
cavity were investigated over a period of 6 months. They were examined at 
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three months interval for the presences of clinical oral candidiasis and their 
CD4 counts were determined. In addition, oral rinse samples were collected, 
cultured on ChromAgar candida plates and Candida were isolated. Adherence 
ability of C. albicans to oral epithelial cells and production of hydrolytic 
enzymes are considered virulence factors in this organism. Therefore, 
quantitative analyses of adherence ability to oral epithelial cells, proteinase 
and phospholipase production by C. albicans were determined. The virulence 
properties of the yeasts isolated at the initial examination and after three 
months and 6 months were investigated and compared. The relationship 
between the quantity of C. albicans and their virulence scores and the 
development of symptoms at each stage was examined using the t-test or a 
non-parametric equivalent and correlation coefficients. Results of this section 
of study are described in Chapter 4.  
c. To examine the occurrence and role of non-C. albicans yeasts in the 
development of  candidiasis. 
Virulence properties of all non-C. albicans Candida isolates were also studied. 
A quantitative analyses of adherence to oral epithelial cells, proteinase and 
phospholipase production were measured. The relationship between the 
virulence score and development of candidiasis was analysed using Mann 
Whitney tests. Results are described in Chapter 4.  
d. To study the antifungal sensitivity of C. albicans isolated from HIV 
positive women. 
The antifungal sensitivity of all the C. albicans isolates (122) to 9 antifungal 
agents was determined using the Sensititre YeastOne® colorimetric 
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microdilution method. Minimum inhibitory concentrations were obtained and 
the results were interpreted using Clinical Laboratory Standard Institute 
revised guidelines. The results were analysed using descriptive statistics. In 
addition, antifungal drug resistant strains were identified.  Results are 
described in Chapter 5.  
e. To determine and compare the genotypes of C. albicans in those colonised 
women at intervals during the follow up period.  
Maintenance and reinfection of the oral cavities with C. albicans strains in 
HIV positive women can only be measured using genotyping. Therefore, the 
ABC genotyping technique and multilocus sequence typing (MLST) 
techniques were used to genotype C. albicans isolated from 17 HIV positive 
women at three and six months follow up intervals. In ABC genotyping, the 
region of the 25S rRNA gene (rDNA) can be divided into 3 types based on the 
size of the DNA fragments. The predominant fragment size is then used to 
type the strain. The product for Genotype A is 450bp, Genotype B 840bp 
while both fragments (450bp and 840bp) are present in Genotype C 
(McCullough et al, 1999). MLST employs the sequencing of some selected 
housekeeper gene fragments (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13 
and ZWF1b) and the identification of polymorphic nucleotide sites. A unique 
Diploid Sequence Type (DST) based on the combination of alleles at different 
loci was used to discriminate between C. albicans strains (Bougnoux et al, 
2003). The genotypes of C. albicans strains were compared to establish the 
status of carriage in these women. Results are described in Chapter 6. 
The findings of the above five studies are summarized in Chapter 7 and the 
raised questions addressed.  
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CHAPTER 3: FACTORS INFLUENCING CARRIAGE OF 
CANDIDA IN THE ORAL CAVITIES OF HIV POSITIVE 
WOMEN 
 
3.1 Introduction 
 
Candida species usually colonise the human oropharyngeal tract and Candida 
albicans occurs most frequently. These yeasts are usually commensals but may act as 
opportunistic pathogens (Cannon et al., 1995). Colonisation does not always lead to 
infection, however, when the host immunity is compromised, the risk of a 
disseminated infection is high (Lott et al., 1999) and candidiasis may develop. Such 
infections are still a major health care challenge (van der Meer et al., 2010). For 
example, Das et al., (2011) reported that the incidence of candidemia was 10.9 
episodes/100 000 bed-days with a crude 30-day mortality of 37% at a UK referral 
centre (Das et al., 2011). 
 
There is a wide variation in the prevalence of yeast colonisation in the mouth. The 
variation depends on the age, location and the immune status of the population 
sampled. For instance, a prevalence of 80% was found in HIV positive children and in 
57.5% of their seronegative siblings (Cerqueira et al., 2010). Similarly, in a previous 
study at Charlotte Maxeke Academic Hospital, Johannesburg, South Africa a 
prevalence of 81.3% was found in HIV positive adults compared with 63% in their 
HIV negative counterparts (Patel et al., 2006). 
 
Higher rates of Candida colonisation are a consistent finding in HIV infection and 
this has a high predictive value for subsequent infection with oropharyngeal 
candidiasis (Vargas and Joly, 2002). With impaired host defence mechanisms, C. 
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albicans assumes a more pathogenic and virulent capacity that can lead to significant 
morbidity (Mercante et al., 2006).  Many factors have been suggested as risk factors 
for oral colonisation; which include diabetes mellitus, head and neck cancer, smoking, 
oral prostheses, extremes of age, race and poor nutritional status. Others are reduced 
salivary flow, use of antibiotics, immunosuppressive states and presence of other 
locally available microflora (Ellepola et al., 2011; Jabra-Rizk et al., 2001; Schelenz et 
al., 2011). In HIV positive patients, the CD4 count, HIV viral load, non availability or 
non usage of Highly Active Antiretroviral Therapy (HAART) and the type of 
antiretroviral medication are possible factors that influence oral colonisation with 
yeasts (Back-Brito et al., 2009; Delgado et al., 2009; Wu et al., 2012). Although Wu 
and colleagues (2012) observed that the initiation of HAART reduced the rate of oral 
colonisation by Candida, Yang et al did not find a reduction in the colonisation of the 
oral cavity with HAART (Yang et al., 2006).  
 
The variation in factors influencing oral colonisation could be attributed to differences 
in study populations, sampling techniques, use and type of antiretroviral therapy and 
other factors. Risk factors may also be peculiar to geographic settings (Cerqueira et 
al., 2010). For example, a study in South Africa described the prevalence of yeast 
carriage in paediatric HIV subjects (Blignaut, 2007) but none have investigated the 
risk factors for colonisation in other age groups. In addition, no study has compared 
the prevalence rates of Candida colonisation in the oral cavity pre and post HAART 
initiation.  
 
This chapter summarises the results of the factors associated with oral colonisation of 
Candida species in a cohort of HIV positive women in South Africa.  
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3.2 Methods and materials 
3.2.1 Study setting, design and subjects 
The study was conducted from January to December 2011 at the HIV clinic at the 
Charlotte Maxeke Academic Hospital, Johannesburg, South Africa. Ethical clearance 
(Certificate no: M10102, appendix 9.1) was obtained from the Human Research 
Ethics Committee of the University of the Witwatersrand, Johannesburg. Confirmed 
HIV positive women willing to participate were enrolled after obtaining written 
consent. A detailed questionnaire (appendix 9.2) was administered to collect data on 
demographics, personal and oral hygiene, HIV treatment, coinfections including oral 
infections, and previous history of oral candidiasis. The most recent CD4 count and 
HIV viral load (within 3 months) were obtained from the clinical records. Where such 
results were not available, blood samples were collected for CD4 counts and viral 
load.  
 
Detailed oral examination was conducted on all participants by trained and 
standardised oral health care personnel supervised by the author who had been trained 
to recognise oral aspects of HIV infections at the University of California, San 
Francisco, USA to screen for oral candidiasis and other HIV related oral conditions. 
The oral hygiene status was measured using the plaque and gingival indices (Loe, 
1967) and the caries status was assessed using the number of decayed, missing and 
filled surfaces (DMFS) as recommended by the World Health Organization (World-
Health-Organization and 1997).  
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3.2.2 Sample collection and laboratory techniques 
A concentrated oral rinse technique (Samaranayake et al., 1986) was used to collect 
samples for analysis before oral examination. Patients were requested to rinse their 
mouth for 60 seconds with 10 millilitre of sterile distilled water and expectorate the 
rinse into a sterile universal container. Oral rinse samples were diluted and 1:10, 
1:100, and 100 µl of the diluted samples were spread on CHROMagar Candida agar 
(CHROMagar, Paris, France) and incubated aerobically at 37°C for 48 hours. The 
number of colonies on the CHROMagar plates was counted and the oral yeast 
carriage rate was expressed as colony forming units per millilitre (cfu/ml) of saliva. 
CHROMagar Candida made it possible to identify Candida spp. using the growth and 
the colour of the yeast colonies (Figure 3.1). Single colonies were subcultured on 
Sabouraud dextrose agar (Oxoid, Hampshire, England) until pure cultures were 
obtained and were further identified.  
 
An API 20C AUX kit (Biomerieux, France) was used to confirm presumptive 
identification of all the Candida isolates. Pure cultures of all yeast positive isolates 
were subcultured on Sabouraud dextrose agar (Oxoid, Hampshire, England) plates 
and suspended in 2ml sterile distilled H2O equivalent to 0.5 McFarland turbidity 
standards. A 100µl aliquot of this preparation was inoculated into the corresponding 
C medium tube provided with the kit. The inoculated C medium was then transferred 
into cupules in a API 20C strip. Each strip was incubated at 30°C for 48-72 hours. 
The strips were examined for the presence of growth. Cupules with turbidity 
significantly greater than the negative control cupule were considered positive.  
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Figure 3.1 CHROMagar Candida plates showing green colour colonies of Candida 
species. [Source; Photographed by the investigator] 
 
3.2.3 Statistical analysis  
Continuous variables that were normally distributed were described using the mean 
and standard deviation, while the non-normal variables were described using the 
median and interquartile range. The t-test was used to compare means in the two 
groups using parametric data while the Mann-Whitney test was applied to non-
parametric data. Categorical variables were compared using Chi-squared statistics or 
the Fisher’s exact test as appropriate. 
 
A multivariable logistic regression model was constructed with Candida colonisation 
as the outcome variable. The best-fit option was used for predictor selection.  Non-
parametric predictors such as CD4 count and viral load were dichotomised and 
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collinear predictors were dropped from the model. The DMFS was skewed but was 
retained as a continuous predictor after normalising with a square root transformation 
as suggested by the ladder of powers (Tukey, 1977). Standard procedures for model 
checking including Hosmer-Lemeshow goodness of fit tests were adopted and 
statistical significance was inferred at p< 0.05. Statistical analysis was performed 
using Stata version 12 (Statacorp, College Station, Texas, USA). 
 
3.3 Results  
 
3.3.1 Socio-demographic factors and oral Candida colonisation of HIV positive 
women  
The results of social factors and Candida colonisation of the oral cavities of HIV 
positive women are shown in Table 3.1. Their ages ranged from 22 years to 69 years 
with a mean of 38 (±8.75) years. Zulu women were in the majority ie 73/199 
(38.62%) out of 189 respondents while Shona were the smallest with one participant 
(0.53%). Most of the women were single, 137/199 (61.19%) of the 198 participants 
and the majority had a high school education 144/198 (72.73%). Most subjects had 
one to two children, 122/197 (61.93%) and the majority (144/196 subjects or 73.47%) 
lived in a household with at least one other member but not more than four people. 
Only 9 out of 198 or 4.55% admitted the regular exchange of utensils with family 
members while eating and only a small fraction were smokers 12/198 (6.06%). 
Colonisation by oral Candida was 59.39% (117/197). 
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Table 3.1 Sociodemographic factors investigated in HIV positive women colonised 
by Candida 
 
Characteristics Results (n=199)* 
Age in years (mean ± SD) 
           range 
38 (±8.75) 
22 - 69 
Tribe – Zulu 
- Sotho 
- Pedi 
- Tswana 
- Xhosa 
- Swathi 
- Venda 
- Tsonga 
- Ndebele 
- Coloured 
- Shona 
    Total  
73(38.62) 
34(17.99) 
6(3.17) 
21(11.11) 
21(11.11) 
8(4.23) 
3(1.59) 
4(2.12) 
13(6.88) 
5(2.65) 
1(0.53) 
189(100.00) 
Marital status –   Married 
- Single 
- Widowed 
- Divorced/Separated 
                      Total 
40(20.2) 
137(61.19) 
11(5.56) 
10(5.05) 
198(100) 
Education      –    None 
- Elementary 
- High School 
- University 
                      Total 
5(2.53) 
21(10.61) 
144(72.73) 
28(14.14) 
198(100) 
Children         –     0 
- 1-2 
-  >2 
                      Total 
18(9.14) 
122(61.93) 
57(28.93) 
197(100) 
Household members – 1-4 
- 5-10 
- >10  
                     Total 
144(73.47) 
51(26.02) 
1(0.35) 
196(100) 
Exchange food during eating – All the time 
                                               - Often 
                                               - Occasionally 
                                               - Never 
                                               Total 
9(4.55) 
5(2.53) 
33(16.67) 
151(76.26) 
198(100) 
Smoke -Yes 
            -No 
             Total 
12(6.06) 
186(93.94) 
198(100) 
Colonised with Candida   - Yes  
              - No 
                                         Total                                               
117(59.39) 
80(40.61) 
197(100) 
*Totals do not add up to 199 in some of the rows due to missing values, 2 women 
completed the questionnaire but did not return for the clinical examination. The total 
for clinical examination and all other results was 197 
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3.3.2 Clinical factors and oral Candida colonisation of HIV positive women  
Clinical factors and oral Candida colonisation of HIV positive women are shown in 
Table 3.2. Oral hairy leukoplakia was the most common oral lesion, found in 27/197 
or 13.71% of the patients. Oral Candida infection was found in 18/197 or 9.14% of 
the subjects. Allergies and hypertension were the most frequently encountered 
systemic diseases in 21.32% (42/197) and 20.81% (41/197) of the patients 
respectively. Active infection with tuberculosis was present in 15.75% (31/197) of the 
subjects while 9.14% (18/197) had one form of cancer whereas diabetes mellitus was 
present in only 4.59% (9/196) of the subjects. Most of the participants 132/197 
(67.01%) brushed their teeth twice daily even though approximately a third 63/197  
(31.98%) had ever visited a dentist. The mean Plaque Index (PI) and Gingival Index 
(GI) for all the subjects were 0.66 (±0.37) and 0.65 (0.42) respectively. The average 
DMFS for all the subjects was 23.12 (±20.93). The colonisation rate with oral 
Candida was 59.39% ie 117 of the 197 respondents carried yeasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
Table 3.2 Clinical factors investigated in HIV positive women  
 
Characteristics Frequency(%) 
Oral lesions –    Candida infection 
- Hairy leukoplakia 
- Kaposi sarcoma 
- Aphthous ulcer 
- NUP* 
- Papilloma 
- Parotid enlargement 
                        
18/197 (9.14) 
27/197 (13.71) 
0/197 (0) 
7/197 (3.55) 
7/195 (3.59) 
3/197 (1.52) 
1/197 (0.51) 
 
 
Other illnesses – Hypertension 
- Heart diseases 
- Asthma 
- Allergies 
- Diabetes Mellitus 
- Cancer 
- Tuberculosis 
                               
Yes No Don’t 
know 
Total 
41(20.81) 155(78.68) 1(0.51) 197(100) 
14(7.11) 182(92.39) 1(0.51) 197(100) 
11(5.58) 185(93.91) 1(0.51) 197(100) 
42(21.32) 155(78.68) 0(0) 197(100) 
9(4.59) 186(94.9) 1(0.51) 196(100) 
18(9.14) 179(90.86) 0(0) 197(100) 
31(15.74) 166(84.26) 0(0) 197(100) 
 
Daily frequency of toothbrushing – 1 
                                                      - 2 
                                                       - 3                            
59(29.95) 
132(67.01) 
6(3.05) 
  
Visit dentist –     Yes 
- No 
63(31.98) 
134(68.02) 
Plaque Index (mean ± SD)  
        range 
0.66(±0.37)  
0-2 
Gingival Index (mean ± SD)  
        range 
0.65(0.42)  
0-2.3 
DMFS(mean ± SD)  
        range 
23.12(20.93) 
0-102 
* Necrotising ulcerative periodontitis 
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3.3.3 HIV treatment, CD4 count and viral load in HIV positive women colonised 
by Candida  
The results of HIV treatment, CD4 counts, viral load and Candida colonisation of oral 
cavities of HIV positive women are shown in Table 3.3. Almost all the participants 
i.e. 186 of 197 (94.42%) were on antiretroviral therapy (ARV) at the time of 
examination. When hospital records were checked, 11/197 (5.98%) of the participants 
had not commenced ARVs.  The prescribed ARV therapy was Highly Active 
Antiretroviral Therapy (HAART). The most common combination was Lamivudine 
(3TC), Tenofovir (TEN) and Efavirenz (EFV). Of the 184 participants with 
documented records of ARV therapy, 101(54.89%) were on this combination whereas 
in 26 participants (14.13%), Nevirapine was substituted for Efavirenz. Approximately 
a quarter of the patients (45/197, 24.32%) had CD4 counts below 200 cells/mm
3
. A 
significant proportion of the patients had no results for the viral load at our initial visit 
because they were not tested routinely at every visit. Of the 125 subjects with data, 17 
(8.63%) had a viral load of more than 1000 copies/ml. 
 
Of the participants who carried yeast, the average count was 254.32 (±485.67), with a 
range of 10 - 3750 cfu/ml. Candida albicans was the most common species isolated ie 
85 (72.65%) of the 117 participants were colonised by this yeast. Other species 
included C. dubliniensis 14 (11.97%), C. tropicalis 7 (5.98%), C. famata 6 (5.13%) 
and C. glabrata 2 (1.71%). C. parapsilosis, C. krusei and Saccharomyces cerevisiae 
were each found in 1 participant (0.85%).   
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Table 3.3 Clinical factors and laboratory investigations of HIV positive women 
colonised by Candida 
Characteristics Frequency(%) 
Patients on ARV – Yes 
- No   
Total                  
186(94.42) 
11(5.58) 
197(100) 
Time on ARV –       0 months 
                                 <12 months 
                                 12-24 months 
                                  >24 months 
                                  Total 
6(3.14) 
46(24.08) 
42(21.99) 
97(50.79) 
191(100) 
Current ARV treatment –  
ARV naïve 
3TC+TEN+EFV                                            
3TC+TEN+Aluvia                                            
3TC+TEN+NVP                                           
3TC+d4t+EFV    
3TC+AZT+Aluvia  
3TC+TEN+AZT                                                                                                                      
TEN+AZT+Aluvia                                          
AZT+EFV+TEN 
3TC+d4t+Aluvia 
DDI+AZT+Aluvia                                          
EFV+TEN+Aluvia 
AZT+d4T+EFV 
 Total     
 
11(5.98) 
101(54.89) 
15(8.15) 
26(14.13) 
12(6.52) 
4(2.17) 
3(1.63)
4(2.17) 
3(1.63) 
2(1.09) 
1(0.54) 
1(0.54) 
1(0.54) 
184(100) 
CD4 count    - <100 
  (cells/mm
3
) - 100-199 
                      - 200-400 
                      - >400 
                      - Not available 
                       Total 
16(8.65) 
29(15.68) 
59(31.89) 
81(43.78) 
12(6.09) 
197(100) 
Viral load   - 0-99 
(copies/ml) - 100-1000 
                   -   >1000 
                      Not available  
                      Total 
96(48.73) 
12(6.09) 
17(8.63) 
72(36.55) 
197(100) 
Candida count (n=117)– Mean ± SD 
         (cfu/ml)                - Range 
254.32(±485.67) 
10-3750 
No. of Candida species isolated (n=117) 
                      -     C. albicans          
- C. glabrata  
- C. tropicalis 
- C. dubliniensis 
- C. parapsilosis 
- C. krusei 
- C. famata 
- Sacharromyces cerevisiae 
 
85(72.65) 
2(1.71) 
7(5.98) 
14(11.97) 
1(0.85) 
1(0.85) 
6(5.13) 
1(0.85) 
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Table 3.4 Demographic, clinical and other characteristics of HIV positive women 
with and without Candida colonisation in the oral cavity 
Characteristic All  
N (%) 
197(100) 
Colonised 
N(%) 117(59.4) 
Not Colonised 
N(%) 80 (41.6) 
p value 
 
Mean age in years 
(SD) 
 
38.3(8.4) 
 
37.9(8.1) 
 
39.1(9.2) 
 
0.45
 
 
Level of education     
        None  3(60.0) 2(40.0)  
        Elementary  10(47.6) 11(52.4)  
        High School  86(59.7) 58(40.3)  
        University  18(66.7) 9(33.3) 0.62
 
 
Smoking     
        Yes  10(83.3) 2(16.7)  
         No  107(57.8) 78(42.2) 0.13
 
 
Concurrent/Recent TB 
infection 
  
 
  
        Present  24(77.4) 7(22.6)  
        Absent  93(56) 73(44) 0.03*
 
 
Diabetes Mellitus     
        Present  3 (30) 7(70)  
        Absent  114(61.3) 72(38.7 0.051
 
 
Antiretroviral Therapy 
(ARV) 
    
        Started  106(57) 80(43.0)  
        Not started  11(100) 0(0) 0.003*
 
 
 
 
Median Time since 
ARV in months (IQR, 
min, max) 
  
 
 
27.5(54, 0, 125) 
 
 
 
36(53,0,133) 
 
 
 
0.39
 
 
Use of Protease 
inhibitors 
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         Yes   17(63) 10(37)  
         No  93(59.6) 63(40.4) 0.742
 
 
Wearing of dentures      
         Yes  8(100) 0(0)  
         No  109(57.7) 80(42.3) 0.022*
 
 
Median CD4 count in 
cell/mm3 (IQR, min, 
max) 
370(364, 7, 
1200) 
 346.5 (311, 7,    
1200) 
418(357, 40, 1172)  
0.024*
 
 
Median viral load in 
copies/mm3(IQR, 
min, max) 
 
25(50, 5, 
315002) 
 
40(105, 5, 
315002) 
 
5(35, 5, 14411) 
 
0.19
 
 
Median Plaque 
index(IQR) 
0.6(0.6)     0.60(0.59)     0.60(0.6) 0.73
 
 
Mean Gingival 
index(IQR) 
0.58(0.5)     0.60(0.3)    0.60(0.2) 0.50
 
 
Median DMFS (IQR, 
min, max) 
20(27,0,102) 19(27, 0,102) 16 (24,0,93) 0.07
 
 
Dry Mouth     
        Present  30(51.7) 28(48.3)  
        Absent  86(61.9) 53(38.1) 0.187
 
 
IQR- Interquartile range. 
 
Table 3.4 compares Candida colonised participants with non colonised. The non 
colonised were older, mean age of 39.1 (±9.2) years compared to 37.9 (±8.1) in the 
colonised group. This difference was however not statistically significant. Both 
groups were also comparable with regards to the level of education and smoking 
status. However, more participants with concurrent tuberculosis (TB) were colonised 
by Candida (77.4%). This difference was significant at p=0.03. There was no 
statistically significant relationship between colonisation status and diabetes mellitus. 
All subjects who were not on ARV were colonised by yeast and this was significant at 
p=0.003.  
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The time of commencement of ARV was slightly longer in the non colonised group 
but this difference was not statistically significantly. The use of protease inhibitor 
ARV drugs had no effect. However, all the participants wearing prosthesis were 
colonised by yeasts and this was highly significant, p=0.022. The median CD4 count 
was lower in the colonised (346.5 cells/ mm
3
, IQR 311) than the non colonised group 
(418 cells/ mm
3
, IQR 357). This was significant at p=0.024. The viral load did not 
differ significantly in the two groups, nor did the plaque and gingival indices. The 
mean DMFS was higher in the colonised group 19 (IQR 27) compared to 16 (IQR 24) 
in the non colonised group. However this was not significantly different (p=0.07). 
The groups were almost equally matched regarding to the presence of a dry mouth i.e. 
51.7% in the colonised and 48.3% in the non colonised group.  
 
Table 3.5 Risk factors for oral colonisation with Candida in HIV positive women 
 Odds Ratio 95%CI P value 
Age (in years) 0.95 0.90, 0.99 0.034* 
Use of Protease inhibitors 0.78 0.25, 2.32 0.64 
DMFS (Decayed, Missing, Filled 
surfaces) 
1.30 1.07, 1.60 0.019* 
Low CD4 count- 
<200cells/mm
3
(reference CD4 count 
>200cells/mm
3
) 
 
1.45 
 
0.46, 4.63 
 
0.53 
High Viral load ->10,000copies/mm
3 
(reference CD4 count 
<10,000copies/mm
3
) 
 
5.87 
 
0.62, 55.57 
 
0.12 
Poor oral hygiene (plaque index >1) 0.75 0.30, 1.88 0.54 
Diabetes present 5.52 1.68, 18.12 0.005* 
Tuberculosis present 0.34 0.11, 1.02 0.06 
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Multivariate logistic regression model was fitted to determine the risk factors for 
colonisation (Table 3.5). Younger age, odds ratio (OR) = 0.95 (95%CI=0.90,0.99; 
p=0.034), the dental caries status (DMFS) OR=1.30 (95%CI=1.07, 1.60; p=0.019) 
and diabetes mellitus OR=5.52 (95%CI=1.68, 18.12; p=0.005) were associated with 
colonisation. The model adjusted for CD4 count, viral load, use of protease inhibitors, 
oral hygiene status and the presence of tuberculosis. The dental caries status, which 
showed borderline association in the bivariate analysis showed significance with 
logistic regression. CD4 count and tuberculosis were significant in the bivariate 
analysis but were not significant after adjusting for other covariates in the regression 
output. Although age appeared to be significant, the upper confidence interval was 
close to 1 and was therefore disregarded.  
 
Table 3.6 Carrier rate, quantity and variety of Candida species in HIV positive 
women 
             N=117                       
 
Carrier rate (%) 
 
59.4 
 
 
 
Count prevalence (%) in cfu/ml   0             1-999        1,000-10,000    >10,000 
        40.6    56.3       3.1        0  
Species prevalence (%)    
      C. albicans 72.7  
      C. dubliniensis 12  
      C. glabrata      1.7  
      C. parapsilosis 0.85  
      C. tropicalis 5.13  
      S. cerevisiae 0.85  
      C. famata 5.13  
      C. krusei 0.85  
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Table 3.7 Multiple Candida carriage in HIV positive women 
No. of Candida species Carriage (%) 
n=117 
1 114 (97.4) 
2 3 (2.6) 
3 0 
 
When the yeast count was broken down into categories, the majority of patients were 
in the lower count ranges. Only 3.1% had counts above 1000 cfu/ml while there was 
no participant with more than 10000 cfu/ml. The predominant species isolated was C. 
albicans followed by C. dubliniensis, C. tropicalis and C. famata. The yeast count 
was negatively correlated with the CD4 count and this was significant, p=0.006 
(Figure 3.1). Only 3 participants (2.6%) of the 117 colonised women were carrying 
more than one species of yeast (Table 3.7).  
 
Figure 3.2 Correlation of CD4 (cells/mm
3
) count with C. albicans count 
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3.4 Discussion 
The innate immune system and the acquired response in a colonised healthy host help 
to keep Candida in check. The innate system comprises the polymorphonuclear 
leucocytes, macrophages and antimicrobial peptides while the acquired response is 
represented by increased circulating/mucosal IgG and mucosal IgA antibodies (Fidel, 
2006). However, very early infection with HIV influences colonisation with oral 
Candida and the development of opportunistic candidiasis (Owotade et al., 2008). 
This is a consequence of defective Th1-type CD4 T cells and changes in saliva 
composition and function (Back-Brito et al., 2009). 
 
3.4.1 Social and demographic factors 
The study focused on women due to the high prevalence of HIV infection in women. 
More than 60% of HIV positive individuals in Sub-Saharan Africa are women (Sia et 
al., 2013). In addition, women also have a higher risk of acquiring HIV infection in a 
heterosexual relationship due to anatomical, social and economic factors(Quinn and 
Overbaugh, 2005). The HIV gender imbalance in South Africa may lead to males 
aged between 15 to 44 years outnumbering their female counterparts by the year 2020 
(US-Census-Bureau, 2004).  
 
The colonised group was younger in our study population. Although increasing age is 
known to predispose to colonization (Schelenz et al., 2011) the age distribution may 
be due to a selection bias with younger subjects more willing to participate. Most of 
our subjects i.e. 128/197, 65.16%, colonised or not colonised were below the age of 
40 years. This is consistent with the global HIV epidemic that affects the younger age 
group. This is particularly noticeable in South Africa where the adult population is 
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declining and the elderly population is increasing. This decline in the adult age group 
is due to AIDS mortality and children born with HIV not attaining adulthood 
(Oramasionwu et al., 2011). The social implication of this is that elderly women with 
limited resources are compelled to cater for younger non productive adults who are 
too ill to work or have died (Schatz, 2007).  
 
It may be advantageous that most of our participants 144/198 (72.73%) had high 
school education. This may be because adolescents who are enrolled in schools are 
less likely to have multiple sexual partners than uneducated adolescents.  In addition, 
education also influences use of condom and other preventive measures because they 
are aware of the biology of HIV transmission (Zuilkowski and Jukes, 2012). Previous 
studies in South Africa show conflicting correlations between education level and 
sexual behavior. Some studies did not find a relationship and surmise that other 
factors may be more influential than just education (Dinkelman et al., 2007). 
Obviously, the relationship between education and sexual behavior needs further 
exploration.   
 
We explored other factors, for example the number of children, household size and 
the frequency of exchanging food or eating utensils. The aim was to assess the 
influence of social status and habits that may influence transmission of yeast from 
colonised to uncolonised individuals. The majority of our subjects i.e. 90.8% had 
children. Vertical and horizontal transmission of Candida occurs from colonised 
mothers to their children. This increases the risk of invasive Candida infection in 
immunocompromised and low birth weight children (Ali et al., 2012; Bliss et al., 
2008). Close social contact may also aid transmission of azole resistant strains of 
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Candida among family members (Muller et al., 1999). This is important considering 
that 144(73.47%) of our subjects lived with at least one other person. Although very 
few 9 (4.55%) admitted routine exchange of food or utensils when eating, the 
possibility of yeast transmission cannot be excluded. 
 
3.4.2 Clinical factors 
Oral lesions in HIV infection are associated with depressed immunity especially 
reduced CD4 counts and progression of the disease, which may indicate poor 
prognosis (Saini, 2011).  Oral Candida infection and oral hairy leukoplakia are the 
most common oral lesions associated with HIV infection. They were the most 
common lesions in our volunteers constituting 9.14% and 13.71% respectively. 
Although a higher prevalence of oral hairy leukoplakia was found in our study, oral 
Candida infection is still the most common oral manifestation in HIV infection. Both 
lesions are strongly associated with HIV infection and form part of the criteria to 
classify HIV disease by the Center for Disease Control and Prevention (Saini, 2011).  
With the introduction of ARV therapy, oral manifestations have declined although 
new challenges are also emerging. Oral lesions are still seen in patients with HIV 
infection while oropharyngeal candidiasis is the most common lesion. However the 
malignant potential of the oral human papilloma virus infection is gaining increasing 
attention recently (Patton et al., 2013). 
Concurrent tuberculosis (TB) was present in 15.74% of our subjects. More colonised 
subjects 24/31 (77.4%) had concurrent TB infection compared to the non colonised 
subjects (7/31) and this was significant, p=0.03 (Tables 3.2 and 3.4). Concurrent TB 
in HIV infection worsens the prognosis for both diseases and increases mortality 
because TB compromises the immune status.  In addition, previous TB infection or 
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anti-TB therapy may predispose to the acquisition of fluconazole resistant strains of 
Candida (Masia Canuto et al., 2000). South Africa has the third largest TB burden 
globally and an increasing annual rate of TB transmission. The adoption of new and 
targeted TB control strategies has been advocated (Wood et al., 2011). These 
strategies may mitigate the possible complications that could follow oral Candida 
colonisation in immune compromised subjects who have two potentially fatal 
conditions. 
 
There were fewer diabetics in our subjects 9/196 (4.59%) than those with TB. 
However, in the multivariate analysis, diabetes mellitus (DM) was a strong risk factor 
for oral colonisation with Candida with an odds ratio of 5.52 (95%CI 1.68, 18.12). 
This is consistent with the findings of other authors who have established a link 
between DM and the risk of oral Candida colonisation (Goncalves et al., 2006). The 
high level of glucose in the tissues of diabetics and impaired cellular mediated 
immunity are contributing factors for yeast colonisation (Tapper-Jones et al., 1981; 
van der Meer et al., 2010). The low prevalence of diabetics in our study requires 
cautious interpretation and needs to be further investigated. 
 
Hypertension was the predominant systemic illness in our study group in 41/197 
(20.81%), while 14 subjects (7.11%) had heart disease. Cardiovascular diseases may 
not have any direct bearing on oral Candida colonisation; however, it may influence 
the management of HIV disease. Some ARVs selectively alter the lipid profile; 
however, the long-term effect on the cardiovascular status is still controversial. ARVs 
such as abacavir, didanosine, lopinavir/ritonavir and indinavir have been associated 
with the development of acute myocardial infarction (Perez-Camacho et al., 2009). 
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The use of ARVs with more favourable lipid profile has been recommended in HIV 
infection. However cardiovascular disease prevention and management programmes 
should be instituted similar to those in non-HIV positive individuals (Masia-Canuto et 
al., 2006). In the long term, the use of ARVs is of benefit because HIV worsens 
hypertensive states. Therefore, the long-term benefit of ARV use outweighs the 
marginal risk of myocardial infarction.      
 
The oral hygiene status (measured by the plaque and gingival indices in Tables 3.4 
and 3.5) and cigarette smoking did not influence the risk of colonisation. This was 
similar to the observations of other investigators (Darwazeh et al., 2010a; Darwazeh 
et al., 2010b). However, a very strong association with the dental caries was observed 
even after adjusting for other predictors with an odds ratio (OR) of 1.30 (95%CI 1.07, 
1.60). Carious lesions are known reservoirs for yeasts and have been established as 
risk factors in oral colonisation (Cerqueira et al., 2010; Jacob et al., 1998). Similarly, 
oral prostheses are reservoirs for oral colonisation with yeasts, and our findings 
confirm this.  All the denture wearers were yeast positive and this was significant at 
p=0.022 (Table 3.4). Oral prostheses provide a means of adherence for Candida while 
precluding the mucosal area below the prosthesis from the protective effects of saliva 
(Zadik et al., 2010).  
 
Although there was no relationship between oral colonisation and a dry mouth, it is 
known that a dry mouth combines with other factors to predispose to colonisation. 
Malignant conditions i.e. cancer were present in 18 of our subjects (9.14%). The 
management of such conditions with cytotoxic chemotherapy or radiotherapy 
compromise the cellular mediated host immunity thereby reducing the protective 
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effects of saliva from hyposalivation. With increasing age, saliva production is 
reduced. In addition, there is a tendency to wear prostheses, be malnourished and 
have poor oral hygiene (Schelenz et al., 2011). These conditions may lead to yeast 
overgrowth and infection. 
 
3.4.3 Antiretroviral therapy 
Antiretroviral therapy was introduced in South Africa between 2004 to 2009. To date, 
only half of the HIV infected population has access to therapy (Webster et al., 2012). 
In 2006 when oral colonisation with Candida was investigated in our study 
population, ARV was not available. The prevalence of oral colonisation and the yeast 
count were much higher than in the present study (Patel et al., 2006). In effect, the use 
of ARV has reduced opportunistic oral infections (Yang et al., 2006). Therefore our 
observation that participants who were yet to commence ARVs were all yeast positive 
(p=0.003, Table 3.4) is consistent with other studies (Cerqueira et al., 2010). 
However, prolonged HAART therapy may be more beneficial in reducing 
opportunistic yeast infections rather than yeast colonisation as suggested by a 
longitudinal study (Chen et al., 2006). This study showed that ARV in the form of 
HAART has reduced the colonisation rate and yeast counts over time (Patel et al., 
2006). Apart from being prone to yeast infection, delay in initiating ARV has been 
linked with increasing mortality. Strategies advocated to reduce the delay in initiating 
treatment include decentralising services, promptly initiating antiretroviral therapy 
counseling, tracing patients who default appointments while protecting patient 
confidentiality. Other measures are reducing user fees, and providing point-of-care 
tests for CD4 cell counts and TB diagnosis (Peterson et al., 2012). 
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Researchers have postulated that the protease inhibitor group of antiretroviral drugs 
inhibit Candida virulence by neutralising the secretory proteinase enzyme production 
(Migliorati et al., 2004; Perezous et al., 2005). Although 14.8% of our subjects were 
on lopinavir/ritonavir combination (protease inhibitors), they did not affect yeast 
colonisation (Table 3.5). This inability of protease inhibitors to influence yeast 
colonisation was corroborated by other studies (Delgado et al., 2009; Wu et al., 2012). 
 
3.4.4 Laboratory investigations 
The median CD4 count was lower in the colonised group. This difference was 
significant usinmg bivariate analysis, p=0.024 (Table 3.4). The difference did not 
attain statistical significance with regression analysis after adjusting for other 
variables. This may be due to confounding by other variables or residual confounding 
in the CD4 count as this was dichotomized in the regression analysis. Similarly, the 
median viral load was higher in the colonised group. This was not statistically 
significant using bivariate or multivariate logistic regression. The effect of these 
variables on oral colonisation has been controversial. Some studies observed a 
relationship between CD4 count <200 cells/mm
3
 and oral colonisation (Delgado et al., 
2009; Ohmit et al., 2003; Wu et al., 2012) while others found no relationship 
(Cerqueira et al., 2010). Delgado and colleagues (2009) conducted their study in a 
population similar to ours i.e. a cohort of HIV positive individuals who were already 
on ARVs. The association of oral yeast colonisation with CD4 count lower than 200 
cells/mm
3
 was quite strong in their study, p=0.003. This association was obtained 
from a bivariate analysis similar to our finding. Unlike the present study, they did not 
conduct a logistic regression analysis to adjust for other confounding variables.  
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A high viral load was associated with colonisation in several reports (Back-Brito et 
al., 2009; Delgado et al., 2009; Tappuni and Fleming, 2001). In contrast, other studies 
did not find any association (Cerqueira et al., 2010; Sanchez-Vargas et al., 2005a). 
Our observations regarding the CD4 count and viral load may be related to the 
relatively consistent recovery of the immune system and reduced viral burden in our 
study population. The average CD4 count and viral load for all the subjects and the 
period since they have been on ARVs indicate a decent immune recovery. The 
median CD4 count of 340 cells/mm
3 
(IQR 364) coupled with a median viral load of 
25 copies/ml (IQR 50) indicates a relatively acceptable average immunological and 
virological profile. However, this observation is mindful that a small fraction of our 
volunteers had very low CD4 count and high viral load. In the colonised group, the 
absolute yeast count was negatively correlated with the CD4 count (p=0.006, Figure 
3.2) which emphasises underscores the importance of the immune system in keeping 
Candida organisms under control. 
 
3.4.5 Candida species isolated 
Many studies have reported the dominance of C. albicans in oral samples irrespective 
of the HIV status of the individual (Back-Brito et al., 2009; Cannon and Chaffin, 
2001; Lott et al., 1999). We found that C. albicans had a prevalence of 72.65% which 
is similar to 78.6% in a study conducted previously in our centre (Patel et al., 2006). 
Non-C. albicans  Candida constituted the remaining 21.4% (Patel et al., 2006). 
However, Delgado and colleagues (2009) found a higher C. albicans prevalence of 
85% (Delgado et al., 2009).  The prevalence of non-C. albicans has been on the 
increase with the HIV pandemic (Costa et al., 2006). A recent study in Nigeria 
recorded a prevalence of 55% non-C. albicans Candida (Nweze and Ogbonnaya, 
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2011).  Non-C. albicans Candida has been implicated in severe oral and pharyngeal 
infections and may be resistant to azole antifungals in the HIV positive 
population(Costa et al., 2006). Several authors have emphasised the importance of 
documenting the prevalent species of yeast and their antifungal sensitivity patterns in 
order to give appropriate therapy when infections break out (Nweze and Ogbonnaya, 
2011). 
 
3.5 Conclusions 
In conclusion, the carrier rate of Candida species was 59.4% in this study population. 
C. albicans was the predominant species isolated and Candida counts were higher in 
patients with low CD4 counts.  Non-implementation of ARVs, wearing of oral 
prostheses, presence of caries, diabetes mellitus and TB infection increased the risk of 
oral Candida colonisation. Therefore, adequate oral care during HIV infection and 
prompt commencement of antiretroviral therapy should be emphasised to reduce the 
risk of Candida carriage and candidiasis. Efforts should also be made to increase the 
availability of HIV medication in Sub Saharan Africa where most of the HIV infected 
population resides. 
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CHAPTER 4: PATHOGENICITY OF C. ALBICANS AND NON-
ALBICANS CANDIDA ISOLATED FROM THE ORAL CAVITIES 
OF HIV POSITIVE PATIENTS 
 
4.1 Introduction 
C. albicans transforms from a harmless commensal to pathogenic yeast due to the 
virulence factors it is capable of expressing, particularly in an immunocompromised 
host. These virulence factors are many and variably expressed. They include the 
ability to switch phenotypes and forms (yeasts to hyphae), the formation of biofilms 
and adherence. As a result, they adhere to and invade epithelial cells and other 
surfaces through the expression of adhesins and invasins (Mayer et al., 2013). The 
ability to haemolyse red blood cells and elaborate hydrolytic enzymes are also 
associated with virulence. The hydrolytic enzymes, proteinases and phospholipases 
assist the yeast to adhere, penetrate and invade host tissues (Mane et al., 2011).  These 
hydrolytic enzymes also play an important role in the acquisition of nutrients from the 
extracellular environment (Naglik et al., 2003). In a study of C. albicans virulence 
isolated from HIV positive subjects with oral Candida infection, 89.7% expressed 
proteinase and 59.0% phospholipase enzymes (Mane et al., 2011). Apart from these 
virulence factors, the “fitness” attributes also contribute to the pathogenicity of C. 
albicans. These include the ability to acquire nutrition and adapt to changes in the pH 
of the environment, metabolic flexibility and being able to respond to stress (Mayer et 
al., 2013).  
 
Unlike C. albicans, there is less information on the virulence characteristics of non-
albicans Candida.  However, studying the virulence attributes of non-albicans 
Candida is crucial as they are increasingly isolated in candidiasis, candidemia and 
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invasive candidiasis (Silva et al., 2011). Non-albicans Candida with pathogenic 
characteristics investigated recently includes C. glabrata, C. tropicalis and C. 
parapsilosis. Cell surface hydrophobicity, a virulence factor associated with 
adherence was observed to be similar in C. glabrata and C. albicans. Hydrophobicity 
fluctuates with growth conditions in C. albicans whereas C. glabrata appears to be 
stable. This may explain why C. glabrata adheres more readily to silicone and acrylic 
surfaces than C. albicans and other non-albicans Candida species (Hazen et al., 1986; 
Luo and Samaranayake, 2002; Silva et al., 2010).  
 
In a recent study, Negri et al (2010b) found that C. tropicalis adhered more to the 
epithelium than to silicone. In addition, all strains produced biofilms and possessed 
haemolytic activity. Only 2 isolates were protease positive whereas one produced 
phospholipase (Negri et al., 2010b). Generally, the few studies on the virulence 
characteristics of non-albicans Candida indicate that they are able to produce 
hydrolytic enzymes though at a much reduced rate compared to C. albicans (Silva et 
al., 2011). Apart from hydrolytic enzyme production, other factors may be responsible 
for their virulence as virulence and pathogenicity appear to be a complex 
phenomenon (Cottier and Pavelka, 2012). 
 
At present, responsible for the expression of virulence factors are not fully 
comprehended. This is owing to the complex and dynamic nature of the interaction 
between the host and yeasts. The signalling pathways initiated by the host-yeast 
interaction may either lead to yeast clearance or increase the elaboration of virulence 
factors. Commensal bacteria may either enhance host immunity or the expression of 
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virulence factors by yeasts. On their own, yeasts are also capable of undergoing 
genomic alterations which can make them more virulent (Cottier and Pavelka, 2012).  
 
Studies that evaluated the virulence characteristics often yield different and 
sometimes conflicting results. This is due to the influence of many factors on the 
expression of virulence by Candida. Research has investigated a variety of subjects 
including healthy carriers, HIV positive individuals, cancer patients undergoing 
chemotherapy, denture wearers, those in Intensive Care Units and adults or neonates. 
In addition, samples have been taken from different sites including the mouth, vagina, 
rectum, bronchial secretions and blood. In addition, some studies evaluated C. 
albicans, others investigated all the Candida species while some restricted their 
investigation to non-albicans Candida species as a group or as individual non-albicans 
Candida species. For practical reasons, studies on the virulence of Candida species 
assessed selected virulence attributes. While some studied biofilm formation, others 
assessed hydrolytic enzyme production with or without biofilm formation and 
haemolytic properties of the yeasts (Gokce et al., 2007; Lyon and de Resende, 2007; 
Mane et al., 2010; Oksuz et al., 2007; Sacristan et al., 2011; Taguti Irie et al., 2006). 
 
In addition to established virulence characteristics of Candida species, fresh insights 
have been gained about other novel virulence capacities, for example,  the production 
of heat shock proteins (Hsps). Yeasts respond to stressful conditions such as oxidative 
stress, high temperature and starvation by elaborating heat shock proteins that prevent 
protein unfolding and aggregation that can lead to their death. An example is Hsp90, 
which is associated with virulence and drug resistance in C. albicans (Singh et al., 
2009). 
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This increase in knowledge makes it imperative to study the expression of virulence 
factors of Candida species and the relationship of those factors to clinical infection. 
Furthermore, the roles of these factors that may be peculiar to yeasts in the 
environment need further investigation. The present chapter investigated the virulence 
properties i.e. proteinase and phospholipase production, and adherence to oral 
epithelial cells of C. albicans and non-C. albicans Candida isolates obtained from 
HIV positive women. Patients with oral candidiasis and asymptomatic carriers were 
followed up for a period of six months. In addition, relationship between virulence 
factors, Candida counts and CD4 counts were investigated. 
 
4.2 Methods and materials 
4.2.1 Sample collection 
The study was undertaken at the HIV clinic at the Charlotte Maxeke Johannesburg 
Academic Hospital, Johannesburg, South Africa. The subjects were 197 HIV-positive 
women who agreed to participate (also described in Chapter 3, section 3.2.1) after 
signing a written consent form (Figure 4.1). Ethical clearance was obtained from the 
Human Research Ethics Committee of the University of the Witwatersrand, 
Johannesburg. Data on HIV treatment, previous history of oral candidiasis and the 
most recent CD4 counts within the past 3 months were obtained from the clinical 
records of the patients. Trained oral healthcare personnel screened patients for the 
presence of oral candidiasis. If present the lesions were categorized using the location 
and the clinical type as described (Samaranayake et al., 2009). Oral rinse samples 
were collected from 117 patients who were colonised with Candida species (see 
chapter 3). Thereafter, they were asked to return after 3 and 6 months and further 
samples were obtained and processed. 
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The samples were transferred to the laboratory in sputum jars and 100 μl of rinse 
sample were inoculated onto CHROMagar Candida plates (CHROMagar Paris, 
France) and incubated at 37 °C for 48 hours. When growth was observed, colonies 
were counted and subcultured on Sabouraud dextrose agar (Oxoid, Hampshire, 
England) for 48 hours. 
Figure 4.1 Study population and design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV positive 
women (197) 
Clinical oral 
Candidiasis (22) 
No Symptoms of oral 
Candidiasis (carriers) 
(95) 
117 asked to return for 
a follow up visit after 3 
and 6 months  
48 came for only one 
visit, 23 twice and 17 
for all three visits 
Factors studied: 
-Candida species  
-Virulence & counts of Candida 
species  
-CD4 counts 
 
Factors studied: 
-Virulence of C. albicans during 
the follow up periods 
-CD4 counts  
17 came for follow up 
visits after 3 and 6 
months and carried C. 
albicans at both visits  
Colonised with 
Candida (117) 
* 
*: Groups compared 
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4.2.2 Yeast identification 
Cultures were identified using the API 20 C AUX system ® (bioMérieux). Yeast cells 
were inoculated into 2 mls of distilled water and concentrated to 2 McFarland of 
turbidity. 100 μl of the suspension was transferred to the C medium supplied with the 
API 20 C AUX and gently homogenised with the pipette to avoid the formation of 
bubbles. The homogenised mix was then transferred to the cupules in the test strip. 
Care was taken not to overfill or underfill the cupules. The test strips were then placed 
in a tray of appropriate size that had been lined with a moist paper towel. The tray 
was covered and incubated at 30°C for 48 hours. The yeast identification was carried 
out based on the presence of turbidity in the cupules compared with the first control 
cupule as described by the manufacturers. A seven-digit numerical profile based on 
the positive reactions was then uploaded to the supplier’s website for definitive yeast 
identification. 
 
4.2.3 Adherence assay 
An adherence assay was performed using a technique previously described 
(Ghannoum et al., 1986) with modifications. Candida isolates from the subjects were 
cultured in Sabouraud dextrose broth (Oxoid, Hampshire, England) and incubated at 
37°C for 2 hours while shaking at 60rpm. Yeast cells were harvested by 
centrifugation, washed three times with sterile distilled water and resuspended into 2 
mls sterile distilled water and adjusted to obtain 10
7
 cells/ml. Buccal epithelial cells 
(BEC) were harvested from healthy non-Candida carriers using sterile cotton buds by 
rubbing the inner lining of the cheeks firmly thereafter rinsing with 4mls of sterile 
distilled water in blue capped tubes until it was sufficiently turbid. The BEC were 
washed twice and reconstituted in 2 mls sterile distilled water.  
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The BEC and the Candida cells were then mixed and incubated for 3 hours at 37°C 
while shaking. The mixture was then filtered through a 20μm nylon filter to remove 
non-adherent Candida cells. The epithelial cells that remained on the filter were 
harvested, washed twice with distilled water and suspended in distilled water. A drop 
of these cells was mounted on a glass slide, air dried, heat fixed and stained with 
crystal violet for 1 minute. The number of adherent yeast cells per 100 BEC was 
counted and reported as the adherence assay. 
 
4.2.4 Proteinase assay  
The method described by Aoki and colleagues for assessing proteinase production 
was used with modifications (Aoki et al., 1990). The method employs bovine serum 
albumin agar plates. Candida strains were cultured on fresh Sabouraud dextrose agar 
(Oxoid, Hampshire, England) for 48 hours. An inoculum of yeast cells was suspended 
in sterile distilled water and ten microlitres of Candida culture suspension with a 
negative control were then placed on paper discs which had been adequately spaced 
on the bovine serum albumin agar plates. C. albicans ATCC 90028 was used as 
positive control. The inoculated plates were incubated at 37° C for 14 days. After 
incubation, the colony diameters were measured before staining with Coomassie 
brilliant blue. The plates were flooded with the staining solution and incubated for 20 
minutes. The staining solution was discarded and a destaining solution was applied 
for the same period of time. Finally the plates were rinsed with water and allowed to 
dry. The clear zones were measured and the proteinase activity (Pr) expressed as the 
ratio of the colony diameter and the clear zone. 
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4.2.5 Phospholipase assay 
The phospholipase assay was undertaken using the egg yolk technique (Ghannoum, 
2000; Samaranayake et al., 2005). Candida strains were cultured on fresh Sabouraud 
dextrose agar (Oxoid, Hampshire, England) for 48 hours. An inoculum of yeast cells 
was made in sterile distilled water and ten microlitres of the culture suspension and a 
negative control with no yeast cells were suspended on paper discs that were placed 
adequately apart on the egg yolk medium. C. albicans ATCC 90028 was used as 
positive control. The plates were incubated for 4 days at 37°C and the colony 
diameter and precipitation zone around the discs were measured. Phospholipase 
activity (designated as Pz) was determined using the ratio of the diameter of the 
colony to the diameter of the colony plus the surrounding precipitation zone.  
 
4.2.6 Statistical analysis   
Variables that were analysed using proportions, mean, median and appropriate 
measures of variability included Candida counts, virulence factors and CD4 counts. 
They were significantly skewed and therefore compared in patients with and without 
oral candidiasis using non parametric tests (Mann-Whitney two-sample statistic). A 
non-parametric correlation (Spearman correlation) was used to explore the 
relationship between the virulence factors and the CD4 count. Statistical significance 
was inferred at p < 0.05 
 
4.3 Results  
4.3.1 Demography and oral candidiasis 
One hundred and ninety seven women were screened with a mean age of 38.3±8.4 
years, 117 (59.4%) were colonised with Candida species.  At the first visit, oral 
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candidiasis was present in 15 (12.8%) of those colonised, 10 (66.7%) were cases of 
pseudomembranous candidiasis while erythematous type and angular cheilitis 
accounted for 4 cases (26.7%) and one case (6.7%) respectively. At the second visit, 
the 3 who were previously infected still had persistent infection whereas one had 
persistent infection at the third visit. The total cases of oral candidiasis were 19 for all 
visits.  
 
4.3.2 Proteinase and phospholipase production and adherence to oral epithelial 
cells assay 
One hundred and ninety seven HIV positive women were screened for the Candida 
carriage. Only 117 women were colonised with Candida species in their oral cavity at 
their first visit. Fifty four of these women were asked to come back for follow up 
visits after 3 and 6 months. Forty eight women came only once and 23 twice during 
the 6 months study period. Only 17 patients came for all three visits and carried C. 
albicans in their oral cavity at each visit (Figure 4.1). If the remaining women came 
more than once, they carried non albicans Candida. The results of the virulence 
factors produced by these C. albicans isolates are shown in Table 4.1. 
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Table 4.1 Production of proteinase, phospholipase and adherence to oral epithelial 
cells by C. albicans isolated from HIV positive women over a six month period 
  
Adherence  
(Adherent Candida count/ 100 
epithelia cells) 
Proteinase (Pr) 
(Colony diameter/ 
precipitation diameter) 
Phospholipase (Pz) 
(Colony diameter/ 
precipitation diameter) 
Study 
ID 
0 
Baseline 
3 
months 
6 
months 
0  
Baseline 
3 
months 
6 
months 
0 
Baseline 
3 
months 
6 
months 
2 1032 1958   .605 .812   .59 1   
3 1221 1502 1664 .6577 .902 .99 .481 .988 1 
5 1796     .564     .58     
6 568 1428 1388 .966 .877 1 .79 .979 1 
10 822 1588 1532 .924 .934 .94 .83 .903 1 
11 918 2184   .769 .978   .976 .998   
12 989 1408 1110 .948 .965 .927 .962 .899 1 
16 1480     .802     .61     
24 273 1725   .93 .994   .55 .933   
25 610     .968     .789     
26 1286     .875     .696     
27 770 1922 1000 .944 .946 1 .65 1 .763 
28 538     .93     .887     
32 1233 1778   .971 .808   .889 .968   
34 1027     .937     .877     
35 1167 1718 1254 .958 .986 1 .951 .926 1 
37 2066 1494   .983 .915   .958 1   
38 2142     .943     .982     
41 1372 1398 1768 .655 .996 .88 .965 .976 1 
42 2226 1030 376 .785 .964 1 .99 .99 1 
45 1816 1408 1040 .822 .998 1 .994 .913 1 
46 1560     .854     .966     
47 1662     .779     .986     
51 2237 1920   .786 .913   .993 .99   
54 2625     .864     .913     
55 1402     .866     .995     
59 1663     .841     .999     
62 956 1840   .784 .894   .935 .943   
64 1554   2584 .798   1 .873   .521 
68 1560   2114 .86   .85 .924   .99 
71 1666     .755     .983     
74 1996 1352   .611 .899   .892 1   
77 1404     .725     .7     
78 1628 908 2310 .707 .956 .93 .94 .99 1 
80 2085     .742     .794     
81 2844 1884   .8 .975   .88 .99   
82 775 1654 570 .671 .837 1 .858 1 1 
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84 1614   1686 .5   1 .98   1 
86 1278     .82     .97     
89 2140     .656     .76     
91 720     .79     .975     
98 2468     .972     .971     
99 1138     .972     .972     
100 2146 560   .953 1   .964 1   
104 2546   692 .809   1 .986   1 
105 1702     .917     .933     
107 926     .929     .832     
110 1525   2142 .904   1 .975   1 
117 2038 1768   .676 1   .973 1   
119 1403 1222   .785 .977   .976 .99   
120 1360     .782     .991     
121 2508     .989     .941     
125 1522     .625     .972     
132 1920 2309 2135 .988 .748 .849 .988 1 1 
134 1430     .99     1     
138 1735     .816     .986     
140 1330 1508 1608 .872 1 .95 .948 1 1 
141 1324     .872     .89     
143 2026 1863   .9 1   .94 1   
144 1700 1812   .872 .898   .942 .95   
149 1503     .873     .927     
156 884     .955     .955     
164 1606   1532 .868   .91 .99   1 
165 1356 1948   .937 .924   .936 1   
166 1542 1302 974 .843 .941 1 .986 1 .99 
167 1430 1470   .833 .892   .975 1   
168 962 2989   .845 1   .989 .853   
169 1622     .956     .718     
170 1584 1750   .842 .895   .905 1   
173 1558 2440 1810 .889 1 1 .972 1 .683 
176 1788     .886     .872     
178 1901     .873     .897     
179 1675     .764     .865     
180 2108     .906     .922     
182 1114     .926     .885     
183 1782     .863     .815     
185 1344 2060 1118 .963 .923 .886 .91 1 1 
186 1420     .899     .969     
187 1626     .779     .716     
188 1176     .962     .89     
190 1338     .905     .868     
191 1434 2178   .783 .846   .918 1   
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193 854 1254 570 .893 .94 1 .952 1 .595 
196 1432 1817   .91 1   .766 1   
197 1556     .949     .904     
Lower Pr and Pz values are indicative of higher phospholipase production and 1 indicates no 
production. 
Highlighted patients kept their appointments and carried C. albicans at all three visits.  
Candida counts and CD4 counts are provided in the raw data in the attached CD-ROM. 
 
Of the 117 subjects who were colonised with Candida from our sample of 197 
participants, 85 were positive for C. albicans and were followed up for 6 months. 
However, only 17 of those who reported for follow up visits were consistently C. 
albicans positive at the follow up visit. These are highlighted in the Table 4.1. 
 
Table 4.2 Virulence of C. albicans during the 6 months follow up period 
Virulence Test Mean ± SD (n=17) 
 0 months 3 months 6 months 
Adherence * 1288.35 (460.09) 1578.65 (411.34) 1307.47 (544.24) 
Proteinase** 0.852 (0.116) 1 (0) 1 (0) 
Phospholipase*** 0.622 (0.425) 1 (0) 1 (0) 
*: Adherent C. albicans count per 100 epithelial cells 
** & ***: Ratio of diameter of colony and the diameter of the colony  plus the precipitation zone 
expressed (1 = no activity and < 1 = enzyme production). 
 
The average virulence characteristics for all the C. albicans positive subjects who 
were available for follow up for six months (highlighted in Table 4.1) indicates that 
the average values fluctuated from visit to visit. Adherence was 1288.35 ±460.09 at 
baseline visit, increased to 1578.65 (±411.34) after 3 months and dropped to 1307.47 
 
 
91 
(±544.24) at 6 months. The mean proteinase level was 0.852 (±0.116) at the baseline 
visit whereas no enzymes were produced at 3 and 6 months. Similarly, the result for 
phospholipase was 0.622 (±0.425) at baseline but showed no enzymatic activity after 
3 months and 6 months (Table 4.2). 
 
4.3.3 Relationship between CD4 counts and virulence factors of C. albicans 
isolated from HIV positive women over 6 months. 
The results of CD4 counts of the HIV positive women and the virulence factors are 
shown in Table 4.3. The CD4 count for the 85 subjects who were C. albicans positive 
and for the 17 subjects who were available for the follow up visit and carried C. 
albicans for the period are highlighted. A non parametric correlation of the virulence 
factors was undertaken using Spearman’s correlation (Table 4.4). A negative 
correlation between CD4 count and adherence assay was observed (-0.0519) 
indicating that adherence increased with declining CD4 count. However, this 
correlation did not reach statistical significance. There was a significant positive 
correlation between proteinase and phospolipase assays (Spearman’s rho 0.2140, 
p<0.05). This indicates there is a strong tendency its assay was elevated when the 
other was also high. 
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Table 4.3 CD4 counts and virulence factors by C. albicans isolated from HIV positive women over 6 months. 
    
CD4 Count 
(cells/mm3)   
Adherence (Adherent 
Candida count/ 100 epithelia 
cells) 
Proteinase (Pr) 
(Colony diameter/ 
precipitation diameter) 
Phospholipase (Pz) 
(Colony diameter/ 
precipitation diameter) 
StudyID 
0 
Baseline 
3      
months 
6 
months 
0 
Baseline 
3 
months 
6 
months 
0 
Baseline 
3 
months 
6 
months 
0 
Baseline 
3 
months 
6 
months 
2 546 490   1032 1958   .605 .812   .59 1   
3 347   701 1221 1502 1664 .6577 .902 .99 .481 .988 1 
5 250     1796     .564     .58     
6 196     568 1428 1388 .966 .877 1 .79 .979 1 
10 418   533 822 1588 1532 .924 .934 .94 .83 .903 1 
11 567     918 2184   .769 .978   .976 .998   
12 571 378   989 1408 1110 .948 .965 .927 .962 .899 1 
16 104     1480     .802     .61     
24 1200     273 1725   .93 .994   .55 .933   
25 595     610     .968     .789     
26 398     1286     .875     .696     
27 370 490 380 770 1922 1000 .944 .946 1 .65 1 .763 
28 393     538     .93     .887     
32 156 561   1233 1778   .971 .808   .889 .968   
34 27     1027     .937     .877     
35 821     1167 1718 1254 .958 .986 1 .951 .926 1 
37 626 496   2066 1494   .983 .915   .958 1   
38 246     2142     .943     .982     
41 1023 1200 821 1372 1398 1768 .655 .996 .88 .965 .976 1 
42 462   350 2226 1030 376 .785 .964 1 .99 .99 1 
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45 35 35 29 1816 1408 1040 .822 .998 1 .994 .913 1 
46 166     1560     .854     .966     
47 194     1662     .779     .986     
51 555 769   2237 1920   .786 .913   .993 .99   
54 86     2625     .864     .913     
55 302     1402     .866     .995     
59 19     1663     .841     .999     
62 202 389   956 1840   .784 .894   .935 .943   
64 58   503 1554   2584 .798   1 .873   .521 
68 640     1560   2114 .86   .85 .924   .99 
71 505     1666     .755     .983     
74 699 510   1996 1352   .611 .899   .892 1   
77 564     1404     .725     .7     
78 307     1628 908 2310 .707 .956 .93 .94 .99 1 
80 321     2085     .742     .794     
81 295 580   2844 1884   .8 .975   .88 .99   
82 34   312 775 1654 570 .671 .837 1 .858 1 1 
84 701   682 1614   1686 .5   1 .98   1 
86 301     1278     .82     .97     
89 108     2140     .656     .76     
91 273     720     .79     .975     
98 167     2468     .972     .971     
99 242     1138     .972     .972     
100 400 296   2146 560   .953 1   .964 1   
104 485   456 2546   692 .809   1 .986   1 
105 400     1702     .917     .933     
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107 260     926     .929     .832     
110 280   319 1525   2142 .904   1 .975   1 
117 410 412   2038 1768   .676 1   .973 1   
119 187     1403 1222   .785 .977   .976 .99   
120 355     1360     .782     .991     
121 228     2508     .989     .941     
125 225     1522     .625     .972     
132 78 63   1920 2309 2135 .988 .748 .849 .988 1 1 
134 748     1430     .99     1     
138 19     1735     .816     .986     
140 584 467 480 1330 1508 1608 .872 1 .95 .948 1 1 
141 146     1324     .872     .89     
143 109 154   2026 1863   .9 1   .94 1   
144 581 485   1700 1812   .872 .898   .942 .95   
149 388     1503     .873     .927     
156 398     884     .955     .955     
164 464   466 1606   1532 .868   .91 .99   1 
165 163     1356 1948   .937 .924   .936 1   
166 350 372   1542 1302 974 .843 .941 1 .986 1 .99 
167 588 544   1430 1470   .833 .892   .975 1   
168 926 885   962 2989   .845 1   .989 .853   
169 236     1622     .956     .718     
170 400 583   1584 1750   .842 .895   .905 1   
173 469 348   1558 2440 1810 .889 1 1 .972 1 .683 
176 377     1788     .886     .872     
178 396     1901     .873     .897     
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179 241     1675     .764     .865     
180 193     2108     .906     .922     
182 270     1114     .926     .885     
183 141     1782     .863     .815     
185 9 69   1344 2060 1118 .963 .923 .886 .91 1 1 
186 770     1420     .899     .969     
187 300     1626     .779     .716     
188 190     1176     .962     .89     
190 253     1338     .905     .868     
191 363 387   1434 2178   .783 .846   .918 1   
193 600 527 793 854 1254 570 .893 .94 1 .952 1 .595 
196 380     1432 1817   .91 1   .766 1   
197 107     1556     .949     .904     
Where lower Pr and Pz values are indicative of higher phospholipase production and 1 represents no production. 
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Table 4.4 Correlation of CD4 count with virulence factors of C. albicans in HIV 
positive women over six months (n=85) 
Correlation Factor 
CD4 
count Adherence Proteinase Phospholipase 
  
    CD4 count 1.0000 
   Adherence -0.0519 1.0000 
  Proteinase 0.0615 -0.1427 1.0000 
 Phospholipase 0.1645 0.1429 0.2140* 1.0000 
Spearman’s rho in boxes *p<0.05 
 
4.3.4 Production of proteinase, phospholipase and adherence to oral epithelial 
cells by non-albicans Candida 
The results of the production of proteinase, phospholipase and adherence to oral 
epithelial cells by non-albicans Candida are shown in Table 4.5 and summarised in 
Figure 4.2 and 4.3. 
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Table 4.5 Production of proteinase, phospholipase and adherence to oral epithelial 
cells by non-albicans Candida isolated from HIV positive women  
    Adherence Proteinase Phospholipase 
Study 
ID Yeast  Baseline 
3 
months 
6 
months Baseline 
3 
months 
6 
months Baseline 
3 
months 
6 
months 
1 C. famata 1498     1     0.82     
5 
C. 
dubliniensis   1404     0.96     1   
7 
C. 
dubliniensis 1190     1     0.94     
14 
C. 
dubliniensis 1172     0.99     0.61     
30 
C. 
dubliniensis 800   
 
0.864     0.942     
32 
C. 
dubliniensis     972     0.88     0.85 
36 C. tropicalis 582     0.945     0.5     
46 
C. 
neoformans                   
58 C. tropicalis 1828     0.98     0.996     
61 C. tropicalis 2444     0.98     0.55     
64 C. tropicalis   1280     1     0.61   
69 C. tropicalis 810     0.98     0.45     
77 C. famata   72     0.88     0.79   
84 C. pelliculosa                   
87 C. famata 1292     0.95     0.51     
90 
C. 
dubliniensis 938     0.98     1     
99 
C. 
dubliniensis   1042     1     0.76   
101 
C. 
dubliniensis 216     0.99     0.93     
108 
C. 
dubliniensis 310     0.99     1     
109 
C. 
dubliniensis 1188     1     0.5     
110 C. tropicalis   860     0.95     0.75   
115 C. tropicalis 204     0.99     0.46     
116 C. krusei 256     1     0.99     
124 
C. 
dubliniensis 302     0.97     1     
126 C. tropicalis 556     0.97     0.42     
127 
C. 
dubliniensis 564     0.96     0.91     
128 
C. 
dubliniensis 1162     1     1     
129 C. famata 922     0.9     0.86     
130 C. famata 740     0.97     0.51     
133 
C. 
dubliniensis 668     1     1     
136 
C. 
parapsilosis                   
141 
C. 
dubliniensis   88     1     0.77   
 98 
146 C. famata 1148     1     0.7     
155 C. famata 70     1     0.75     
157 C. glabrata 1514     1     1     
158 C. glabrata 446     0.91     1     
162 S. cerevisiae                   
164 
C. 
dubliniensis   1570     0.98     0.89   
170 C. famata     620     0.99     0.57 
175 
C. 
dubliniensis 1378     0.98     0.97     
178 
C. 
dubliniensis   270     0.96     0.59   
181 
C. 
dubliniensis 408     0.91     0.64     
198 
C. 
dubliniensis 2174     0.93     0.52     
199 C. tropicalis 582     0.96     0.52     
 
Figure 4.2 Adherence to oral epithelial cells by C. albicans and non-albicans 
Candida isolated from HIV positive women   
 
None of the non-albicans Candida showed as much adherence as C. albicans ie mean 
of 1540 yeast cells/100 BEC) as indicated in Figure 4.2 as a reference (red bar). Non-
albicans Candida species that showed the most adherence was C. tropicalis with 1016 
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yeast cells/100 BEC. It was followed by C. glabrata with 980 yeast cells/100 BEC 
and C. dubliniensis with 890 yeast cells/100 BEC. C. famata and C. krusei produced 
the least adherence with 795 and 256 yeast cells/100 BEC respectively. 
 
Figure 4.3 Production of proteinase, phospholipase by C. albicans and non-albicans 
Candida isolated from HIV positive women (Virulence of 1 indicates no enzyme 
production and < 1 indicates enzyme production) 
 
 
None of the non-albicans Candida species produced as much proteinase as C. 
albicans with an average of 0.886 (Lower number indicates greater production, 1 
represents no production). Of the non-albicans Candida species, C. glabrata had the 
highest proteinase production with an average of 0.955. This was followed by C. 
famata (0.961) and C. dubliniensis (0.967) and C. tropicalis (0.973) respectively. C. 
krusei hardly produced any enzyme and had an average of 1. Phospholipase 
production was highest with C. tropicalis (0.584) and this was much higher than the 
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average phospholipase production by C. albicans (0.922). C. famata and C. 
dubliniensis followed with 0.689 and 0.841 respectively. C. glabrata and C. krusei 
were not producing the enzyme with 1 and 0.99 respectively.  
 
4.3.5 Comparison of production of proteinase, phospholipase and adherence to 
oral epithelial cells by C. albicans and non-albicans Candida 
When the production of virulence factors of C. albicans and non-albicans Candida 
was compared (Table 4.6), C. albicans showed a much higher adherence rate 
1540.6±42.3 compared to the non albicans strains with 888.5±90.5. This was highly 
significant at p<0.001. Likewise, the C. albicans yeasts showed greater proteinase 
activity with an average of 0.89±0.009 compared to 0.97±0.005 in the non-albicans 
Candida. This was also significant at p<0.001. Conversely, the non-albicans yeasts 
showed more phospholipase activity with an average of 0.76±0.032 compared to 
0.92±0.009 in C. albicans. This was also significant at p<0.001. (Table 4.6) 
 
Table 4.6 Comparison of average virulence factors of C. albicans  and non-albicans 
Candida  
Virulence Factor C. albicans 
(N=145) 
Non-albicans Candida 
(N=40) 
p value 
Adherence (mean±SD) 1540.6±42.3 888.5±90.5 <0.001* 
Proteinase (mean±SD) 0.89±0.009 0.97±0.005 <0.001* 
Phospholipase (mean±SD) 0.92±0.009 0.76±0.032 <0.001* 
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Table 4.7 Comparison of the proportion of C. albicans and non-albicans Candida 
producing virulence factors  
Species 
Adherence assay 
No. of isolates (%) 
Proteinase 
production  
No. of isolates (%) 
Phospholipase 
production  
No. of isolates (%) 
C. albicans 
145/145 (100%) 116/145(80%) 83/145(57%) 
C. dubliniensis 
19/20(95%) 8/20(40%) 14/20(70%) 
C. famata 
6/8(75%) 4/8(50%) 8/8(100%) 
C. krusei 
1/1(100%) 0/1(0%) 0/1(0%) 
C. tropicalis 
9/9(100%) 4/9(44%) 8/9(89%) 
C. glabrata 
2/2(100%) 1/2(50%) 0/2(0%) 
Non- albicans 
combined 
37/40(92.5%) 17/40(42.5%) 30/40(75%) 
 
The average values of the virulence factors are given in Table 4.6; this is based on the 
data generated by the Candida producing virulence factors.  Not all the Candida 
produce the virulence factors, Table 4.7 and Figure 4.3 shows the percentage of yeasts 
producing the virulence factors. All the C. albicans strains adhered to BEC, 80% 
produced proteinase and 57% phospholipase. Adherence of the non-albicans Candida 
was lower i.e. with 92.5%, proteinase production 42.5% and phospholipase 
production 75%. The percentage of different Candida species producing virulence 
factors is displayed graphically for easier comprehension (Figure 4.4). 
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Figure 4.4 Proportion of Candida species producing virulence factors  
 
4.3.6 Virulence factors and Candida count in patients with and without oral 
candidiasis 
Twenty two of the 197 women were clinically diagnosed with oral candidiasis at the 
first visit (11.2% prevalence). No yeasts were cultutered from three on further 
laboratory investigations and were therefore not included in the statistiscal analysis. 
This explains why there were only 19 with oral candidiasis (Tables 4.9 and 4.10). 
However, not all the patients with candidiasis at the initial visit returned for follow up 
visits. A comparison of the virulence factors of the isolates showed there was no 
significant difference between patients with clinical infection and their counterparts 
with no infection but may have been colonised (Table 4.8). However, much higher 
yeast counts were related to clinical infection. The median yeast count in patients with 
oral candidasis was 280 cfu/ml compared to 70 cfu/ml in patients without candidiasis. 
This was significant at p=0.003. The median count was used for comparison because 
the variable was not normally distributed. 
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Table 4.8 Relationship of virulence factors and yeast count to oral candidiasis  
Factor 
(median value) 
Infection 
Present 
Infection 
Absent 
p value 
Adherence 1408 1431 0.4130 
Proteinase .944 .93 0.9476 
Phospholipase .952 .965 0.4319 
Candida count 280 70 0.003* 
*All the patients carried yeasts at all the visits 
 
4.3.7 Relationship of Candida species to oral candidiasis 
When the presence of C. albicans and non-C. albicans in the symptomatic and 
asymptomatic state was compared (Table 4.9), the results showed that the majority of 
the infection (78.95%) was caused by C. albicans. The non-albicans Candida only 
accounted for 21.05%. However, this difference was not statistically significant. 
 
Table 4.9 Relationship of Candida species to oral candidiasis (Candida positively 
identified, all visits) 
Type of Candida 
Candidiasis 
present 
N(%) 
Candidiasis  
absent 
N(%) 
Total (%) 
C. albicans  15 (78.95) 130 (69.52) 145 (70.39) 
Non-C. albicans 
Candida 
4 (21.05) 57 (30.48) 61 (29.61) 
Total 19 (100) 187 (100) 206 (100) 
 Fishers exact =0.598, percentages reflected are column percentages 
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Figure 4.5 Comparison of virulence characteristics of Candida species with non-
albicans Candida in those with and without oral candidiasis (colonisation) 
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Table 4.10 Comparison of virulence attributes of Candida species isolated from HIV 
positive women with and without candidiasis 
Subjects Isolates  
(n) 
Mean ± SD 
Adherence Proteinase Phospholipase 
Yeast no./100BEC p Pr p Pz p 
All C. albicans 
(145) 
1540.6±42.3  
 
<0.01* 
0.89±0.01  
 
<0.01* 
0.92±0.01  
 
<0.01* 
Non-albicans 
(40) 
888.5±90.5 0.97±0.01 0.76±0.03 
With Oral 
candidiasis 
C. albicans (15) 1407.6±509.8  
 
0.19 
0.899±0.07  
 
0.09 
0.9164±0.12  
 
0.02* 
Non-albicans (4) 961±571.7 0.968±0.04 0.7275±0.19 
No oral 
candidiasis 
C. albicans 
(130) 
1555.9±509.4  
 
<0.01* 
0.885±0.10  
 
<0.01* 
0.923±0.11  
 
0.44 
Non-albicans 
(36) 
 880.4±580.3  0.967±0.04 0.7685±0.21 
Adherence: No. of Yeast cells/100 epithelial cells. 
Pr: ratio of the colony diameter and the clear zone. 
Pz: ratio of the colony diameter and the precipitation zone. 
*Significant 
 
The virulence of C. albicans and non-albicans Candida isolated from patients with 
oral candidiasis and without (colonised) is shown in Figure 4.5 and Table 4.10. The 
virulence properties of C. albicans were consistently higher than the non-albicans 
group irrespective of the development of clinical infection. In the group without oral 
candidiasis, the mean adherence of C. albicans was 1555.9±509.4 compared with 
880.4±580.3 for non-albicans Candida, p<0.01. In the group with oral candidiasis 
who carried C. albicans, adherence was also higher with a mean of 1407.6±509.8 
compared to 961±571.7 for non-albicans Candida. This difference did not attain 
statistical significance, p=0.19. A similar trend was observed with proteinase assay, 
enzyme production was higher with C. albicans in patients with or without oral 
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candidiasis. In patients who did not develop oral candidiasis, C. albicans produced 
more enzyme than the non-albicans Candida. However, this was not statistically 
significant (mean of 0.899±0.07 in C. albicans compared with 0.968±0.04 in the non-
albicans group, p=0.09). 
The trend was opposite in patients with oral candidiasis. Phospholipase production 
was much higher in the non-albicans group with a mean of 0.7275±0.19 compared to 
0.9164±0.12 and this difference was significant at p=0.02. 
 
4.4 Discussion 
4.4.1 Virulence of C. albicans in HIV infection 
Opportunistic oral candidiasis was prominent as an indicator of the presence and 
progression of HIV infection from the onset. Oral candidiasis was adduced to 
compromise in host immunity present in HIV infection. The immune compromise is 
mainly in the depletion Th17 subset of the CD4 cells, a situation that allows Candida 
organisms to cause mucosal disease (Cassone and Cauda, 2012). At a point, it was 
proposed that oral candidiasis was initiated by more virulent strains replacing the 
commensal strains rather than just the deficient immunity. This assertion prompted 
investigations into the virulent characteristics of Candida species in HIV infection 
(Sweet et al., 1995). Research thus confirmed greater adherence to buccal epithelial 
cells in HIV infected subjects compared to HIV negative controls (Sweet et al., 1995).  
 
In our study, all the isolates of C. albicans had adherence, 80% produced proteinase 
and 57% produced phospholipase (Table 4.7) thus indicating that the isolates were 
capable of initiating infection. Furthermore, Candida species obtained from HIV 
positive subjects with TB infection had more virulence attributes (phospholipase 
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enzyme production) than HIV and TB negative controls (Ramesh et al., 2011). In 
addition, C. albicans strains from HIV infected patients were more adherent, and 
produced more haemolysins, proteinases and phospholipases than the HIV negative 
controls (Mane et al., 2012). Conversely, yeasts from HIV positive subjects did not 
differ in biofilm forming ability (a virulence factor) compared with HIV negative 
controls. This is in spite of increased yeast carriage in the HIV positive group. This 
was attributed to the presence of other virulence determinants (Jin et al., 2003). 
Unquestionably, there is evidence is that Candida organisms are more able to express 
their virulence characteristics in an immune depleted host such as in HIV infection. 
The principal mechanisms are the increased expression of SAPs and growth of the 
Candida hyphae (Heilmann et al., 2011). In addition, the HIV virus interacts with 
Candida organisms whereby the envelope proteins of HIV such as GP160 and Tat are 
able to induce SAP production by Candida (Gruber et al., 2001). 
 
4.4.1.1 Adherence assay 
Our findings confirm the presence of virulence attributes in the Candida species 
isolated from HIV positive women in Tables 4.1 and 4.2. The average value of the 
adherence assay in this study is larger than other studies. We found an average of 
1288.35 (±460.09) yeast cells/BEC compared with the maximum range of 989 in a 
similar study in HIV positive subjects (Mane et al., 2011). This difference may be due 
to differences in strain variation because the expression of virulence factors are strain 
specific (Ghannoum, 2000). Adherence assays are also sensitive to differences in 
technique and buccal epithelial cells vary in their affinity for yeast cells (Sandin et al., 
1987).  Apart from the average adherence values, the proportion of the yeasts 
expressing particular virulence characteristics also indicates the degree of virulence. 
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All the C. albicans yeasts and 92.5% of the non-albicans Candida in our study 
showed adherence ability (Table 4.9). This is similar to the finding of Mane and co-
workers who showed that 95% of isolates were able to adhere (Mane et al., 2011). 
The high level of adherence in our study and others confirm the ability of Candida to 
adhere to the epithelial cells in HIV infection. This is usually a precursor to invasion 
and subsequent infection.    
 
4.4.1.2 Proteinase production 
The average proteinase value of 0.89 (±0.009) for C. albicans (Table 4.7) is slightly 
higher (less proteinase production) than 0.765(±0.107) reported by Mane and 
colleagues. A larger proportion of C. albicans in their study (89.7%) were proteinase 
positive compared to 80% in this study (Table 4.7). Their C. albicans strains showed 
more proteinase activity probably because they took samples from HIV subjects who 
had active oral Candida infection whereas not many of our subjects had oral 
candidiasis.  Furthermore in another study, in HIV positive subjects with cancer, 
83.6% of all Candida species and 94.1% of C. albicans were proteinase positive 
(Kumar et al., 2006). Although proteinase activity is associated with virulence, not all 
SAPs are needed for invasion of the epithelium, and only SAP5 gene expression may 
aid invasion (Lermann and Morschhauser, 2008). In our study, proteinases were not 
differentiated and the detection is often technique sensitive. 
 
4.4.1.3 Phospholipase production 
Phospholipase production was relatively low in our subjects. The average of 0.92 
(±0.009) in C. albicans was much higher (indicating low enzyme activity) than what 
was obtained in similar studies. For instance, Ramesh and colleagues found an 
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average of 0.48 (±0.007) and Mane and co-workers reported 0.710 (±0.109). This 
may be due to the differences in the sample population as they studied individuals 
who were more immunocompromised (Mane et al., 2011; Ramesh et al., 2011). In 
terms of the proportion of yeasts showing phospholipase activity, our samples were 
only 51% positive for C. albicans (Table 4.7). Other studies have varied from as high 
as 100% (Kumar et al., 2006) to 73.3% (Tay et al., 2011), 60% (Gokce et al., 2007) 
and 59% (Mane et al., 2011). A significant observation in the present study is that 
phospholipase production was higher in non-albicans Candida compared to C. 
albicans isolates. 
 
4.4.1.4 CD4 count and virulence 
A low CD4 count along with other risk factors predict the development of 
oropharyngeal candidiasis (Chattopadhyay et al., 2004). We monitored the CD4 
changes in our subjects during the follow up period to see if there was any correlation 
with the virulence factors (Table 4.4). There was a weak negative correlation between 
adherence and CD4 count. The proteinase and phospholipase levels were positively 
correlated with the CD4 count; however, these did not attain statistical significance. 
While a low CD4 count has been conventionally associated with the development of 
clinical Candida infection, the relationship with virulence factors is less well defined. 
In a study on the adherence properties of C. albicans in HIV positive children with 
HIV negative controls, there was no significant correlation with the CD4 count and 
the viral load. This is in spite of a greater adherence of C. albicans isolated from the 
HIV positive children (Portela et al., 2010). Of note is the statistically significant 
correlation of 0.2140 between proteinase and phospholipase assays. A similar 
correlation between virulence factors has been observed in other surveys. Mane and 
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colleagues reported a significant correlation between adherence and proteinase assay 
(p=0.01) and between proteinase and phopspolipase (p=0.002). They stated the p 
values but did not specify the correlation coefficients (Mane et al., 2011). Correlation 
of virulence factors indicate the variety of pathogenic abilities of Candida yeasts. 
 
Unlike other studies that were purely cross sectional, our subjects were followed up 
for 6 months and the trend in virulence characteristics over time was captured. The 
virulence characteristics varied over time and many factors may be responsible. Yeast 
strains may be different at follow up visits; which may be due to exogenous strains or 
mutations of endogenous strains. The host’s potent innate and adaptive immune 
responses that influence the virulence of this organism may also change with time. 
This fluctuation did not result in clinical infection in the follow up period. Scientific 
debate on the establishment of oral candidiasis has revolved around the balance of the 
pathogenic ability of the yeast versus the host immune capabilities. The factors 
necessary for the establishment of oral candidiasis in our study population appears to 
go beyond the virulence factors that we studied. 
   
4.4.2 Comparison of virulence and clinical infection in C. albicans and non-
albicans Candida 
The non-albicans Candida in our subjects had virulence characteristics i.e. adherence, 
proteinase and phospholipase production (Tables 4.5, 4.6 and Table 4.7). Non-
albicans species express virulence factors with varying ability according to the 
species. In their study, Silva and colleagues demonstrated biofilm formation in non-
albicans species, C. tropicalis and C. parapsilosis showed a greater capacity than C. 
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glabrata (Silva et al., 2011).  Similarly, C. glabrata exhibited a higher capacity for 
adherence than other non-albicans Candida yeasts (Negri et al., 2010a).  
 
Compared with C. albicans, there were significant differences in the virulence 
characteristics of the non-albicans Candida. In many studies, C. albicans 
demonstrated greater virulence characteristics compared with non-albicans Candida. 
The increased adherence of C. albicans (Table 4.7, Figure 4.2 and Figure 4.4) is 
similar to Irie and colleagues’ observation where C. albicans from vaginal specimens 
showed greater adherence than non-albicans Candida (Taguti Irie et al., 2006). In the 
same study, C. albicans from blood culture samples showed greater virulence 
properties compared with non-albicans Candida yeasts. Proteinase production was 
present in 89.7% and 25.8% respectively. Furthermore, a similar study reported 
phospholipase production of 60% in C. albicans and 0% in non-albicans Candida 
yeasts (Gokce et al., 2007). In a study in blood culture samples, proteinase production 
by C. albicans species was 93.7% i.e. higher than 88.5% in non-albicans Candida 
yeasts. In addition, phospholipase was 73.3% in C. albicans compared to 7.7% in 
non-albicans Candida. This was statistically significant (Tay et al., 2011). Our 
findings followed a similar trend with 80% of C. albicans yeasts producing proteinase 
compared with 43% in the non-albicans Candida yeasts (Table 4.7). However, a 
higher proportion of the non-albicans Candida yeasts produced phospholipase i.e. 
75% versus 57% in C. albicans. The reason for this variation is not immediately clear 
and requires further investigation. However, it has been documented that 
phospholipase production may be influenced by the predominant Candida strains 
(Ghannoum, 2000). 
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C. albicans and non-albicans Candida yeasts are all capable of causing oral 
candidiasis. Although we found a higher proportion (78.95%) of C. albicans in 
patients with infection (Table 4.9), non-albicans Candida were present and they 
expressed virulence factors (Table 4.10). This suggests that they may play a role in 
the development of infections and indeed non-albicans Candida related infections are 
becoming more prevalent. In a survey of hospital infections caused by Candida 
species, non-albicans Candida yeasts were significantly more predominant and their 
biofilms showed a higher metabolic activity compared to C. albicans yeasts (Ferreira 
et al., 2013). 
 
4.4.3 Virulence of Candida species and oral Candida infection 
We reported a very small prevalence of oral Candida infection (9.2% all visits) in 
Table 4.9. This is consistent with the era of widely available ART where the 
prevalence of opportunistic Candida infection has declined. A recent survey of HIV 
positive subjects with the majority already on ART showed a prevalence of 27% with 
oropharyngeal Candida infection (Patel et al., 2012). The expression of virulence 
factors was not significantly different in our subjects with oral candidiasis compared 
with those subjects that were colonised but without infection. However, the yeast 
count was much higher in those with infection (p=0.003).  This is to be expected as 
previous studies have associated an increased yeast count with clinical infection 
(Altarawneh et al., 2013). Candida yeasts that express virulence factors are capable of 
causing infection, although the combination of several virulence factors and other 
underlying variables are involved in the establishment of clinical Candida infection 
(Sacristan et al., 2011). In addition, a cumulative effect of the small amount of 
hydrolytic enzymes produced by a high number of C. albicans can cause pathological 
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changes. The elevated yeast count related to oral candidiasis may be due to a 
quantitative effect of the virulence factors. If yeasts are able to multiply, the ability to 
cause tissue damage and infection is much greater. Furthermore, as virulence factors 
are expressed in the milieu of a host environment, the effect of investigating the 
virulence factors in a culture medium rather than in the host requires further 
investigation. However, practically all the published studies on virulence 
characteristics are in vitro studies similar to ours in view of the difficulty in 
conducting in vivo studies. 
 
As shown in Table 4.2, the number and virulence of Candida fluctuate over time due 
to the immune response and many other factors. Studies have shown high levels of 
virulence factors in isolates of C. albicans from the oral cavities of HIV positive 
patients compared to HIV negative patients. From our study it is apparent that the 
presence and quantity of virulence factors alone is not responsible for the infection. 
This suggests that C. albicans isolates may be more virulent but if their count is very 
low, infection may not occur. This suggests it is important to keep the number of 
Candida in the oral cavity as low as possible to prevent the occurrence of infection. 
Maintaining a high CD4 count and optimum oral hygiene with antifungal mouthrinses 
can achieve this goal. Triclosan and fluoride containing mouthrinses can reduce the 
Candida count in oral cavity (Patel et al., 2008). Virulence of C. albicans can also be 
reduced using therapeutic agents (Gauwerky et al., 2009).  
 
The difficulty of constructing an acceptable model for the development of clinical 
yeast infection has been emphasised.  This is owing to the complex interaction 
between the yeast in a commensal and pathologic state, the host and other 
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microorganisms. Continuous research incorporating microbiological, immunological 
and evolutionary genomics are needed to further clarify this complex process (Cottier 
and Pavelka, 2012). 
 
4.5 Conclusions 
Virulence factors of C. albicans isolated from all the HIV positive women who were 
available for six months follow up fluctuated from visit to visit. This fluctuation 
showed no correlation with CD4 counts. Colonised women carried C. albicans and 
non-albicans Candida in their oral cavity and these Candida species showed virulence 
factors, which suggests potential to cause infection. However, there was no difference 
in the proportion of C. albicans and non-albicans Candida in patients with oral 
candidiasis and with no infection. This study also showed that there was no 
significant difference in the measured virulence factors of C. albicans isolated during 
the infection and colonisation state. However the C. albicans counts were 
significantly high in the oral cavities of patients with candidiasis. 
 
The prevalence of oral Candida infection was low (9.2%) which is consistent with the 
era of widely available antiretroviral therapy. The yeast count was significantly 
associated with clinical infection but not the virulence characteristics of adherence, 
proteinase and phospholipase. This implies that the establishment of infection is a 
complex process and virulence characteristics need to be further evaluated in relation 
to clinical infection. However, a large number of C. albicans collectively would 
produce a large amount of virulence factors, which would trigger the development of 
infection. 
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CHAPTER 5:  ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA ALBICANS 
ISOLATED FROM HIV POSITIVE WOMEN  
5.1 Introduction 
Prior to the introduction of HAART, and to a lesser extent in the era of HAART, 
recurrent oral candidiasis still occurs. Development of antifungal resistance has been 
associated with antifungal agents used to treat recurrent candidiasis in HIV infection. 
In these situations, the appropriate doses prescribed for the usual duration become 
ineffective (Hamza et al., 2008).  
 
5.1.2 Antifungal testing methods 
The Clinical and Laboratory Standards Institute (CLSI) M27-A3 protocol, formerly 
called the National Committee for Clinical Laboratory Standards (NCCLS) has been 
the reference standard method for in vitro testing of conventional antifungal agents 
since 1997 (Espinel-Ingroff et al., 1999). The protocol uses either broth microdilution 
(BMD) or agar based techniques to evaluate amphotericin B, azole antifungals, 
echinocandins and 5-flucytosin. Some of the challenges associated with the method 
include the lack of efficiency and convenience for routine laboratory testing. With 
increasing demand for routine laboratory testing of antifungal agents, more efficient, 
simple, ready to use and reproducible methods such as the Etest® and the Sensititre 
YeastOne® Colorimetric Panel (TREK Diagnostic Systems, Cleveland, OH, USA) 
have been developed (Lu et al., 2004). The Sensititre YeastOne® is a 96-well 
colorimetric microdilution panel that uses a colour change to indicate growth. The 
wells contain serially arranged 2-fold dilutions of the antifungal agents (Figure 5.1). 
The panel evaluates anidulafungin, micafungin, caspofungin, 5-flucytosine, 
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posaconazole, voriconazole, itraconazole, fluconazole and amphotericin B (Pfaller, 
2008). 
Studies have compared the degree of agreement between the CLSI M27-A3 protocol 
and the Sensititre YeastOne® Colorimetric Panel. A recent study found 70.6% to 
92.2% for essential agreements. Within categories, an agreement of 94.1% was 
obtained for 5-flucytosin and 72.6% for Amphotericin B. Consequently, the Sensititre 
YeastOne® Colorimetric was judged to be reliable for the in vitro evaluation of 
antifungal agents (Bertout et al., 2011). A similar study comparing the YeastOne® 
method with the CLSI method for testing the antifungal sensitivity of Candida species 
to the 3 echinocandins showed 99% reproducibility and 100% essential agreement 
between the two methods (Pfaller et al., 2008). 
 
5.1.3 Antifungal susceptibility patterns 
Candida species have a very high level of variability in the pattern of sensitivity to 
antifungal agents (Bertout et al., 2011). This variability can be attributed to the 
resistance capacity of the species studied or previous use of antifungal agents. 
Furthermore, the source of the yeast and the immune status of the individual may also 
play a role (Badiee et al., 2010; Sanchez-Vargas et al., 2005b). 
 
In Africa, routine antifungal susceptibility testing is not undertaken becuase oral 
thrush infection is treated with empirical antifungal agents or local herbs such as 
lemon juice (Wright et al., 2009). Consequently, data on the antifungal susceptibility 
profile of Candida species from South Africa is still very sparse. The last study on the 
antifungal susceptibility profile of oral isolates was published more than 10 years ago, 
before fluconazole was widely available (Blignaut et al., 2002a).  Since then, 
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antifungal testing has become standardized globally and recommended to detect 
susceptibility patterns and resistant strains which is a growing problem (Pfaller, 
2012). It is therefore important to characterise the pattern of antifungal susceptibility 
of Candida species in the era of moderate availability of antifungal agents. This 
knowledge will serve as a guide for antifungal therapy and can also help to predict the 
outcomes of therapeutic interventions. 
 
5.2 Methods and materials 
5.2.1 Sample collection 
An oral rinse with 10 mls of sterile distilled water was used to collect samples from 
the participants (117 HIV positive women whose oral cavities were colonized with C. 
albicans as described in Chapter 3, section 3.3). The samples were transferred in 
sputum jars and 100 μl of rinse sample inoculated onto CHROMagar® Candida plates 
(CHROMagar Microbiology) and incubated at 37 °C for 48 hours. Where there was 
growth, colonies were counted and subcultured on Sabouraud dextrose agar (Oxoid, 
Hampshire, England) for 48 hours. 
 
5.2.2 Yeast identification 
This was undertaken using the API 20 C AUX system ® (bioMérieux). Yeast cells 
from a fresh yeast culture were inoculated into 2 mls of distilled water and 
concentrated to 2 McFarland of turbidity. A100 μl was transferred from the 
suspension to the C medium supplied with the API 20 C AUX and gently 
homogenised with the pipette care was taken to avoid the formation of bubbles. The 
homogenised mix was transferred to the cupules in the test strip taking care not to 
overfill or underfill the cupules. The test strips were then carefully placed in a tray of 
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appropriate size that had been lined with a moist paper towel. The tray was covered 
and incubated at 30°C for 48 hours. The yeast identification was carried out based on 
the presence of turbidity in the cupules compared to the control cupule. A seven-digit 
numerical profile based on the positive reactions was then uploaded to the website for 
definitive yeast identification. 
 
5.2.3 Determination of antifungal susceptibility 
Antifungal susceptibility tests were performed using the principles of the Broth 
Microdilution minimum inhibitory concentration system described by Clinical 
Laboratory Standards Institute (CLSI, 2008a). Sensititre YeastOne® microdilution 
colorimetric microtitre plates (Figure 5.1) containing twofold diluted and dehydrated 
9 antifungal agents were obtained (Separation Scientific Pty Ltd).  The antifungal 
agents were Anidulafungin, Micafungin, Caspofungin, 5-Flucytosine, Posaconazole, 
Voriconazole, Itraconazole, Fluconazole and Amphotericin B. The panels also 
contains AlamarBlue®, an established cell viability indicator. It converts resazurin to 
the fluorescent molecule, resorufin by exploiting the natural reducing power of living 
cells. The active ingredient of AlamarBlue® (resazurin) is a blue nontoxic and 
nonfluorescent compound that can permeate the cell.  On entering the cells, resazurin 
is reduced to resorufin, a compound which produces very bright red fluorescence. 
Fresh yeast cultures were inoculated into normal saline and adjusted to a turbidity of 
0.12 McFarland standards. 20μl from the inoculum was then added to the Sensititre 
YeastOne® broth and gently vortexed (Figure 5.2). From the inoculated broth, 100 μl 
was added to each well of the Sensititre YeastOne® panel using a multichannel 
pipette and incubated at 35 °C for 24 hours. The results were read after incubation and 
the minimal inhibitory concentration was determined as the lowest concentration that 
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prevented growth (the first blue well). The wells with growth turned red (Figure 5.3). 
Control strains of C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were tested 
based on CLSI guidelines. 
 
Figure 5.1 96-well Sensititre YeastOne® panel containing antifungal agents 
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Figure 5.2 Sensititre YeastOne® broth after inoculation 
 
Figure 5.3 Sensititre YeastOne® microdilution colorometric microtitre plate after 
incubation showing MIC values 
 
 
 
MIC 
concentrations 
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5.2.4 Determination of clinical breakpoints and epidemiologic cutoff values 
The broth microdilution method that the Sensititre YeastOne® Colorimetric Panel 
uses has been standardised for Candida species by the CLSI and the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST). The methods from 
both bodies are similar.  Recently, the CLSI developed a revised standard with the 
following advantages over the previous standard. Firstly, antifungal sensitivity 
reading after 24 hours has been validated. Secondly, epidemiologic cutoff values 
(ECV) have been established for the various Candida species and the clinical 
breakpoint (CBP) for each antifungal has been determined for each species (Pfaller 
and Diekema, 2012). Previously, clinical breakpoints and epidemiologic cutoff values 
were determined irrespective of the Candida species, which failed to distinguish wild 
type yeasts from non-wild types ie mutant and resistant yeasts. This had significant 
clinical implications (Pfaller et al., 2012). The clinical breakpoints of the CLSI and 
the EUCAST were used to characterise the sensitivity profile of the Candida yeasts 
(Arendrup et al., 2011; Lass-Florl et al., 2011; Pfaller and Diekema, 2012). 
Important terminologies for interpreting antifungal sensitivity data are defined 
(EUCAST, 2013) and the revised standards can be found in Tables 5.1. 
 
Clinically Susceptible (S) 
 This is antimicrobial activity level with a high likelihood of therapeutic success. The 
microorganism is categorised as susceptible (S) by using the appropriate breakpoint in 
a defined phenotypic test system. This breakpoint can be altered. 
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Clinically Intermediate (I) 
In this category, the antimicrobial agent activity level is associated with uncertain 
therapeutic effect. Infection due to the organism may be appropriately treated in the 
sites of the body where the drugs are physically concentrated. Furthermore, high drug 
dosages can be used. A buffer zone to prevent small, uncontrolled, technical factors 
from causing major discrepancies in interpretations is also indicated. The 
predetermined breakpoint is used to categorise the organism as intermediate (I). This 
cutoff may be modified when legitimate changes in circumstances demand. 
 
Clinically Resistant (R) 
Antimicrobial activity level in this category is associated with a high likelihood of 
therapeutic failure. The organism is categorised as resistant (R) using the appropriate 
breakpoint, which may be legitimately changed when the circumstances demand. 
Clinical breakpoints are defined as S<x mg/L; I>x, <y mg/L; R>y mg/L 
 
Wild type (WT) 
 Wild type microorganism species do not exhibit acquired and mutational resistance 
mechanisms to a particular drug. The organism is categorised as the wild type with 
the application of a defined epidemiologic cutoff value that can be changed when the 
circumstances require. The wild type strains may or may not show a clinical response 
to antifungal therapy. 
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Non-Wild Type (NWT) 
The non-wild type (NWT) species have acquired or innate mutational resistance 
mechanism to a particular drug, which is categorized using a defined epidemiologic 
cutoff value. This can change as the circumstances require. The non-wild type strains 
may or may not show a clinical response to the antifungal therapy.         
The epidemiological cutoff value is therefore an MIC threshold value that allows a 
discrimination of wild type strain from a non-wild type strain for each particular 
antifungal and species combination. 
The wild type is presented as MIC ≤ ECV and non-wild type as MIC > ECV.  
 
Table 5.1 Clinical breakpoints (CBP) for the interpretation of Sensititre YeastOne® 
Colorimetric Panel for C. albicans 
 CBP (μg/mL)        ECV (μg/mL) 
Antifungal S SDD I R  WT Non-
WT 
AND < 0.25  0.5 > 1  < 0.12 > 0.12 
MF < 0.25  0.5 > 1  < 0.03 > 0.03 
CAS < 0.25  0.5 > 1  < 0.12 > 0.12 
FC < 4   8-16 > 32  < 0.5 > 0.5 
PZ < 0.06   > 0.06  < 0.06 > 0.06 
VOR < 0.12  0.25-0.5 > 1  < 0.03 > 0.03 
IZ < 0.12  0.25-0.5  > 1  < 0.12 > 0.12 
FZ < 2 4  > 8  < 0.5 > 0.5 
AB      < 2 > 2 
        
CBP- clinical break point, ECV- epidemiological cutoff values, S-sensitive, SDD,-sensitive dose 
dependent, I-intermediate, R- resistant, WT-wildtype, Non-WT- non wild type, AND- anidulafungin, 
MF-micafungin, CAS-caspofungin, FC-5-flucytosin, PZ- posaconazole, VOR- voriconazole, IZ-
itraconazole, FZ-fluconazole, AB-amphotericin B. 
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5.3 Results 
One hundred and twenty two isolates identified as C. albicans were tested. They were 
made up of 72 isolates from the first visit, 29 from the second and 21 from the third 
visit. The results are presented in Tables 5.2 and 5.3. 
 
The majority of the isolates were sensitive to the test antifungals with posaconazole 
showing the highest prevalence of resistant strains (1.7%). All the echinocandins 
demonstrated 0.8% resistance similar to the other azole antifungals apart from 
posaconazole. No strains were resistant to amphotericin B and the clinical break 
points for 5-flucytosin is yet to be determined. However, 5-flucytosin had the most 
non-wild type strains.  
 
Table 5.2 Antifungal susceptibility profiles of Candida albicans isolates  
Antifungal CBP (μg/mL)       ECV (μg/mL) 
 S SDD I R (%) WT Non-WT 
AND 121   1 (0.8) 121 1 
MF 121   1(0.8) 120 2 
CAS 120   1(0.8) 120 1 
FC ND ND ND ND 115 7 
PZ 120   2(1.7) 120 2 
VOR 121   1(0.8) 121 1 
IZ 121   1(0.8) 121 1 
FZ 121   1(0.8) 119 3 
AB 122   0(0) 122 0 
 
CBP- clinical break point, ECV- epidemiological cutoff values, S-sensitive, SDD,-sensitive dose 
dependent, I-intermediate, R- resistant, WT-wildtype, Non-WT- non wild type, AND- anidulafungin, 
MF-micafungin, CAS-caspofungin, FC-5-flucytosin, PZ- posaconazole, VOR- voriconazole, IZ-
itraconazole, FZ-fluconazole, AB-amphotericin B. ND- not defined yet 
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Table 5.3 Antifungal susceptibility profiles of Candida albicans isolates showing the 
MICs 
Antifungal MIC(μg/mL) 
 Range MIC50 MIC 90 
AND 0.015-8 0.03 0.03 
MF 0.08-8 0.08 0.08 
CAS 0.015-8 0.015 0.06 
FC 0.06-64 0.06 0.25 
PZ 0.008-8 0.008 0.015 
VOR 0.008-8 0.008 0.008 
IZ 0.015-16 0.015 0.003 
FZ 0.12-128 0.12 0.12 
AB 0.12-0.5 0.12 0.12 
MIC- minimum inhibitory concentration 
 
5.4 Discussion 
The majority of yeasts in our study population were C. albicans, which is confirmed 
by other reports. It is also the reason why the sensitivity profile of C. albicans has 
been described most often (Hamza et al., 2008). As with other previous studies in 
Africa, the proportion of resistant strains of Candida to antifungal agents is also low, 
although the echinocandins were not tested in earlier studies (Blignaut et al., 2002a; 
Hamza et al., 2008). In our study only 0.8% of C. albicans isolates were resistant to 
echinocandins. A very recent study from Ethiopia that tested for antifungal resistance 
found 2% resistance to echinocandins (Mulu et al., 2013). This is certainly due to the 
recent introduction of the echinocandins, which are not often used in Africa. Of all the 
echinocandins (anidulafungin, micafungin, and caspofungin) that were tested in our 
study, the resistant strains were less than 1% (Tables 5.2 and 5.3). This is consistent 
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with other reports that documented a range between 95% to 99% susceptibility to 
echinocandins (Badiee et al., 2010; Garcia-Agudo et al., 2012; Mulu et al., 2013). It is 
not certain why we observed a case of resistance to echinocandins but this has been 
confirmed in other samples (Pfaller, 2012).  Although C. parapsilosis and C. glabrata 
exhibited a high resistance to echinocandins, they remain the drugs of choice as 
alternatives to azoles and in cases of invasive candidiasis (Garcia-Agudo et al., 2012).  
 
The range of azole resistance in our subjects was also low, ranging from 0.8% to 
1.6% in C. albicans yeasts (Table 5.2). This is just a marginal increase from the 0.4% 
reported in 2002 when azoles were first introduced in South Africa (Blignaut et al., 
2002a). It appears that more than one decade of azole therapy has not had a 
significant impact on the development of azole resistant strains of C. albicans. The 
study by Blignaut et al (2002) and our study were conducted on isolates from the 
northern part of South Africa. A recent study from the southern parts of South Africa 
has reported fluconazole resistance of 50% (Abrantes et al., 2013). Higher percentage 
of azole resistant C. albicans strains has also been reported from Iran (10%) and India 
(12.5%). However, these studies were conducted in settings where the patients were 
HIV positive and had been exposed to repeated therapy with azole antifungals 
(Badiee et al., 2010; Mane et al., 2010). More recently, 32% of Candida isolates were 
found to be resistant to multiple antifungals (Mulu et al., 2013). However, in this 
study over half the resistant strains were non-albicans Candida species, which reflects 
the increasing role of these yeasts in antifungal resistance (Mulu et al., 2013). This 
high level of resistance may also be due to the subjects, the majority of whom had 
been exposed to repeated azole therapy due to recurrent oropharyngeal candidiasis. In 
addition, they were all late presenting AIDS patients (Mulu et al., 2013). This finding, 
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however, points to the danger that may ensue if antifungal therapy becomes 
indiscriminate and use repeated as the authors also observed a shift to resistant non-
albicans Candida in the same subjects. 
 
With regards to non-albicans Candida, 5% fluconazole resistance to C. glabrata was 
documented in recent reports from Tanzania and 50% from India (Hamza et al., 2008; 
Mane et al., 2010). We isolated non-albicans Candida including C. glabrata but did 
not subject them to antifungal sensitivity tests because very few (6 types of non-
albicans Candida in total 26 isolates, Chapter 3, Table 3.6) non-albicans Candida 
were isolated. This would not have given meaningful results. However, azole 
resistance to C. glabrata has been sufficiently reported as a serious concern. The 
clinical breakpoints for C. glabrata regarding fluconazole have the highest cuttoffs 
(>64 μg/mL). The yeast is known to possess a high ability to mutate in a single 
individual and azoles or amphotericin B are not able to control this change. For this 
reason, institutions need to be on the lookout for multidrug resistant C. glabrata 
(Pfaller, 2012).  
 
The previous use of any azole antifungal is a risk factor for azole resistance. 
Furthermore, azoles share cross-resistance as previous use of one azole may 
predispose to resistance to another. A study in Tanzania found a significant 
relationship between previous use and the development of resistant Candida species 
strains with fluconazole and itraconazole (Hamza et al., 2008).  Prior treatment with 
fluconazole was also found to be a strong predictor for the development of 
candidaemia (Garnacho-Montero et al., 2010). Every subject in our study was asked 
for a history of previous antifungal use; however, the majority could not indicate 
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which drugs they had taken previously. From the records it was discovered that the 
same subject (Study ID 10) carried yeast that were resistant to all the azole 
antifungals. In her history, she did not reveal that she had taken antifungal agents 
previously, even though she carried C. albicans and had an HIV positive partner. It is 
possible that she was on antifungal previously but did not understand what treatment 
she was receiving. It is also possible that she acquired azole resistant strains from her 
partner because she did not have candidiasis when she was examined originally. If she 
develops candidiasis, azole antifungals will be ineffective if prescribed. This case 
typifies the danger of multiple resistance to azoles.  
 
No case of resistance to amphotericin B was documented, unlike 8.4% resistance 
found previously (Blignaut et al., 2002a). This was probably because amphotericin B 
and nystatin were the antifungal drugs generally available at the time of the study. In 
addition, azoles were relatively new and echinocandins were not available in this part 
of the world when the study was conducted. However, the maximum MIC of 0.5 
μg/mL reported in C. albicans in this study is below the limit of 2 μg/mL where 
treatment with other antifungal agents is recommended (Pfaller and Diekema, 2012). 
This is consistent with reports from across the world where Candida species generally 
have low MICs to amphotericin B and the drug recommended as an effective therapy 
(Brito et al., 2011; Hamza et al., 2008). 
 
The need for guidelines for testing antifungal susceptibility has been emphasised 
(Table 5.3) and a guide provided (Pfaller and Diekema, 2012). Antifungal 
susceptibility testing should not be performed for the routine treatment of oral 
candidiasis except when the response to therapy is inadequate. However, 
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determination of the antifungal sensitivity profile of Candida yeasts from time to time 
is necessary to guide empirical therapy and acts as a surveillance measure to detect 
the development of resistance. 
 
Table 5.4 Guidelines for the use of antifungal susceptibility testing [Source: Pfaller 
and Diekema, 2012] 
Clinical scenario Recommendation (s) 
Routine  All Candida isolates from deep sites 
(blood, normally sterile body fluids, 
tissues, abscesses) must be identified to 
the species level 
 Sensitivity testing of fluconazole and an 
echinocandin against C. glabrata from 
deep sites recommended 
 Sensitivity testing of fluconazole and an 
echinocandin against other species of 
Candida may be helpful but 
susceptibility usually predictable by 
species 
 Apply the CBPs or ECVs to interpret 
results as appropriate (Table 5.1) 
 Completion of cross-resistance between 
fluconazole and all other azoles to be 
must be considered for C. glabrata 
 Create an antifungogram 
Mucosal candidiasis   Determination of azole susceptibility not 
routinely necessary 
 Susceptibility testing of azoles may be 
useful for patients unresponsive to 
therapy 
Species with high rates of intrinsic or 
acquired resistance causing infection 
 Susceptibility testing not necessary when 
intrinsic resistance is known 
o C. lusitaniae and amphotericin 
o C. krusei and fluconazole, 5-
flucytosine 
o C. guilliermondii and 
echinocandins 
 With high rates of acquired resistance, 
monitor closely for signs of failure and 
perform susceptibility testing 
o C. glabrata and fluconazole, 
amphotericin B, and 
echinocandins 
o C. krusei and amphotericin B 
o C. guilliermondii and 
amphotericin B 
o C. rugosa and amphotericin B, 
fluconazole, and echinocandins 
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Unusual species or new treatment options 
(e.g., echinocandins, voriconazole, 
posaconazole) 
 Susceptibility of Candida spp. to 
echinocandins may be assumed unless 
initial response is suboptimal 
 Susceptibility testing warranted if there 
was prior exposure to echinocandins or 
fluconazole 
 Selection of therapy based on published 
consensus guidelines and review of 
survey data on the organism-drug 
combination in question 
 Susceptibility testing may be helpful 
when patient is not responding to what 
should be effective therapy 
Clinical response in patients despite 
being infected with an organism later 
found to be resistant 
 Best approach not clear. Take into 
account severity of infection, patient 
immune status, consequences of 
recurrent infection, etc. 
 Consider alternative therapy for 
infections with isolates that appear to 
be highly resistant to initial therapy 
Choice of susceptibility testing  CLSI methods 
o Broth based, M27-A3 
o Agar based, M44-A2 
 EUCAST EDef 7.1 
 Commercial methods 
o Etest 
o Sensititre YeastOne 
o Vitek 2 
 
5.5 Conclusions 
With the low prevalence of antifungal resistance in C. albicans isolated from our 
subjects, the likelihood of response to therapy with any conventional azole, 
amphotericin B or echinocandins is very high. This is assuming that the other factors 
determining response to therapy remain favourable. The factors include the immune 
response of the host, the virulence of the organism, drug pharmacodynamics and 
pharmacokinetics. All these factors contribute to how an individual will respond to an 
antifungal agent (Pfaller, 2012; Pfaller and Diekema, 2012). Certainly our data is a 
valuable addition to the baseline data on the antifungal sensitivity profile of yeasts in 
our study population. This should be undertaken on a regular basis and not every 
decade. 
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CHAPTER 6 GENOTYPING OF C. ALBICANS ISOLATED FROM THE HIV 
POSITIVE WOMEN OVER 6 MONTHS’ FOLLOW UP PERIOD 
6.1 Introduction 
6.1.1 Genotyping of C. albicans 
Genotyping of yeasts evolved with the development of more accurate and portable 
methods which enables results to be compared across the globe. Furthermore, it aids 
in deciphering the epidemiological distribution of yeasts,  identifies the predominant 
strains in individuals and associated factors with colonisation. Genotyping is more 
accurate in the study of strain colonisation in individuals to deteremine persistence of 
the same strain and acquisition of exogenous strains. Genotyping is also used in 
monitoring outbreaks of infection (Vanhee et al., 2010). However, knowledge on 
genotyping is scarce. 
 
 Knowledge of C. albicans strain diversity and evolutionary changes over time are 
relatively scanty in the global populaton (Pires-Goncalves et al., 2007). Data is 
lacking from some countries and individuals have to be followed up by conducting 
serial genotyping of isolates. This genotyping may yield more than one strain per 
individual. Consistently taking samples from individuals over time and sampling 
several strains to determine the molecular epidemiology requires considerable time 
and money. In addition, genotyping techniques are many and varied, and results may 
not be comparable across laboratories and countries. Consequently, different 
genotyping methods are still being evaluated to identify their strengths and drawbacks 
(Vanhee et al., 2010). 
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The population structure of C. albicans strains are usually consistent in the same 
person. In addition, colonising strains are related with respect to age, same site in the 
body, family members, geographic location and subjects with similar conditions such 
as HIV infection. However, geographic strain epidemiology is becoming less distinct 
due to human travel. Furthermore, more than one genotype can exist in the same body 
part or individual thereby indicating the dynamic nature of colonisation (Clemons et 
al., 1997; Kleinegger et al., 1996; Odds, 2010; Xu et al., 1999). 
 
6.1.2 ABC Genotyping  
ABC genotyping is one method of genotyping C. albicans. It offers a simple way of 
genotyping C. albicans in spite of the poor discriminatory ability relative to some 
other methods. ABC genotyping is used alone or as an adjunct to other genotyping 
methods (Abdulrahim et al., 2013; Chaves et al., 2012; Kumar et al., 2006). It is 
useful where sequence typing facilities and other more sophisticated genotyping 
methods are not available (Kumar et al., 2006). However, ABC genotyping alone is 
not recommended when the pleomorphism in the strains differ by more than a single 
nucleotide (Chaves et al., 2012). To illustrate this, ABC genotyping was combined 
with microsatellite typing to monitor strain epidemiology in subjects with candidemia. 
In the study, similar ABC genotypes were found to be present in different anatomic 
sites in subjects who developed candidemia in contrast to a diveristy of strains in 
subjects without candidemia (Chaves et al., 2012). A comparable investigation 
combined ABC genotyping with MLST (Multilocus Sequence Typing) genotyping to 
monitor C. albicans involvement in leukoplakia. Enrichment of genotype C was 
found in leukoplakia (Abdulrahim et al., 2013).  
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6.1.3 Multilocus Sequence Typing (MLST)  
This highly discriminatory genotyping method is used to characterise the molecular 
epidemiology of Candida species. The polymorphisms of seven housekeeping genes 
are used to characterise the strains. Details of the housekeeping genes for C. albicans 
MLST is illustrated in Table 6.1 (Spampinato and Leonardi, 2013). 
 
Table 6.1 Housekeeping genes for C. albicans MLST [Source: Spampinato and 
Leonardi, 2013] 
 
 
The combination of the allele numbers of the seven genes is used to derive a unique 
sequence type (ST or DST number) for every strain. Currently on the MLST database 
(http://calbicans.mlst.net/), there are 2142 sequence types for C. albicans (as at 17
th
 
October 2013). This is the largest global database of strain type information for C. 
albicans. DST 69 is the most common globally and 290 distinct DSTs are from oral 
isolates. The DSTs representing the strains are also categorised into 24 clonal 
complexes by the eBURST algorithm to describe relatedness. Clonal complex 1 
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(CC1) is the most common. Furthermore, MLST classified C. albicans yeasts into 5 
major and many minor clades.  The major clades are 1, 2, 3, 4 and 11 (Odds, 2010). 
 
Recent updates on the Candida MLST database include renaming of one of the C. 
albicans housekeeping genes MPIb to PMIb. Typing schemes for other important 
Candida yeasts such as C. glabrata and C. tropicalis have also been developed on the 
MLST database. Unlike C. albicans, six housekeeping genes are used to type both 
yeasts. Similar gene sets have also been described for C. krusei and C. dubliniensis 
(Spampinato and Leonardi, 2013). The major advantages of MLST include having a 
high discriminatory ability, high portability (similar results are obtainable across 
laboratories) and the database is available on the Internet for global accessibility. 
  
6.1.4 Carriage of Candida strains  
C. albicans is a diploid yeast without a sexual cycle. Mating is extrememly rare and 
occurs without meiosis. Furthermore, C. albicans yeasts show a clonal pattern of 
reproduction but are able to shuffle chromosomes leading to duplicate genes and 
reassortment of genes. Consequently, C. albicans strains tend to reveal a high genetic 
diversity from clonal reproduction and a very high rate of recombination events 
(Bougnoux et al., 2008b; Odds et al., 2007). The eBURST software on the MLST 
database show clonal clusters of related yeasts from the same clone with a lot of 
singleton strains. Clonal relationship is determined by similarity of six out of the 
seven housekeeping genes on the MLST database. 
  
As similar or closely related strains persist in individuals, the distinction between 
microevolution of a colonising strain and a replacing strain may be difficult to 
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determine because of the significant genetic relatedness. Differentiation is only 
possible when the replacing strain is markedly different but this is not always the 
case. However, it is important to determine the difference between colonising and 
exogenous strains of C. albicans strains due to their implications in pathogenesis. On 
the other hand, few individuals carry more than one predominant strain and 
replacement of a strain is not always from an exogenous source (Odds, 2010). The 
correct identification of a colonising strain versus an exogenous (reinfecting) strain is 
important in order to determine the virulence of the strain which relates to the ability 
to cause infection. 
 
Studies that follow up subjects to determine the yeast strain epidemiology over time 
are few and none has characterised the C. albicans strains from the oral cavity using 
MLST in South Africa. With the highest HIV burden in the world, it is important to 
deteremine if the strains present in HIV infected individuals in South Africa are 
colonising strains or exogenous infecting strains because they tend to have recurrent 
candidiasis. Furthermore, conditions that predispose to microevolution of colonising 
strains are also poorly understood (Odds et al., 2006) and to date, no study has 
monitored strain maintenance or occurrence of new strains of C. albicans in a 
longitudinal study in an African population. The objective of this chapter was to 
determine and compare the genotypes of C. albicans in colonized women at intervals 
during the follow up period to detect the acquisition of exogenous strains using ABC 
genotyping and MLST techniques.  
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6.2 Methods and materials 
6.2.1 Subjects, sample collection and Candida species isolation 
One hundred and seventeen HIV positive women carried Candida in their oral cavity 
(Chapter 3) and they were asked to come for follow up visits after 3 and 6 months. 
Only 17 women kept their appointments and carried C. albicans at all 3 visits (0, 3 
and 6 months). Oral rinse samples were collected, cultured and C. albicans was 
identified using the API technique (full method described in Chapter 3). The samples 
from 17 women who carried C. albicans (17 x 3 = 51 isolates) at all the three visits 
were subjected to ABC genotyping and MLST technique. 
 
6.2.2 DNA extraction 
Genomic DNA was extracted from C. albicans samples using the technique 
previously described with modifications (De Baere et al., 2002). One colony from 
each sample was inoculated into 1.5ml Eppendorf tubes containing sterile distilled 
water, boiled for 6 minutes, centrifuged for 4 minutes at 14680 rpm and placed on ice. 
The supernatant was collected, DNA concentration was confirmed with the 
NANODROP 2000
®
 (Thermo Scientific, Wilmington, DE, USA) and the samples 
stored at -75°C until required. The samples had an average DNA material of 38.7 
ng/μl. 
 
6.2.3 ABC genotyping  
A 50 μl PCR mix was prepared using the primers described for the technique 
(McCullough et al., 1999). From the 2 primers CA-Int L (5
/
-
ATAAGGGAAGTCGGCAAAATAGATCCG TAA-3
/
) and CA-Int R (5
/
-
CCTTGGCTGTGGTTTCGCTAGATAGTAGAT-3
/
), 0.5 μl of each primer was 
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added to the mix. The other components of the mix were 10 μl of Taq buffer, 10 μl of 
MgCl2, 2 μl of dNTPs, 0.5 μl of Taq polymerase enzyme and 5 μl of DNA from 
respective samples and 21.5μl of sterile distilled water. Amplification was carried out 
using the MJ Mini Personal Thermal Cycler
®
 (BIO-RAD Hercules, CA, USA) with 
the protocol – initial denaturation, 95°C for 2 minutes and subsequently 30 seconds, 
annealing 57 °C for 1 minute, extension 72 °C for 2 minutes and the cycle repeated 
for 34 times with final temperature of 72°C for 10 minutes. Agarose gel 
electrophoresis was used to separate and demonstrate the PCR products. The gel was 
constituted with 0.3 g agarose powder and 30mls of 1x TBE (Tris borate EDTA) 
buffer. The loading buffer (100 μl) was mixed with 4 μl of ethidium bromide. A drop 
of this mix was then added to 10 μl of PCR product from each sample. A 1kb ladder 
was used with every gel. The electrophoresis was run for one hour at 300 mA and 120 
V in a tank with TBE buffer. The gel was viewed under UV illumination and the 
images captured and analysed using the VersaDoc QuantityOne machine
®
  (BIO-
RAD Hercules, CA, USA). The genotype of each sample was determined by the size 
of the fragments, A=450bp, B=840bp, C=450bp & 840bp and categorised using the 
ABC scheme. 
 
6.2.4 MLST genotyping 
The 50 μl PCR mix contained 0.5 μl of the forward and 0.5 μl of the reverse primers 
of each of the housekeeping genes (Table 6.1). Each mix also contained 10 μl of Taq 
buffer, 10 μl of MgCl2, 2 μl of dNTPs, 0.5 μl of Taq polymerase enzyme and 5 μl of 
DNA from respective samples and 21.5 μl of distilled water. Each sample was 
subjected to seven PCR reactions, one for each gene. Agarose gel electrophoresis 
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described in 6.2.4 was performed using 10 μl of the PCR product. The remaining 
amplified gene content (40 μl) was subjected to DNA sequencing. 
 
6.2.5 Sequencing 
DNA sequencing for the MLST samples was undertaken using the ABI Big Dye V3.1 
on the ABI 3500XL machines as per manufacturer instructions. 
 
6.2.6 Genotyping and strain identification using the MLST database 
The forward and reverse sequences of each of the housekeeping genes from every 
sample were subjected to further analysis using the Geneious 6R software 
(Biomatters, http://www.geneious.com). A consensus sequence conforming to the 
number of base pairs for each gene was obtained by aligning and trimming the 
forward and reverse sequences for each gene sequence. The trimmed sequences were 
compared with the existing allele sequences on the MLST database. Conformity with 
existing allele sequence produced the allele number and when there is no perfect 
agreement the MLST database indicated the closest allele and percentage closeness. 
Allele numbers for the seven genes were then used to generate a diploid sequence 
type (DST) number unique to that strain. Existing DST numbers were noted. 
Sequence data were sent to the MLST curator at the Institut Pasteur (Paris) to assign 
new numbers for the alleles and DSTs that were novel.  
 
Using the Geneious
®
 6R software (Biomatters, http://www.geneious.com), 
dendrograms were generated from the sequence data of respective alleles. The 
unweighted pair group method with arithmetic averages (UPGMA) algorithm was 
used. Tree gap alignment option was 65% similarity and the gap open penalty was 12. 
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Using cluster analysis, another UPGMA dendrogram was generated in Stata
®
 12 
(StataCorp, College Station, Texas) from all the alleles and for all the visits per 
subject. The method used to interpret the data was based on the similarity coefficient 
as previously described. The algorithm computed a distance between isolated strains 
from which a number was generated, 0 representing no relationship and 1 indicating 
identical strains. From 0.9 to 1 indicated microevolution, 0.8-0.9 indicated moderate 
relationship and less than 0.8 was unrelated. A matrix of similarities was generated 
for all the observations. The correlation option was used for the analysis rather than 
the Euclidian distance as similarities was easier to interpret (Boriollo et al., 2006; 
Soll, 2000). 
 
6.2.7 Association between virulence and genotypes 
A repeated measures analysis of variance was used to determine the variation in the 
virulence factors during the follow up visit after categorising into two groups, those 
reinfected with different strains and those carrying the same strain at all visits. 
 
6.3 Results 
6.3.1 ABC genotyping 
ABC genotyping revealed a predominance of the genotype B in 31 (60.8%) of the 51 
strains. This was followed by genotype A in 14 (27.4%) and genotype C in 6 (11.8%). 
Sixteen (94.1%) out of the 17 women followed up carried the same ABC genotype for 
all the three visits (Table 6.2). Figure 6.1 shows the gel samples for subjects 3, 6, 10, 
12, 27 and 35. Subjects 3 and 10 carried genotype A consistently for all visits. 
Likewise, Subjects 6 and 12 carried genotype B consistently for all visits and Subjects 
27 and 35 were colonised with the same genotype C at all visits. 
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Table 6.2  Strain characteristic using V3 region of the 25S rRNA gene of C. 
albicans isolated from 17 patients (ABC genotyping)  
 
 C. albicans strains genotypes (A=450bp, B=840bp, C=450bp & 
840bp) 
No. Baseline 3 months 6 months Comment 
003 A A A Consistent 
006 B B B Consistent 
010 A A A Consistent 
012 B B B Consistent 
027 C C C Consistent 
035 C C C Consistent 
041 A A A Consistent 
042 B B B Consistent 
045 B B B Consistent 
078 B B B Consistent 
082 A A B Inconsistent 
132 B B B Consistent 
140 B B B Consistent 
166 B B B Consistent 
173 B B B Consistent 
185 B B B Consistent 
193 A A A Consistent 
Total- Genotype A=14(27.5%), Genotype B=31(60.8%), Genotype C=6 (11.7%) 
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Figure 6.1 PCR products of the V3 region of the 25S rRNA of C. albicans.  
 
 
[1000bp molecular weight marker, C: negative control, Subject 3 & 10: genotype A 
(450 bp), Subjects 6 & 12: genotype B (840bp), Subjects 27 & 35: genotype C (450 
bp & 840 bp)] 
 
 
6.3.2 MLST genotyping 
Some of the amplified PCR products of test genes are shown in figure 6.2 to 6.7. The 
results of all seven alleles tested and the DST numbers generated in MLST technique 
are shown in Table 6.3.  
 
 
 
 
 
 
 
840 bp-- 
 
 450 bp-- 
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Figure 6.2 PCR products of the AAT1a gene of C. albicans using MLST technique.   
 
 
 
Figure 6.3 PCR products of the ADP1 gene of C. albicans using MLST technique 
   
 
 
   349 bp- 
   443 bp- 
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Figure 6.4 PCR products of the MP1b gene of C. albicans using MLST technique 
 
 
 
Figure 6.5 PCR products of the SYA1 gene of C. albicans using MLST technique 
 
 
 
    375 bp- 
391 bp- 
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Figure 6.6 PCR products of the VPS13 gene of C. albicans using MLST technique 
 
 
 
 
 
Figure 6.7 PCR products of the ZWF1b gene of C. albicans using MLST technique 
 
 
 
403 bp- 
491 bp- 
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Table 6.3 Strain characteristics of C. albicans isolated from HIV positive women 
over 6 months follow up period using MLST  
 
New alleles and DSTs are highlighted in red 
 
Fourteen undocumented alleles and 28 diploid sequence types (DSTs) unique to this 
study group were identified and added to the C. albicans MLST database by the 
curator. New allele numbers and DSTs are highlighted in red (Table 6.3). Strain 
STUDYID VISIT AAT1a ACC1 ADP1 MPIb SYA1 VPS13 ZWF1b 	DST
3.1 1 31 3 2 2 2 24 12 2164
3.2 2 35 4 4 4 34 4 4 808
3.3 3 31 91 2 2 2 24 12 2177
6.1 1 143 14 8 4 7 10 8 2178
6.2 2 143 92 8 4 7 10 8 2179
6.3 3 52 14 8 4 7 10 8 2165
10.1 1 31 2 5 2 2 24 241 2182
10.2 2 31 2 5 2 2 24 25 2166
10.3 3 31 2 5 2 2 24 25 2166
12.1 1 8 7 8 4 2 10 22 2167
12.2 2 144 7 8 4 2 10 22 2180
12.3 3 70 7 8 4 2 10 22 2168
27.1 1 8 14 125 4 7 10 8 2183
27.2 2 8 14 8 4 7 10 8 124
27.3 3 8 14 8 4 7 10 8 124
35.1 1 8 3 8 4 7 13 8 210
35.2 2 8 3 8 4 186 13 8 2186
35.3 3 8 3 6 4 7 13 8 2187
41.1 1 8 14 8 4 7 3 8 95
41.2 2 8 14 8 4 7 3 22 1909
41.3 3 8 14 8 4 7 3 22 1909
42.1 1 70 14 6 4 84 10 8 2169
42.2 2 145 14 6 4 76 10 8 2181
42.3 3 70 14 6 4 84 10 8 2169
45.1 1 14 14 8 4 50 10 8 2170
45.2 2 14 14 8 4 50 10 8 2170
45.3 3 14 14 30 4 50 10 8 2171
78.1 1 14 3 6 4 2 10 8 2172
78.2 2 70 3 6 4 2 10 8 2173
78.3 3 14 3 6 4 2 10 8 2172
82.1 1 35 4 4 4 185 26 4 2185
82.2 2 4 4 4 4 34 26 4 646
82.3 3 8 7 8 4 7 26 4 2174
132.1 1 54 93 10 36 184 113 242 2188
132.2 2 53 31 10 36 83 113 111 1019
132.3 3 53 31 10 36 83 113 111 1019
140.1 1 8 3 6 4 7 10 8 915
140.2 2 70 3 6 4 7 10 8 619
140.3 3 70 3 6 4 7 10 8 619
166.1 1 8 7 8 4 7 10 8 144
166.2 2 70 7 8 4 7 10 8 661
166.3 3 63 7 8 4 7 10 8 2175
173.1 1 70 14 8 4 7 249 8 2189
173.2 2 70 14 8 4 7 10 8 656
173.3 3 8 14 8 4 7 10 8 124
185.1 1 8 3 8 4 7 10 8 392
185.2 2 8 3 8 4 7 10 8 392
185.3 3 8 94 8 4 7 10 8 2184
193.1 1 31 5 5 12 2 21 5 2176
193.2 2 31 95 5 12 2 21 5 2190
193.3 3 31 5 5 2 2 21 5 375
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consistency (indicated by the DST number) was less distinct from visit to visit in the 
same person unlike ABC genotyping which showed a more consistent pattern. This 
data was simplified by separating the DST numbers at each visit (Table 6.4). Nine 
subjects (52.9%) carried the same strain at 2 visits, and 8 subjects (47.1%) carried 
different strains at all visits (Table 6.4). It should be noted that genetically similar 
strains might have divergent DST numbers. The more sensitive polymorphism of the 
alleles was used to assess strain relatedness in Figures 6.8, 6.9 and Table 6.5. 
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Table 6.4 Genotypes with DST numbers of C. albicans isolated from the HIV 
positive women over 6 months 
No. Patient DST of C. albicans at various 
visits 
Same DST 
at 2 visits 
Same DST 
at 3 visits 
Different DST 
at all visits 
1 3 2164 808 2177   X 
2 6 2178 2179 2165   X 
3 10 2182 2166 2166 X   
4 12 2167 2180 2168   X 
5 27 2183 124 124 X   
6 35 210 2186 2187   X 
7 41 95 1909 1909 X   
8 42 2169 2181 2169 X   
9 45 2170 2170 2171 X   
10 78 2172 2173 2172 X   
11 82 2185 646 2174   X 
12 132 2188 1019 1019 X   
13 140 915 619 619 X   
14 166 144 661 2175   X 
15 173 2189 656 124   X 
16 185 392 392 2184 X   
17 193 2176 2190 375   X 
     9/17 (52.9%) 0/17 (0%) 8/17 (47.1%) 
New DSTs Unique from this study are highlighted 
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Figure 6.8 UPGMA Dendrogram to show relatedness of the C. albicans alleles  
AAT1a ACC1 CaADP1 
   
MP1b SYA1 VPS13 
  
 
ZWF1b   
 
  
 
 
 
 
 
 
Where 3.1, 3.2 & 3.3 means 
patient number 3 and isolate 
of C. albicans at visit 1, visit 
2 and visit 3 respectively. 
This is applicable to all the 
strains described in this 
dendrograms 
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Figure 6.9 UPGMA Dendrogram to show relatedness of the C. albicans DST 
genotyping  
 
 
*Mod. related= moderately related 
 
 
 
 
 
 
Where 3.1, 3.2 & 3.3 means patient number 3 and isolate of C. albicans at visit 1, visit 2 and visit 3 
respectively. This is applicable to all the strains described in this dendrograms 
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Table 6.5 Similarity matrix table and percentage similarities for all C. albicans strains 
No. Patient Parameters Comparison of strains Final 
interpretation 
Visit 1 & 2 Visit 1 & 3 Visit 2 & 3 
1 3 Isolate 3.1 to 3.2 3.1 to 3.3 3.2 to 3.3 Reinfection 
% Similarity <80 <80 <80 
Interpretation different different different 
2 6 Isolate 6.1 to 6.2 6.1 to 6.3 6.2 to 6.3 Reinfection 
% Similarity 100 <80 <80 
Interpretation same different different 
3 10 Isolate 10.1 to 10.2 10.1 to 10.3 10.2 to 10.3 No reinfection 
% Similarity 81-90 81-90 100 
Interpretation Moderately 
related 
Moderately 
related 
same 
4 12 Isolate 12.1 to 12.2 12.1 to 12.3 12.2 to 12.3 Reinfection 
% Similarity 100 <80 <80 
Interpretation same different different 
5 27 Isolate 27.1 to 27.2 27.1 to 27.3 27.2 to 27.3 Reinfection 
% Similarity <80 <80 100 
Interpretation different different same 
6 35 Isolate 35.1 to 35.2 35.1 to 35.3 35.2 to 35.3 No reinfection 
% Similarity 100 91-99 91-99 
Interpretation same Micro 
evolution 
Micro evolution 
7 41 Isolate 41.1 to 41.2 41.1 to 41.3 41.2 to 41.3 Reinfection 
% Similarity <80 <80 100 
Interpretation different different same 
8 42 Isolate 42.1 to 42.2 42.1 to 42.3 42.2 to 42.3 Reinfection 
% Similarity <80 91-99 <80 
Interpretation different Micro 
evolution 
different 
9 45 Isolate 45.1 to 35.2 45.1 to 35.3 45.2 to 45.3 No reinfection 
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% Similarity 100 81-90 81-90 
Interpretation same Moderately 
related 
Moderately 
related 
10 78 Isolate 78.1 to 78.2 78.1 to 78.3 78.2 to 78.3 No reinfection 
% Similarity 81-90 100 81-90 
Interpretation Moderately 
related 
same Moderately 
related 
11 82 Isolate 82.1 to 82.2 82.1 to 82.3 82.2 to 82.3 Reinfection 
% Similarity <80 <80 <80 
Interpretation different different different 
12 132 Isolate 132.1 to 132.2 132.1 to 132.3 132.2 to 132.3 No reinfection 
 % Similarity 100 100 100 
Interpretation same same same 
13 140 Isolate 140.1 to 140.2 140.1 to 140.3 140.2 to 140.3 Reinfection 
% Similarity <80 <80 100 
Interpretation different different same 
14 166 Isolate 166.1 to 166.2 166.1 to 166.3 166.2 to 166.3 Reinfection 
% Similarity <80 <80 100 
Interpretation different different same 
15 173 Isolate 173.1 to 173.2 173.1 to 173.3 173.2 to 173.3 Reinfection 
% Similarity 100 <80 <80 
Interpretation same different different 
16 185 Isolate 185.1 to 185.2 185.1 to 185.3 185.2 to 185.3 Reinfection 
% Similarity 100 <80 <80 
Interpretation same different different 
17 193 Isolate 193.1 to 193.2 193.1 to 193.3 193.2 to 193.3 No reinfection 
% Similarity 91-99 91-99 91-99 
Interpretation Micro 
evolution 
Micro 
evolution 
Micro evolution 
Summary:        11 (64.7%) –reinfection, 6 (35.3%) – no reinfection (microevolution/same strain) 
 Where 3.1, 3.2 & 3.3 means patient number 3 and isolate of C. albicans at visit 1, visit 2 and visit 3 
respectively. This is applicable to all the strains described in this dendrograms 
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Analysis of the individual alleles showed that they were closely related and not more 
than 5 clusters per alleles were present in Figure 6.8. This group of dendrograms 
shows the relationship of the individual alleles for subjects. The very few clusters 
present show the distinct relatedness. Compared with the dendrogram in Figure 6.9, 
there is less variability, which underscores the importance of strain typing using more 
than one locus. Some patients are not shown in some dendrograms due to the 
algorithm used to generate the dendrogram. 
 
The dendrogram in Figure 6.9 from the combination of all the alleles in all the 
subjects showed 4 distinct clusters which has the highest Duda/Hart coefficient of 
0.99. At 80% similarity (broken line above with the value of 0.8), 11 clusters are 
apparent and 17 clusters at 90% similarity. The largest cluster contained 17 isolates 
from 9 subjects, followed by 14 isolates from 8 subjects. The other clusters had 11 
isolates from 6 subjects and 9 isolates from 4 subjects. Strains from individual 
subjects were found in more than 1 cluster. A correlation matrix was generated from 
the dendrogram that showed the relatedness of the strains (Table 6.5). The strain 
relatedness in Table 6.3 was confirmed with the dendrogram. Similar strains are 
grouped (for instance, 10.2 and 10.3 have the same DST number and have 100% 
similarity. The detailed correlation (similarity) between the strains is displayed in the 
correlation matrix table (Table 6.5). In this table, 100% similarity between strains 
were interpreted as same strains, >90% similarities as microevolution, >80% 
similarities as moderately related and <80% similarities as different strains (Boriollo 
et al., 2006; Soll, 2000). These results showed that in 11 subjects (64.7%) reinfection 
with different strains occurred in the follow up period while 6 (35.3%) had no 
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reinfection. These subjects either carried the same strains all the time or the strains at 
follow up visits were closely related including microevolution. 
 
6.3.3 Association between virulence and genotypes 
An attempt was made to investigate an association between the virulence of C. 
albicans isolated from the women who were reinfected with other strains during the 
study period and women who carried the same strain throughout the study period. The 
results are shown in Figure 6.10 and Table 6.6. Proteinase production was 
significantly high in C. albicans isolated from the women who were reinfected with 
other strains (p=0.0033) compared to the women who carried the same strains of C. 
albicans for 6 months. There was no difference in the adherence property and 
phospholipase production. 
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Figure 6.10 Virulence properties of C. albicans on follow up visits comparing 
isolates from women reinfected with other strain and women who carried the same 
strain 
Adherence ability 
 
Proteinase production 
 
Phospholipase production 
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Table 6.6 Virulence properties of C. albicans isolated from the women reinfected 
with other strains and women who carried the same strain throughout the study 
period. 
Category Virulence 
factor 
Mean Square F p value 
Reinfected with 
different strains  
Adherence 514425.545  2.57 0.1013 
Proteinase .052885627  7.71 0.0033* 
Phospholipase .041711997  3.08 0.0683 
     
Same strain all 
visits 
Adherence 41021.5556  0.20 0.8222 
Proteinase .007774386  0.99 0.4057 
Phospholipase .000786055  0.07 0.9373 
 
 
6.4 Discussion 
6.4.1 Comparison of genotyping methods 
ABC genotyping is not the gold standard for Candida genotyping; however, it 
enabled the comparison of genotypes from visit to visit in our study population. 
Overall, the most predominant genotype was the B type in 31 strains (60.8%) in Table 
6.2. The genotype B was also prevalent in HIV infected individuals unlike genotype 
A, which is the most predominant in the general population and patients with 
candidiasis (Vidotto et al., 1999). Furthermore, ABC genotyping revealed a 
predominance of genotype A in HIV infected and cancer patients (Kumar et al., 
2006); however, there was no association between the ABC genotype and antifungal 
resistance. The predominance of genotype B requires further investigation to 
determine if this is a general trend in our study population or peculiar to HIV patients. 
This is necessary as an association was found between genotype B and vulvovaginal 
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candidiasis and itraconazole resistance (Li et al., 2008; Liu et al., 2009). A similar 
study found a predominance of genotype C in oral leukoplakia, especially the 
potentially premalignant Candida leukoplakia (Abdulrahim et al., 2013). Therefore 
there is a need to determine association of the predominant genotype with unusual 
virulence and antifungal resistance in our population. 
 
In spite of the limitations, ABC genotyping can be used to monitor strain types at 
different body sites in critically ill patients. The same ABC strain colonising multiple 
sites was found to predict the development of candidemia (Chaves et al., 2012). 
However, ABC genotyping is not the most sensitive technique and therefore it may 
not have fulfilled our objective of determining strain persistence. 
 
6.4.2 Carriage and strain diversity 
Using more than one genotyping method allowed comparison of the discriminatory 
abilities of ABC and MLST techniques. ABC genotyping showed a consistent C. 
albicans strain in 16 of the 17 subjects followed up for 6 months. On the contrary, 
consistent strain carriage was not present with MLST genotyping using the DST 
numbers. Only 6 subjects carried the same strain in all the visits, the majority 11 or 
64.7% were reinfected with other strains (Table 6.5). This finding is not surprising as 
MLST uses a scheme involving more areas of polymorphism unlike ABC genotyping 
that employs one.  
 
The observed reinfection in the majority of women could have been due to the 
following reasons. Firstly, it may be due to gene re-assortment and duplication of a 
colonising strain. It is known that succeeding clones may acquire an alteration in 
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genetic information. The genotyping techniques would interpret this as either 
microevolution or closely related. Secondly, exogenous strains may account for the 
differently isolated strains in multiple visits and thirdly, a different strain may be 
sampled at subsequent visits when multiple colonising strains are present. The 
determination of the mechanism at play is not an easy task (Odds, 2010). A 
predominant strain is usually present in the same individual and may colonise 
multiple sites (Odds et al., 2006; Verma et al., 2003) or multiple colonising strains 
may be present in the same individuals (Samaranayake et al., 2003). The differences 
in the observations might have arisen from the very dynamic nature of strain 
evolution. In addition, infection and other environmental factors may trigger 
microevolution of colonising strains. Apart from microevolution, individuals may 
acquire strains from the environment, family members, from hospital staff and other 
patients in a hospital setting. Multiple strains may also be present in the same site or 
in different body sites in the same person,  (Kam and Xu, 2002; Taylor et al., 2003).  
 
From the clonal pattern of our isolates in the dendrograms in Figure 6.8 and 6.9, there 
were less than 4 distinct clonal patterns with many strains belonging to the branch of a 
tree. It may be inferred that the closely related but different strain types found in our 
population may reflect the ability of the yeast to shuffle chromosomes due to the need 
to adapt to changing environmental conditions. This usually ensures adaptation and 
survival. As indicated, a clonal and diploid organism like C. albicans yields a greater 
variety of chromosomal patterns compared with a purely clonal and haploid organism 
(Odds, 2010). The probable scenario in our subjects is that both microevolution of 
colonizing strains and reinfection with different strains are occurring.  
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Microevolution or microvariation has been previously defined as a difference of only 
one allele of the seven MLST genes when comparing two strains (Jacobsen et al., 
2008). It may arise due to changes in karyotype or through a loss of heterozygosity. 
These changes, which result from stimuli within the environment lead to 
rearrangement of genomic sequences. Microevolution can occur in either the state of 
colonisation or infection and it not only fosters environmental adaptation, it also 
diversifies the strain molecular characteristics (Bougnoux et al., 2007).  
 
Microevolution of yeast strain may also indicate a transition to a pathogenic state or a 
change towards antifungal resistance. Some workers have suggested that strain or 
clade type may be related to virulence (Tavanti et al., 2005). Our results showed that 
the newly acquired oral cavity strains produced large amount of proteinase. Although 
there was no development of infection in these subjects during this follow up period, 
these women may be at the risk of developing infection, particularly if other risk 
factors permit.  
 
A previous South African study on strains isolated from patients with clinical 
infection did not show any strain being specifically related to oropharyngeal infection 
(Blignaut et al., 2002b). The previous use of antifungal agents was subjectively 
determined in our study population and most of the subjects were not certain about 
taking antifungal agents and the type of these agent. However, a study that 
investigated antifungal resistance with C. albicans genotype did not find any 
relationship and many studies have yielded inconsistent findings (Girish Kumar et al., 
2006; Liu et al., 2009). On the other hand, other workers have observed that Clade 1 
in the MLST database has demonstrated a resistance to flucytosin (Odds and 
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Jacobsen, 2008). The role of such strain diversity in the light of the other multiple 
host factors that may lead to clinical infection in our study population would require 
further studies to address such objectives. This is in light of the low prevalence of 
antifungal resistance in our study population (described in Chapter 5) and the 
differences in antifungal use and prescription. 
 
Reinfection involves colonisation by a strain from another body site or other 
individuals. This has been demonstrated in immune compromised subjects such as 
HIV infected, neonates and cancer patients. The danger is that such strains may be 
more virulent or more resistant to antifungal drugs thereby predisposing the carrier to 
mucosal or disseminated infections. Disseminated infections may sometimes be fatal 
(Bliss et al., 2008; Bougnoux et al., 2008a; Cliff et al., 2008). In our HIV infected 
subjects, their fluctuating immune status is a cause for concern. The danger of 
reinfection, particularly with highly virulent and resistant strains is high. This may 
occur when the immune status is low and requires constant vigilance and monitoring. 
 
The eBURST has been used previously to determine the phylogeny of C. albicans 
yeast strains. The knowledge of the ancestry of colonizing strains is important from 
epidemiologic and pathogenic viewpoints (Tavanti et al., 2005). However, eBURST 
analysis of our samples on the MLST website could not be performed because it was 
not functional. Several messages to the primary curator at the Imperial College in 
London have not yielded results. It should be noted, however, that the reliability of 
the eBURST algorithm in predicting ancestry and correctly grouping genetically 
similarly strains into clades has been questioned (Turner et al., 2007). It appears to 
perform better for mutations rather than recombination. In C. albicans, recombination 
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occurs more frequently (Turner et al., 2007). For these reasons the UPGMA 
dendrogram was used to analyse and interpret our results. 
 
From earlier studies, some of the previously typed strains in our subjects belonged to 
clade 4, which carried the most frequently occurring clonal complex of 124 
(Alastruey-Izquierdo et al., 2013).  The relationship between the strains sampled at 
different visits is particularly striking in Subjects 27 and 173 where the strains at all 
visits belonged to the same clonal cluster and clade even though the DSTs varied 
slightly (Table 6.3). The new DSTs are yet to be fully characterised since they are yet 
to be isolated in other locations. The determination of their characteristics requires 
further investigation. To reduce the possibility of missing multiple colonising strains, 
multiple yeast colonies need to be sampled and patients followed up for a longer 
period of at least 12 months (Samaranayake et al., 2003).  While this is possible, the 
logistics required are enormous besides the difficulty of keeping contact with subjects 
to arrange a follow up visit. Genotyping and sequencing requires considerable amount 
of time and money. Perhaps, it is for this reason that many studies (including ours) on 
strain distribution and evolution in C. albicans only sampled single colonies (Odds, 
2010; Pires-Goncalves et al., 2007). 
 
In spite of the relationship noted in the strains in our subjects, scientists globally 
realise that the whole exercise of DNA typing to identify strains is evolving. The only 
foolproof means to conclude that two strains are related is to compare whole genome 
sequences (Soll, 2000).  
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6.4.3 Newly identified strains and demographic characteristics 
A study (Ca3 technique) on oral C. albicans strains from South Africa revealed a 
peculiar clade restricted to South Africa. It was surmised that the strains were 
established commensals restricted to the location where they were isolated (Blignaut 
et al., 2002b). In that study, samples were taken once and patients were not followed 
up to monitor changes. Since then, no study has genotyped oral Candida yeast 
samples to determine the prevalent strains in that area and the persistence of such 
strains. It was difficult to confirm if the strains in our subjects were related to the C. 
albicans clade isolated previously in South Africa since the genotyping methods were 
different. The basis for strain typing in Ca3 probing is the variability of the major 
repeat sequences on the Candida genome, while MLST employs single nucleotide 
polymorphism of selected housekeeping genes. Some workers have however 
identified a moderate correlation in the clades identified by both methods in spite of 
the differences in technique (Odds et al., 2007; Odds and Jacobsen, 2008; Tavanti et 
al., 2005). The advantages of MLST genotyping compared to Ca3 probing include 
lower cost of processing, detection of genetic variations from single nucleotide 
pleomorphisms in the same subjects followed up over time (which Ca3 cannot detect). 
The MLST global database is also considerably larger (Chowdhary et al., 2006).  
 
Our study confirmed that there are native strains that have not been isolated 
previously using MLST. While the new strains are oral strains, some of the previously 
identified strains we found in the mouth have been previously isolated from blood 
samples taken from South African subjects. The details of the global and South 
African strain types on the MLST database is shown in Appendix 9.5 and 9.6. To 
date, 74 strains of C. albicans from South Africa are on the MLST database and 28 of 
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these are the newly isolated strains from our samples and they constitute the only oral 
strains. Obtaining the same strain in multiple body sites is an independent risk factor 
for invasive candidiasis in immunocompromised subjects (Chaves et al., 2012). The 
need to maintain adequate immune competence becomes very crucial in our study 
population to obviate colonisation of multiple body sites by the same strains. 
 
The distribution of C. albicans in Appendix 9.5 shows a global distribution. The 
genetic diversity is as varied as the distribution. This pattern may have arisen due to 
recent acquisition of the yeast by human beings, which has compelled adaptation to 
different environments. Alternatively, it is possible that the yeast has been evolving 
with humans right from inception (Odds, 2010).  Distinct strains have been tied to 
particular geographic regions, although several strains have been found in multiple 
locations (Takakura et al., 2008). Some of the previously documented strains present 
in our subjects have been found elsewhere. DST 95 is the most ubiquitous, found in 
UK, Switzerland, India, Pakistan, Australia, Morocco, France, and Austria. DST 124 
has been previously isolated in the UK, Israel, France, USA, Morocco, Austria 
(Appendix 9.8). Geographic localisation of C. albicans strains has become more 
difficult due to extensive human travel and interaction. It is therefore necessary to 
further evaluate the newly identified strains to determine distributional and virulence 
characteristics. This should be a continuous exercise in order to monitor evolutionary 
changes. 
 
One major disadvantage of the MLST system is that the current scheme does not 
include any gene from chromosome 3 and 5 of the Candida genome. An ideal MLST 
system would be to have representative genes from both ends and centre of each of 
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the eight chromosomes, thereby requiring 24 housekeeping genes for MLST typing. 
While that may be more discriminatory than the present scheme, the future of 
genotyping for any organism is whole genome sequencing. For a yeast like C. 
albicans, single nucleotide pleomorphisms on all the eight chromosomes could serve 
as the basis for strain typing in the near future (Odds, 2010).  
 
6.4.4 Conclusion 
MLST genotyping identified C. albicans unique to this region with previously 
undocumented DSTs and alleles in our study population. Although ABC genotyping 
showed that the majority of the subjects carried the same genotype for all three visits, 
MLST technique identified a mixture of genetically related and unrelated strains in 
follow up visits. This indicates microevolutionary changes and reinfection with 
different strains occurring in our subjects. Newly acquired strains produced more 
proteinase, suggesting that reinfection with different strains could be one of the 
reasons for the reoccurrence of candidiasis. Therefore, the factors that are responsible 
for these changes and the implications of virulence and clinical infection require 
further investigation. Apart from newly identified strains, some of the strains 
identified in oral samples have been previously isolated from blood samples. The 
need to further evaluate and monitor strain epidemiology becomes more paramount as 
the immune status of individuals is constantly changing. In addition, the role of 
human travel and other factors that may predispose to development of infection also 
require further evaluation.  
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CHAPTER 7:  SUMMARY AND CORRELATION OF RESULTS 
 
7.1 Summary of results 
Oral candidiasis (OC) has been associated with the HIV pandemic and it still poses a 
threat to the life and well being of an HIV positive individual. When it occurs in HIV 
infection, it is often due to severely depressed immunity or failure of treatment in 
patients on antiretroviral therapy. Apart from the diagnostic and prognostic 
importance of oral candidiasis, colonised individuals harbouring opportunistic 
pathogens like Candida species can progress from mucosal infection to invasive and 
life threatening disseminated infections (van der Meer et al., 2010). 
 
With the introduction of highly active antiretroviral therapy (HAART) in 1996, the 
prevalence of oral candidiasis abated but the condition did not disappear. 
Furthermore, HAART has not significantly changed the unusual high prevalence of 
oral colonisation by Candida in HIV positive subjects (Yang et al., 2006).  In 
addition, in sub Saharan Africa many HIV positive patients are still prone to OC due 
to inadequate HAART coverage which is almost 50% of the 23.2 million infected 
(Decroo et al., 2013). Furthermore, some HIV positive subjects on HAART may not 
comply with antiretroviral therapy for a variety of reasons (dos Reis HL et al 2011). 
As a result, opportunistic infections such as OC often occur and impact negatively on 
the quality of life and increase the likelihood of unfavourable outcomes (dos Reis HL 
et al 2011). 
 
 165 
The factors that predispose to oral colonisation and oral candidiasis are still very 
controversial. The exact role of the virulence and type of Candida organism, and the 
host immune status remain unresolved. Similarly, the molecular epidemiology of 
Candida yeasts; their virulence and antimicrobial characteristics are poorly 
understood in the HIV positive population in Africa. 
The study, therefore, investigated the relationship between carriage rates, virulence 
and genotypic diversity of Candida, social and clinical factors and the development of 
clinical infection. A series of objectives were drawn to investigate these factors. A 
summary of results is depicted as a flow diagram (Figure 7.1) and described here. 
 
1. To examine the carrier rate of Candida among HIV-positive women: 
prevalence, types and quantities of Candida, influence of oral hygiene, social and 
clinical factors (Chapter 3).  
Of the 197 women screened, 117 (59.39%) were colonised with yeasts. Colonisation 
rate has dropped from 81.3% reported in a previous study undertaken in the same 
setting (Patel et al., 2006). Oral hairy leukoplakia was the most common oral 
manifestation of HIV infection, in 27 (13.71%), followed by oral candidiasis in 15 
(12.8%) of those colonised. Without doubt, the lower rate of oral colonisation and 
candidiasis may be due to the introduction of HAART because the majority of the 
women 186 (94.42%) were on antiretroviral therapy at the time of recruitment. In the 
117 colonised with yeasts, 85 (72.65%) were colonised with C. albicans which shows 
that C. albicans is still the predominant species. C. dubliniensis was the most 
common non-albicans Candida in 14 subjects (11.97%), which is higher than 
elsewhere (Owotade et al., 2013). While it is beneficial that the prevalence of oral 
colonisation and candidiasis has reduced, the potential for recurrent mucocutaneous 
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and invasive infection is still a cause for concern. Candida with its repertoire of 
pathogenic capacity has not been completely eliminated and its presence in immune 
suppressed HIV positive individuals is not reassuring (Anwar et al, 2012). 
 
Principal factors associated with colonisation by Candida yeasts include concurrent 
infection with tuberculosis (p=0.03), diabetes mellitus (p=0.005) and not being on 
antiretroviral therapy (p=0.003).  This is of concern because South Africa has one of 
the highest estimated TB rates in the world. In addition, Candida colonisation could 
be due to reduced immune response since low CD4 counts were also associated with 
the colonisation (p=0.022) and higher Candida counts (r= -0.26, p=0.006). However, 
increased HAART coverage has been proposed as a means of stemming the rising 
incidence and mortality of HIV related TB in South Africa (Pretorius et al 2014), 
which will have additional benefits for other opportunistic infections such as oral 
candidiasis. 
 
Other associated factors with colonisation were the wearing of dentures (p=0.022) and 
having a high DMFT (p=0.019). Adherence ability of Candida species to oral 
prostheses and association with dental caries is well described (Raja et al., 2010; 
Witzel et al., 2012) and this may explain the findings in this study. Although 86.87% 
of patients were educated only 67% claimed to brush their teeth twice a day. 
However, only 32% visited dentists, which is necessary for the diagnosis and 
treatment of dental caries (Table 3.1, 3.2). This may be the probable reason why the 
median DMFS (Decay Missing Filled Surfaces) was 20 with IQR 27 and range 0-102 
(Table 3.4). Consequently, 30/148 surfaces either had caries, restorations or were 
missing. If these patients were not visiting dentists regularly, these surfaces probably 
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became decayed and may have been colonized by Candida as well (Witzel et al., 
2012). 
Results in this section stress the importance of implementing HAART to improve the 
immune response and maintain lower counts of Candida in the oral cavity. These 
results also highlight the importance of oral hygiene and monitoring of carious status. 
These measures should reduce the chances of recurrent oral candidiasis. 
2. To determine the virulence of C. albicans during the study period and the 
influence of quantity and/or virulence of C. albicans on the development of oral 
candidiasis during the study period and to examine the occurrence and role of 
non-C. albicans yeasts in the development of  candidiasis in the study period 
(Chapter 4). 
The virulence characteristics of the yeasts isolated from the Candida carriers 
fluctuated and did not correlate with the CD4 counts in the 6 months follow up 
period. In addition, virulence factors did not differ in patients with oral candidiasis 
and those without infection. However, the yeast count was higher in the infected 
group. These results suggest that a high count without a commensurate increase in the 
virulence may cause infection due to a cumulative effect. These results stress the 
importance of maintaining low counts of Candida in the oral cavity. 
  
In spite of the lower prevalence of non-albicans Candida yeasts (21%) in the oral 
cavity, their role in oral candidiasis cannot be excluded. Therefore, virulence 
characteristics of C. albicans and non-albicans Candida in the colonisation state and 
during active infection were compared. Virulence properties were significantly higher 
in C. albicans isolated from colonised and infected individuals. C. albicans is an 
aggressive yeast and produce invasive hydrolytic enzymes when conditions are 
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favourable (Ells et al, 2014).  However, non-albicans Candida isolated from the 
patients with oral candidiasis produced a significantly larger amount of 
phospholipase. In addition, this enzyme is responsible for tissue damage and is clearly 
implicated in the pathogenesis of oral candidiasis due to non-albicans Candida. In the 
oral cavity, non-albicans Candida and C. albicans usually reside together. For this 
reason, their individual role in pathogenesis cannot be determined. However non-
albicans Candida yeasts are capable of causing systemic infections (Al-Rawahi and 
Roscoe, 2013) which establishes their role in the pathogenesis of infection. 
 
Clinical infection is a complex process due to many other factors apart from the 
virulence of the yeasts. Although we could not relate the limited virulence 
characteristics (adherence ability, proteinase and phospholipase production) with 
infection, their role, fitness attributes of the yeasts and host factors in initiating 
clinical infection need further investigation. As our study follow up time is limited, 
the likelihood of developing clinical infection in our population is very likely to occur 
beyond the study period as yeasts constantly elaborate virulence factors while host 
immunity fluctuates. In addition, the current antifungal armamentarium is still 
limited; hence, new antifungal strategies are being developed to target the virulence 
properties of yeasts (Peirce and Lopez-Ribot 2013).  This confirms that the study of 
the virulence attributes of the yeasts remains relevant. 
 
Suppression of C. albicans with antifungal drugs sometimes causes over growth of 
intrinsically resistant non-albicans Candida (Kamikawa et al., 2014). In addition, the 
regular use of antifungal agents for recurrent oral candidiasis favours the development 
of drug resistant strains of C. albicans (Bondaryk et al., 2013). For this reason, the 
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antifungal sensitivity of C. albicans isolated from our study population was 
investigated. 
 
3. To study the antifungal sensitivity of C. albicans isolated from HIV positive 
women (Chapter 5). 
Antifungal resistance was low in the study population. The prevalence of resistance to 
posaconazole was 1.7% (2/120), while it was 0.8% i.e. 1/120 of the strains were 
resistant to echinocandins and the azole antifungals, fluconazole, itraconazole and 
voriconazole. Posaconazole resistance is a problem because it is a second-generation 
extended-spectrum triazole and is recommended for prophylaxis of invasive fungal 
diseases in immunocompromised hosts (Lyseng-Williamson KA, 2011). No 
antifungal resistance to amphotericin B was observed.  This is contrary to the finding 
of Blignaut et al. (2002) who reported 8.5% resistance to this drug. Large studies are 
required to confirm these findings. Azole resistance was only found in one subject 
which supports the theory that multi-azole resistance is probably due to previous 
repeated antifungal exposure (Pfaller, 2012). Antifungal resistance was low in our 
study population, nonetheless, the isolation of strains resistant in particular to 
echinocandins is a cause for concern because it is a new drug. Furthermore, this 
resistance could be the cause poor outcomes and increased fatality (Parmeland et al, 
2013). Furthermore, a single resistant strain of C. albicans in an immune 
compromised individual can rapidly progress from thrush to fatal candidemia 
(Gautam et al, 2010). The risk factors for antifungal resistance in our study population 
needs to be investigated further. In addition, azole non-responsive patients should be 
treated with other types of antifungal drugs. 
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4. To determine and compare the genotypes of C. albicans in those colonised 
women at intervals during the follow up period (Chapter 6).  
The present study has limitations because the study investigated a very dynamic and 
complex process with constantly variable host and yeast factors. Furthermore, these 
factors are constantly interacting at the molecular, microbial and subclinical level 
(Thein et al., 2009). 
 
ABC genotyping revealed a predominance of genotype B in 31(60.8%) of the 51 
strains isolated from the 17 women sampled at three visits followed by genotype A 
i.e. 14 (27.4%) and genotype C in 6 (11.8%). Sixteen (94.1%) out of the 17 women 
carried the same ABC genotype for all the three visits and showed the less 
discriminatory nature of this technique. However MLST, a more discriminatory 
technique showed that only 6/17 (35.3%) women carried the same strains at all three 
visits whereas 11 subjects (64.7%) were reinfected with different strains. Further 
analysis showed that both microevolution and reinfection with other strains was 
occurring in our study population. The source of reinfection could be colonization 
from other parts of body, the living environment or family members. In our study 
population 99% of patients had families of between 1-10 members. In addition, 24% 
of patients shared their food during meal times (Table 3.1). This may have been the 
reason why large number of patients 11/17 (64.7%) were reinfected with different 
strains over a 6 month period. This observation may be significant because virulence 
activity and antifungal resistance have been associated with particular strain types and 
their source (Nawrot et al, 2008). Reinfection may lead to recurrent oral candidiasis if 
highly virulent or drug resistant strains are acquired. Although the correlation 
between virulence factors and clinical infection was not established (Chapter 4, Table 
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4.8), newly acquired C. albicans strains during the follow up period produced large 
amount of the tissue damaging proteinase (Table 6.6 and Figure 6.10) which suggests 
possible initiation of pathogenic activity. Highly virulent newly acquired strains of C. 
albicans may even lead to severe local and disseminated infection in HIV positive 
patients if the immune status becomes severely compromised.  
 
In the present study, 14 previously undocumented alleles and 28 diploid sequence 
types (DSTs) unique to our study population and region were identified and added to 
the C. albicans MLST database by the curator. As previously shown by Blignaut et al, 
(2002) these results confirmed that oral cavity isolates of C. albicans in the African 
population are different from those documented elsewhere and many native strains are 
yet to be discovered.  
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Figure 7.1 Illustrative summary of principal findings 
HIV positive women and Candida colonisation 
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In this study, colonised women were distinctly different from those who did not carry 
yeasts. In addition, they were more likely to be more immune compromised because 
they were not on HAART, had tuberculosis, diabetes mellitus and a low CD4 count. 
The low prevalence of clinical infection and contributing factors to being 
symptomatic were less distinct. However, the absence of HAART and a high yeast 
count contributed to the development of clinical infection. Obviously, the 
compromised immune status aided yeast multiplication leading to infection. Although 
the virulence of the yeasts did not increase during infection, other virulence factors or 
fitness attributes of the yeasts may have contributed to yeast infection. Furthermore, 
the study captured a brief part of a continuum where infection may supervene if the 
circumstances are favourable. Although the non-albicans Candida yeasts were not as 
aggressive as C. albicans, their role in the development of infection needs to be 
evaluated further. 
The process of infection is complex and involves many factors. The level of virulence 
versus the state of immunity required to initiate infection has not been determined. In 
this study both fluctuated throughout the follow up period without definite 
correlation. With the present state of knowledge, it is extremely difficult to produce a 
model to explain when the interaction between the host immune status and a 
commensal yeast will lead to clinical infection (Cottier and Pavelka, 2012). 
The genotyping of the yeast further revealed an on-going dynamic process in the 
subjects. Most subjects appear to be reinfected with other strains, which may play a 
role in colonisation and infection. Although resistance to antifungal therapy remains 
low, with reinfection and microevolution occurring, the low resistance pattern may 
change and the few resistant individuals may develop life threatening candidemia. 
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With this complex and dynamic process, constant monitoring of the intervening 
factors is not just necessary but highly recommended. 
 
7.2  Recommendations 
 Efforts should be made to improve HAART coverage and retain enrolment in 
African subjects.  This can be further achieved by going into the communities 
and not waiting for the patients to come to tertiary hospitals such as Charlotte 
Maxeke (Decroo et al., 2013). 
 It is important to keep the yeast count low in the colonised HIV positive 
subjects. Simple mouthwashes such as triclosan are effective (Patel et al., 
2008). This is particularly crucial for patients wearing dentures and other 
forms of prosthesis. 
 Oral examinations should be conducted with every clinic visit of HIV positive 
patients. Attention should be paid to other factors that may encourage oral 
yeast colonisation such as caries and immune status as reflected by the CD4 
count. Early access to oral care to prevent complications is advocated in HIV 
infection (Liberali et al., 2013).  
 The antifungal resistance profile of Candida in colonised patients should be 
constantly monitored and guidelines strictly followed when prescribing 
antifungal drugs. 
 Attention should be paid to personal and oral hygiene in order to minimise 
reinfection (Muzurovic et al., 2012). 
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7.3 Limitations of the study 
 Genotyping and virulence of the strains could not be undertaken for 
more than one colony due to the complexity of logistic requirements ie 
117 patients X 3 visits X 2 to 5 colonies: identification, virulence 
properties, genotyping with 7 genes and sequencing reverse and 
forward. It is possible that the same strain or new strains may have 
been missed in the follow up visit. Furthermore, the cost of 
investigating is an additional limiting factor. 
 The role of virulence in infection is ideally studied in the host 
environment where the immune and other host factors directly interact 
with the virulence of the organism. Apart from animal models of 
Candida infection, studying the virulence of Candida species in human 
volunteers is extremely difficult. Most studies still rely upon in vitro 
snapshot observations. 
 Even when strains are totally identical using current molecular 
methods, it cannot be assumed that strains are the same. This will 
remain a limitation until the whole genome sequencing is available for 
biological species. 
 Follow up is difficult in any cohort of HIV positive individuals. 
Uncertain social and psychological status, unforeseen illnesses, 
complications and even death are reasons for attrition. Therefore out of 
117 eligible subjects, only 17 women were available at follow up visits 
and carried C. albicans. A larger group may have yielded more 
information. 
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 The role of other possible contributory factors to colonisation, such as 
history of previous antifungal use or previous Candida infection could 
not be accurately determined. Most of the subjects were not able to 
accurately recall information that was not in their case notes. Even the 
information they gave may be biased. 
 C. albicans is a commensal carried by women in their oral cavities, 
vagina and gut. Ideally all these cavities should have been sampled to 
isolate C. albicans and genotype. This would have clarified the source 
of transmission of C. albicans between body cavities of an individual. 
However, it was impossible to collect samples from these cavities for 
many reasons. Therefore patients classified as being reinfected with 
new strains of C. albicans in Chapter 6 may have acquired these strains 
from other body cavities. 
 
7.4  Future Research 
 The epidemiology of oral candidiasis in HIV infection should be 
further explored with larger regional surveys that include rural 
hospitals and communities. Thus risk factors and other yeasts may be 
further clarified compared to data from subjects attending a tertiary 
level clinic such as the Charlotte Maxeke Hospital. 
 The role of the risk factors should be assessed in males and children to 
determine if the pattern is similar in all three groups. 
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 Other virulence and fitness factors of C. albicans not evaluated here 
for example elaboration of heat shock proteins should be studied to 
determine their role in oral infection. 
 Mother-child pairs who are HIV positive should be studied to 
determine whether they carry the same strains and have acquired 
resistant strains from their mothers. 
 The role of oral strains that may cause disseminated infection in our 
study population needs to be further explored. Studies show that 
disseminated infection can occur without mucosal infection because  
oral strains have been isolated from blood samples. 
 Studies are needed to explore the demographic and pathogenic 
characteristics of the new genotypic strains of C. albicans isolated in 
our study.  
 Antifungal susceptibility profile of Candida organisms from other 
setting should be performed to determine whether the resistance level 
is similar. 
 The role of non-albicans Candida in colonisation and oral infection 
needs to be clarified. 
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7.5 Conclusion  
In conclusion, in our study population of HIV positive women prevalence of oral 
candidiasis and colonization with Candida was low. Factors associated with oral 
Candida colonisation were tuberculosis, diabetes mellitus, low CD4 count, dental 
caries, wearing oral prosthesis and not being on HAART. Production of proteinase 
and phospholipase, and the adherence ability Candida isolated from these patients 
fluctuated over time. Although there was no relationship between virulence properties 
of C. albicans, CD4 count and symptomatic infection, there was an increase in the 
yeast count during symptomatic candidiasis. In addition, C. albicans produced 
significantly higher levels of virulence factors than non-albicans Candida isolated 
from both symptomatic and asymptomatic women. C. albicans isolates from these 
women were sensitive to commonly used antifungal agents. However, microevolution 
was evident in C. albicans isolates.  The majority of women were became reinfected 
with extraoral or exogenous strains that produced more proteinase. In addition, new 
genotypic strains of C. albicans unique to this region were identified and placed in the 
MLST C. albicans database.     
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CHAPTER 9: APPENDIX 
9.1 Ethical clearance certificate 
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9.2 Questionnaire 
A. BASELINE EXAMINATION FOR ALL PARTICIPANTS 
DATE:       HOSPITAL NO: 
Willing to participate:  Yes  No 
Available for 6 months: Yes  No 
Included in the study:  Yes  No 
Contact details: Tel no:……………………. 
   Home Address:……………… 
 
 
A. BIODATA/DEMOGRAPHICS 
1. Study ID………………….   2. Age last birthday (years)……………………  
3. Nationality……………………..    4. Tribe/Ethnic group……………………….  
5.  Marital Status-  (1) Married (2) Single (3) Widow   (4) 
Divorced/Separated 
6. Highest Educational Attainment- (1)No formal schooling  (2).Elementary 
school 
 (3)High school (4)College/University  
7. Occupation…………………………. 8. Annual Income ………………………. 
9. Number of children………………………… 
10. Ages of children………………. 
 
B. LIVING CONDITIONS/HABITS. 
1. Area of residence………………………………. 2. Household size……………. 
3. Number of rooms……………… 
4. How often do you eat together from the same plate?  
(1) All the time  (2) Often  (3) Occasionally (4) Never 
5. Do you routinely exchange utensils while eating?  
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All the time  Often   Occasionally   Never 
6. Do you premasticate (chew food in your mouth for your child and then feed them) 
food for your children before they have teeth?    Yes 
 No 
7. Are you currently breastfeeding a child?    Yes  No  
8. Are you a smoker?       Yes  No 
9. If your response to B9 was yes, how many packs of cigarette do you smoke in a 
day?…………….. 
10. For how long have you been smoking (years) ?................ 
11. How often do you brush your teeth daily? Once    Twice   More than 2 times 
 
12. Have you ever being to a dentist before?    Yes  No 
13. Do you have a regular dentist?     Yes  No 
 
C. MEDICAL HISTORY 
1. Have you been hospitalized before?    Yes  No 
2. Do you suffer from any of the following? 
 Yes No 
High blood pressure/Hypertension   
Heart disease other than Hypertension   
Asthma   
Allergies   
Diabetes   
Liver disease   
Bleeding disorder   
Kidney disease   
Cancer   
Malaria   
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Tuberculosis   
 
3. Are you currently on any medications?  Yes  No 
4. If yes, please list. 
 Steroids     Antihypertensive    HAART   Others (List)  
5. Time since HIV Diagnosis (Months)…………………………… 
6. Time since the commencement of HAART (Months)……………… 
7. Current HAART Medications with PI? 
 1.………………………………….     2…………………………………. 
 3………………………………….     4………………………………….. 
8. Is partner or significant other also HIV positive?  Yes  No Don’t 
know 
9. Have you ever had oral thrush since HIV diagnosis? Yes No Don’t 
know 
10. If yes to C9, How many times?.......................times.  
11. Have you ever taken medication for oral thrush? Yes  No Don’t 
know 
12. Have you ever had to change your medication for oral thrush? Yes No
 Don’t know 
13. Do you currently have oral thrush?  Yes  No  Don’t know 
14. Do you currently have vaginal thrush?   Yes  No  Don’t 
know 
15. Are you currently taking any medication for thrush?  Yes  No 
16. Current thrush medication 
 1.Fluconazole   2Nystatin   3Miconazole  4Ketoconazole       5 
Itraconazole 
 0. None 
 
D. ORAL EXAMINATION (Baseline) 
 222 
1. Oral Hygiene using Plaque Index…………………………………… 
2. Dental Caries status using DMFT……………………………………. 
3. Oral Candida Infection present? Yes  No.  
4. If present, location (using the attached chart, Appendix A)………….  
5. Type of candidiasis-  (1)Erythematous (2)Pseudomembranous  (3) Angular 
cheilitis 
6. Any other oral lesion? Yes  No. 
7. If yes, tick the appropriate 
 Hairy Leukoplakia 
 Papilloma/Wart 
 Kaposi Sarcoma 
 Ulcer 
 NUP 
 Parotid enlargement 
 Other 
 
8. Any oral prosthesis such as dentures and bridges? Yes  No 
9. Is mouth abnormally dry? Yes  No 
 
 
E. LABORATORY VALUES (Baseline) 
1. CD4 count………………. 4. Viral Load……………….. 
 
F.  Baseline Oral rinse collected:  yes   No 
 
Travel and meal allowance given: R………….   
Signature of participant:………………………… 
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Next appointment given:…………….Date:…………………… 
 
NOTE- TO BE RECALLED IF COLONISED WITH CANDIDA. (RESULTS IN 
SECTION G, PAGE 8) 
 
D. ORAL EXAMINATION (3 months)     DATE: 
1. Oral Hygiene using Plaque Index…………………………………… 
2. Dental Caries status using DMFT……………………………………. 
3. Oral Candida Infection present? Yes  No 
4. If present, location (using the attached chart, Appendix A)…………. 
5. Type of candidiasis-  1.Erythematous 2.Pseudomembranous 3.Angular 
cheilitis 
6. Any other oral lesion? Yes  No. 
7. If yes, tick the appropriate 
 Hairy Leukoplakia 
 Papilloma/Wart 
 Kaposi Sarcoma 
 Ulcer 
 NUP 
 Parotid enlargement 
 Other 
 
8. Any oral prosthesis such as dentures and bridges? Yes  No 
9. If yes to D8, time since wearing prosthesis (years)………………….. 
10. Is mouth abnormally dry? Yes  No 
E. LABORATORY VALUES (3 Months) 
1. PCV………..% 2. HCT……………g/dl 
3. CD4 count………cells./ml3       4. Viral Load………..copies/ml 
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F. 3 months oral rinse collected:  yes   No 
Travel and meal allowance given: R………….   
Signature of participant:………………………… 
Next appointment given:…………….Date:…………………… 
D. ORAL EXAMINATION (6 Months)     DATE: 
1. Oral Hygiene using Plaque Index…………………………………… 
2. Dental Caries status using DMFT……………………………………. 
3. Oral Candida Infection present? Yes  No. 
4. If present, location (using the attached chart, Appendix A)…………. 
5. Type of candidiasis-  Erythematous Pseudomembranous   Angular 
cheilitis 
6. Any other oral lesion? Yes  No. 
7. If yes, tick the appropriate 
 Hairy Leukoplakia 
 Papilloma/Wart 
 Kaposi Sarcoma 
 Ulcer 
 NUP 
 Parotid enlargement 
 Other 
 
8. Any oral prosthesis such as dentures and bridges? Yes  No 
9. If yes to D8, time since wearing prosthesis (years)………………….. 
10. Is mouth abnormally dry? Yes  No 
 
E. LABORATORY VALUES (6 Months) 
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1. PCV………..% 2. HCT……………g/dl 
3. CD4 count………cells/ml3………. 4. Viral Load………copies/ml 
 
F. 6 months Oral rinse collected:  yes   No 
Travel and meal allowance given: R………….   
Signature of participant:………………………… 
Do not forget to thank the participant. 
 
G. (Laboratory Results)   Study No:  
I Baseline 
1. Candida count……………………..cfu/ml 
2. Yeast identification: Number   (using API 20c sheet)     
3. Adherence to oral epithelial cells:……………….yeast cells/100 epithelial cells   
4. Proteinase:………………….mg/ml (Pr) 
5. Phospholipase…………………….Pz  
6. Genotype of C. albicans:…………………(Assign a number for each) 
7. Sensitive to Amphotericin B, Fluconazole, Ketoconazole, Itraconazole 
Nystatin 
 
II 3 months 
1. Candida count……………………..cfu/ml 
2. Yeast identification:………………… 
3. Adherence to oral epithelial cells:……………….yeast cells/100 epithelial cells   
4. Proteinase:………………….mg/ml  
5. Phospholipase…………………….Pz  
6. Genotype of C. albicans:………………………………………. 
3. Adherence to oral epithelial cells:……………….yeast cells/100 epithelial cells   
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4. Proteinase:………………….mg/ml  
5. Phospholipase…………………….Pz  
6. Genotype of C. albicans:………………………………………. 
7. Sensitive to Amphotericin B, Fluconazole, Ketoconazole, Itraconazole 
Nystatin 
 
 
III 6 months 
1. Candida count……………………..cfu/ml 
2. Yeast identification:………………… 
3. Adherence to oral epithelial cells:……………….yeast cells/100 epithelial cells   
4. Proteinase:………………….mg/ml  
5. Phospholipase…………………….Pz  
6. Genotype of C. albicans:………………………………………. 
7. Sensitive to Amphotericin B, Fluconazole, Ketoconazole, Itraconazole 
Nystatin 
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9.3  Raw data 
Table 9.3.1 Social factors investigated in HIV positive women colonised with 
Candida 
StudyI
D 
Ag
e Tribe Marital Status 
Educatio
n 
Childre
n 
Househol
d size 
Exchange 
food 
Smoke
r 
Colonise
d 
1 34 Swathi Single 
High 
School 1 2 Never No Yes 
2 38 Zulu Single 
High 
School 1 2 Never No Yes 
3 46 Zulu Single 
High 
School 1 2 Never No Yes 
4 56 Zulu Single 
High 
School 4 4 Never No No 
5 58 Xhosa Single 
High 
School 3 3 Never No Yes 
6 38 Zulu Married 
High 
School 1 2 Never No Yes 
7 34 Zulu Married 
High 
School 3 8 Never No Yes 
8 36 Tswana Single 
High 
School 0 3 Never No No 
9 41 Sotho Married 
High 
School 2 5 
Occasionall
y No No 
10 38 Venda Single 
High 
School 3   All the time No Yes 
11 34 Tsonga Single 
High 
School 1 6 Never No Yes 
12 34 Sotho Single 
High 
School 2 9 Never No Yes 
13 39 Zulu Married University 3 3 Never No No 
14 46 Sotho Single 
High 
School 4 3 Never No Yes 
15 52 Zulu Single 
High 
School 2 4 Never No No 
16 27 Tswana Single 
High 
School 0 1 Never Yes Yes 
17 39 Sotho Single 
High 
School 2 1 Never No No 
18 36 Zulu Single 
High 
School 3 4 Never No No 
19 57 Zulu Single 
Elementar
y 2 5 Never No No 
20 34 Tswana Single 
High 
School 0 4 Never No No 
21 34 Zulu Single 
High 
School 2 4 Never No No 
22 32 Zulu Single 
High 
School 1 3 
Occasionall
y No No 
23 34 Zulu Married 
High 
School 3 6 All the time No No 
24 34 Zulu Single 
High 
School 4 5 Never No Yes 
25 25 Zulu Single 
High 
School 2 4 
Occasionall
y No Yes 
26 25 Ndebele Single 
High 
School 3 4 
Occasionall
y No Yes 
27 38 Tswana Single 
Elementar
y 1 1 Never No Yes 
28 51 Zulu Single 
High 
School 3 10 
Occasionall
y Yes Yes 
29 26 Zulu Single University 2 4 Never No No 
30 40 Tswana Single 
High 
School 2 2 All the time No Yes 
31 28 Zulu Single 
High 
School 1 4 Often No No 
32 40 Pedi Single 
Elementar
y 0 1 Never No Yes 
33 38 Zulu Single 
Elementar
y 1 4 All the time No No 
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34 42 Xhosa Single 
High 
School 2 2 Never No Yes 
35 41 Xhosa Single 
High 
School 1 3 Never No Yes 
36 45 Xhosa 
Divorced/Separat
ed 
Elementar
y 3 5 Never No Yes 
37 38 Zulu Single University 1 2 Never No Yes 
38 22 Zulu Single 
High 
School 1 3 Never No Yes 
39 58 Tswana Single 
Elementar
y 3 3 Never No No 
40 38 Zulu Single 
High 
School 2 3 Never No No 
41 41 Tswana Married University 2 4 
Occasionall
y No Yes 
42 31 Zulu Single None 2 2 Never No Yes 
43 51 Zulu Married 
High 
School 2 4 Never No No 
44 32 Sotho Single 
High 
School 0 3 Never No No 
45 30 Pedi Single University 2 3 
Occasionall
y No Yes 
46 30 Tswana Single 
Elementar
y 2 4 Never No Yes 
47 36 Ndebele Single 
High 
School 2 3 Never No Yes 
48 33 Zulu Married 
High 
School 2 4 Often Yes No 
49 50 Xhosa Single 
High 
School 1 2 Never No No 
50 27 Sotho Single 
High 
School 1 2 Never No No 
51 34 Zulu Single 
High 
School 1 2 Never No Yes 
52 37 Sotho Single 
High 
School 0 1 Never Yes No 
53 60 Swathi Single 
Elementar
y 1 1 Never No No 
54 44 Ndebele Single 
High 
School 3 5 Never No Yes 
55 49 Zulu 
Divorced/Separat
ed 
High 
School 4 6 Never No Yes 
56 34 Zulu Single 
High 
School 2 1 Never No No 
57 37 Zulu Single 
High 
School 0 1 Never No No 
58 33 Zulu Single 
High 
School 2 4 
Occasionall
y No Yes 
59 31 Zulu Single University 2 3 Never No Yes 
60 32 Sotho Married 
High 
School 3 5 
Occasionall
y No No 
61 42 Sotho Married 
High 
School 1 8 Never No Yes 
62 43 Sotho Single 
High 
School 3 4 
Occasionall
y Yes Yes 
63 63 Ndebele Single 
Elementar
y 2 4 Never No No 
64 34 Zulu Single 
High 
School 2 3 Never No Yes 
65 32 Tswana Single 
High 
School 2 4 Never No No 
66 29 Tswana Married University 1 2 Never No No 
67 29 Xhosa Single 
High 
School 2 8 
Occasionall
y No No 
68 33 Zulu Single 
High 
School 2 3 Never No Yes 
69 39 Ndebele Single University 2 4 Never No Yes 
70 25 Ndebele Single 
High 
School 1 4 Never No No 
71 43 Venda Single 
High 
School 2 3 Never No Yes 
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72 32 
Coloure
d Married 
High 
School 2 4 
Occasionall
y No No 
73 41 Tswana Single 
High 
School 1 1 Never No No 
74 41 Xhosa Single 
High 
School 4 6 
Occasionall
y No Yes 
75 51 Tswana Widowed 
High 
School 3 2 Never No No 
76 37 Zulu Single None 3 3 Never No No 
77 48 Zulu Single 
High 
School 2 1 Never No Yes 
78 35 Tsonga Married 
High 
School 2 5 Never No Yes 
79 38 Zulu Married 
Elementar
y 2 5 Never No No 
80 51 Swathi Widowed 
High 
School 3 5 Never No Yes 
81 26 Xhosa Single 
High 
School 0 1 Never No Yes 
82 28 Swathi Single None 1 1 Never No Yes 
83 29 Sotho Single 
High 
School 1 2 Never No No 
84 38 Xhosa Single 
High 
School 1 8 Never No Yes 
85 37 Sotho Married 
High 
School 4 3 Never No No 
86 38 Xhosa Single 
High 
School 2 3 Never No Yes 
87 34 Tswana Single University 0 3 Never No Yes 
88 52 Sotho Married 
High 
School 2 4 Never No No 
89 41 Tswana Widowed 
High 
School 3 4 Never No Yes 
90 26 Xhosa Single 
Elementar
y 1 2 Never No Yes 
91 39 Tswana Single 
High 
School 3 2 
Occasionall
y No Yes 
92 23 Ndebele Single 
High 
School 1 4 Never No No 
93 37 Zulu Married 
High 
School 3 2 
Occasionall
y No No 
94 40   Married University 2 4 Never No No 
95 42 Zulu Single 
High 
School 1 3 Never No No 
96 43 Zulu Single 
High 
School 2 4 Never No No 
97 42 Zulu Single 
Elementar
y 4 6 
Occasionall
y No No 
98 34 Xhosa Single 
High 
School 1 2 
Occasionall
y No Yes 
99 64 Tswana Single 
Elementar
y 3 5 Never No Yes 
100 33 Zulu Single 
High 
School 2 1 Never No Yes 
101 35 Xhosa Married 
High 
School 2 12 Never No Yes 
102 40 Ndebele Single 
High 
School 3 4 
Occasionall
y No No 
103 47 Sotho Widowed University 2 5 
Occasionall
y No No 
104 45 Sotho Single 
High 
School 2 3 Never No Yes 
105 24 
Coloure
d Single 
High 
School 3 8 Never Yes Yes 
106 29 Xhosa Single 
High 
School 2 8 Never No No 
107 31   Single 
High 
School 2 5 Never No Yes 
108 40 Zulu Single 
High 
School 4 1 Never No Yes 
109 28 Xhosa Single 
High 
School 2 6 Never No Yes 
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110 42 Xhosa Single 
High 
School 2 1 Never No Yes 
111 27 Ndebele Single 
High 
School 1 3 Never No No 
112 31 Zulu Single 
High 
School 2 2 Never No No 
113 45 Zulu Single 
High 
School 2 6 
Occasionall
y No No 
114 55 Sotho Widowed 
Elementar
y 4 7 Never No No 
115 69 Zulu Widowed 
High 
School 3 5 Never Yes Yes 
116 38 Sotho Married 
High 
School 3 7 Often No Yes 
117 42 Zulu Single 
High 
School 3 2 Never No Yes 
118 47 Zulu Single 
High 
School 3   Never No No 
119 39   Widowed 
High 
School 2 3 Never No Yes 
120 46 Zulu Single 
High 
School 4 3 Often No Yes 
121 46 Xhosa Single 
High 
School 2 3 Never No Yes 
122 40 Sotho Single University 3 4 Never No No 
123 30 Zulu Single 
High 
School 1 3 Never No No 
124 33 Zulu Married 
High 
School 4 5 Never No Yes 
125 25 Sotho Single 
High 
School 0 3 Never No Yes 
126 32 Xhosa Single University 1 4 Never No Yes 
127 29 Zulu Married 
High 
School 1 3 Never Yes Yes 
128 37 Tswana Single 
High 
School 2 7 Never No Yes 
129 28 Ndebele Married 
High 
School 2 3 Never No Yes 
130 37 Sotho Single 
High 
School 4 3 Never No Yes 
131 46 Zulu Married University 1 3 
Occasionall
y No No 
132 30 Zulu Single 
High 
School 0 2 Never No Yes 
133 28 Zulu Single 
High 
School 3 6 Never No Yes 
134 31 
Coloure
d Single 
High 
School 2 3 Never Yes Yes 
135 31 Sotho Single 
High 
School 0 2 Never No No 
136 29 Xhosa Married University 3 5 
Occasionall
y No Yes 
137 27 
Coloure
d Single 
High 
School 3 4 
Occasionall
y No No 
138 53 Sotho 
Divorced/Separat
ed University 4 5 
Occasionall
y No Yes 
139 54 Sotho 
Divorced/Separat
ed 
High 
School 3 2 Never No No 
140 35 Zulu Single 
High 
School 2 6 
Occasionall
y No Yes 
141 29 Sotho Married 
High 
School 1 4 Never Yes Yes 
142 43 Zulu Single 
Elementar
y   1 
Occasionall
y No No 
143 28 Zulu 
Divorced/Separat
ed 
High 
School 2 1 Never No Yes 
144 42 Sotho Single 
High 
School 1 4 Never Yes Yes 
145 30 Zulu Single 
High 
School 1 2 Never No No 
146 39 Ndebele Widowed 
High 
School 3 5 All the time No Yes 
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147 50 Zulu 
Divorced/Separat
ed University 4 1 Never No No 
148 32 Zulu Single 
High 
School 5 4 All the time No No 
149 40 Tswana Widowed 
High 
School 2 3 Never No Yes 
150 47 Sotho Married 
High 
School 2 4 Never No No 
152 36 Zulu Married 
Elementar
y 4 4 
Occasionall
y No No 
153 30 Tswana Married 
High 
School 2 4 All the time No No 
154 39 Sotho Single 
High 
School 2 3 Never No No 
155 47 Zulu Married 
High 
School 1 2 Never No Yes 
156 36 Sotho Married University 2 4 Never No Yes 
157 49 
Coloure
d 
Divorced/Separat
ed 
High 
School 2 1 Never Yes Yes 
158 45 Sotho Single 
High 
School 3 7 Never No Yes 
159 47 Sotho Married 
Elementar
y 1 6 Never No No 
160 30 Zulu Single 
High 
School 2 3 Never No No 
161 32 Zulu Single 
High 
School 1 3 Never No No 
162 30 Zulu Single 
High 
School 0 2 
Occasionall
y No Yes 
163 45 Zulu Married 
High 
School 1 4 Never No No 
164 46 Swathi 
Divorced/Separat
ed 
High 
School 1 3 Often No Yes 
165 40 Sotho Single University 2 2 
Occasionall
y No Yes 
166 34 Zulu Single 
High 
School 2 5 Never No Yes 
167 38 Swathi Married 
High 
School 2 3 Never No Yes 
168 41   Single 
High 
School 2 3 Never No Yes 
169 32 Sotho Single 
High 
School 1 1 Never No Yes 
170 48 Pedi Single 
High 
School 3 3 Never No Yes 
172 38   Married 
High 
School 3 5 Never No No 
173 43   Single University 1 2 Never No Yes 
174 27 Zulu Single 
High 
School 0 8 Never No No 
175 27 Ndebele Single 
Elementar
y 1 6 Never No Yes 
176 32 Tsonga Married 
High 
School 2 3 
Occasionall
y No Yes 
177 56 Pedi Single None 4 5 
Occasionall
y No No 
178 30 Xhosa Single 
Elementar
y 0 5 Never No Yes 
179 32   Single University 2 3 
Occasionall
y No Yes 
180 29   Single 
High 
School 1 4 Never No Yes 
181 52 Zulu Single 
Elementar
y 1 1 Never No Yes 
182 26 Ndebele Single 
High 
School 1 2 Never No Yes 
183 32   Single University 0 6 Never No Yes 
184 42 Zulu Single 
High 
School 1 3 Never No No 
185 39 Pedi Single University 3 4 Never No Yes 
186 33 Xhosa Widowed 
High 
School 2 3 Never No Yes 
 232 
187 33 Zulu Single 
High 
School 1 2 Never No Yes 
188 53 Tswana Widowed None 4 2 Never No Yes 
189 40 Venda Single University 4 6 Never No No 
190 37 Swathi Married University 2 4 Never No Yes 
191 48 Zulu Married 
Elementar
y 3 5 Never No Yes 
192 36 Shona Single 
High 
School 1 2 
Occasionall
y No No 
193 30 Swathi 
Divorced/Separat
ed 
High 
School 0 1 Never No Yes 
194 41 Pedi Single 
High 
School 1 2 Never No No 
195 46 Zulu 
Divorced/Separat
ed 
High 
School 1 6 Never No No 
196 37 Sotho Single University 1 5 Never No Yes 
197 35 Zulu Single 
High 
School 2 3 All the time No Yes 
198 37 Sotho Married 
High 
School 2 6 Never No Yes 
199 26 Tswana Married University 0 2 Never No Yes 
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Table 9.3.2 Clinical factors investigated in HIV positive women colonised with Candida  
StudyI
D 
Candida  
Infectio
n HL 
K
S 
Aphthous  
Ulcer 
NU
P 
Papillom
a 
Parotid 
swellin
g 
Hypertensio
n 
Heart 
Disease Asthma 
Allergie
s DM 
Cance
r TB 
Daily 
brus
h 
times 
Seen 
Dentis
t PI GI 
DMF
S 
Colonise
d 
1 No No No No No No No Don't know Yes No No No No No   Yes .9 1.8 28 Yes 
2 No No No No No No No No No No No No No No 3 No .5 1.4 43 Yes 
3 No No No No No No No No No No No No No No   No .6 1.2 76 Yes 
4 No No No No No No No No No No Yes No No No   No 1 1.1 35 No 
5 No No No No No No No No No No No No No No 1 No .5 .9 102 Yes 
6 No No No No No No No No No No No No No No   No .3 .6 77 Yes 
7 No No No No No No No No No No Yes No No No   Yes .5 .8 10 Yes 
8 No No No No No No No Yes No No Yes No No No 4 No .5 1.4 11 No 
9 No 
Ye
s No No No No No No No No No No No 
Ye
s   No .08 .9 13 No 
10 No No No No No No No No No No No No No 
Ye
s   No .5 1.1 9 Yes 
11 No No No No No No No No No No No No No No   No .7 .8 6 Yes 
12 Yes No No Yes No No No No No No No No No No   Yes 1 1.5 6 Yes 
13 No No No No No No No No No Yes Yes No No No   No .5 .4 0 No 
14 No No No No No No No No No No No No No No   Yes .2 .5 24 Yes 
15 No No No No No No No Yes No No No No Yes No 4 No .9 .8 30 No 
16 Yes No No No No No No No No No No No No 
Ye
s   No .7 .6 29 Yes 
17 No No No No No No No No No No Yes No No No 1 No .5 .7 34 No 
18 No No No No No No No No No No No No No No   No .1 .6 7 No 
19 No No No No No No No No Yes No No No No No   No .4 .3 35 No 
20 No No No No No No No No No No Yes No No No   No .5 .5 15 No 
21 No No No No No No No No No No No No No No   Yes .1 .4 30 No 
22 No No No No No No No No No No No No No No 3 No .8 .6 6 No 
23 No No No No No No No No No No No No No No 1 No .1 .6 42 No 
24 No No No No No No No No No Yes No No No 
Ye
s   No .5 .5 5 Yes 
25 No No No No No No No No No No No No No No   No 1.2 .9 36 Yes 
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26 No No No No No No No No No No No No No No   No 1 1.4 18 Yes 
27 Yes No No No No No No No No No No No No No   No .3 .7 20 Yes 
28 No No No No No No No No No No Yes No No No   No .2 .6 33 Yes 
29 No No No No No No No No No No No No No No   No .4 .5 2 No 
30 No No No No No No No No No No No Yes No No   No .2 .3 11 Yes 
31 No 
Ye
s No No No No No No No Yes Yes No No No 4 No .5 1 2 No 
32 No No No No No No No No No No No No Yes No   Yes .2 .5 32 Yes 
33 No No No No No No No No No No No No No No   Yes .1 .8 21 No 
34 No No No No No No No No No No No No No No 1 No 1.3 .6 37 Yes 
35 No No No No No No No No No No Yes No No No   Yes 1 .7 41 Yes 
36 No No No No No No No Yes No No No No No 
Ye
s   Yes .4 1.1 18 Yes 
37 No No No No No No No Yes No No Yes No No No   No .5 .3 16 Yes 
38 No No No No No No No No No No No No No 
Ye
s   No .3 .4 7 Yes 
39 No No No No No No No Yes Yes No No No No No   No 1 .6 42 No 
40 No No No No No No No No No No No No No No 1 No .5 .6 7 No 
41 No No No No No No No No No No No No No No   No .4 .01 15 Yes 
42 No No No No No No No No Yes No No No Yes No   No .83 .7 16 Yes 
43 No No No No No No No Yes No No Yes No No No   Yes 
1.0
8 
1.0
8 49 No 
44 No No No No No No No No No No Yes No No 
Ye
s 1 No .7 .3 14 No 
45 No No No Yes No Yes No No No No No No No No   Yes .5 0 8 Yes 
46 No No No No No No No No No No No No No No   Yes .4 .8 16 Yes 
47 No No No No No No No No No No No No No No   No .3 .5 11 Yes 
48 No 
Ye
s No No No No No No No No No No Yes No   Yes .3 .5 3 No 
49 No No No No No No No Yes No No No No No No 1 No .6 1.1 17 No 
50 No No No No No No No No No No No No No No 0 Yes .4 .1 17 No 
51 No No No No No No No No Yes No No No No No   No .3 .3 23 Yes 
52 No No No No No No No No No No No Yes No 
Ye
s 2 Yes .3 .3 21 No 
53 No No No No No No No Yes No No Yes No No No 0 No     92 No 
54 No No No No No No No No No No No No No No   No 1.1 1.1 62 Yes 
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55 No 
Ye
s No Yes No No No Yes No No No No No No 1 No 1.1 .6 35 Yes 
56 No No No No No No No No No Yes No No No No   No 1.2 .6 14 No 
57 No No No No No No No No No No No No No No   No 1.5 .5 21 No 
58 No No No No No No No No No No No No No No   No .6 .5 5 Yes 
59 No No No No No No No No No No No No No No   No .7 .6 12 Yes 
60 Yes No No No No No No No No No No Yes No No   No 1 1.5 25 No 
61 No No No No No No No Yes No No Yes No No 
Ye
s 2 No .8 .7 8 Yes 
62 No 
Ye
s No No No No No No No No Yes No No No 1 Yes 1 .6 34 Yes 
63 No No No No No No No Yes Yes No partner Yes Yes No No   No     93 No 
64 Yes 
Ye
s No Yes No No No No No No Yes No No 
Ye
s   No 1 .67 14 Yes 
65 No No No No No No No No No No No No No No 6 Yes .58 .33 10 No 
66 No No No No No No No No No No No No No No 8 Yes 
1.6
6 
1.6
6 20 No 
67 No No No No No No No No No No No No No No   No 
1.1
7 .5 20 No 
68 No No No No No No No No No No No No No 
Ye
s 4 No .83 .67 23 Yes 
69 No No No Yes No No No No No No No No No No   Yes .83 .17 20 Yes 
70 No No No No No No No No No No No No No No 2 No .83 .5 45 No 
71 No No No No No No No Yes No No No No No No   No .92 .67 4 Yes 
72 No No No No No No No No No No Yes No No No   No .3 .42 11 No 
73 No No No No No No No No No Yes Yes No No No 0 No 1 .33 28 No 
74 No No No No No No No No No No No No Yes No 0 No 1 .9 12 Yes 
75 No 
Ye
s No No No No No Yes No No Yes No No No 4 No 1 .67 20 No 
76 No No No No No No No No No No No No No No   No 1 .67 23 No 
77 No 
Ye
s No No No No No No No No Yes No No No   No 1.3 .8 64 Yes 
78 No No No No No No No No No No Yes Don't know No No 2 No .8 .6 14 Yes 
79 No 
Ye
s No No No No No No No No Yes No No No   Yes .5 .1 31 No 
80 No No No No No No No Yes No No No No No No   Yes .5 0 58 Yes 
81 No No No No No No No No No No No No No No   No .8 .5 26 Yes 
82 No No No No No No No No No No Yes No No 
Ye
s 1 No 1 .6 0 Yes 
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83 No No No No No No No Yes Don't know No Yes No No No 5 No .6 .8 11 No 
84 No No No No No No No No No No No No No No   No .1 .5 24 Yes 
85 No No No No No No No Yes Yes Yes No Yes Yes No   Yes .1 .4 28 No 
86 No No No No Yes Yes No No No No No No No 
Ye
s   Yes 1.6 2 61 Yes 
87 No 
Ye
s No No No No No No No No No No No No   Yes .5 .3 5 Yes 
88 No No No No No No No Yes Yes No No Yes Yes No   No .3 1 67 No 
89 No No No No No No No No No No No No No No   Yes .5 .5 18 Yes 
90 No No No No No No No No No No No No No No   No .9 1 8 Yes 
91 Yes No No No No No No No No No No No Yes No 0 No .5 .3 3 Yes 
92 No No No No No No No No No No No No No No   No .9 .5 0 No 
93 No No No No Yes No No Yes No No No No No No 2 No 1.1 .6 30 No 
94 No No No No No No No No No No No No No No   No .5 .5 12 No 
95 No No No No No No No No No No No No Yes No 0 No .7 
1.3
3 5 No 
96 No No No No No No No No No No No No No No 4 No .5 .6 4 No 
97 No No No No No No No No No No No No No 
Ye
s   No .7 .5 0 No 
98 No No No No No No No No No No Yes No No No   Yes 1 .6 64 Yes 
99 No 
Ye
s No No Yes No No Yes No No Yes No No No   No 2 2.3 58 Yes 
100 No No No No No No No Yes No No No Yes No No   No .1 .6 4 Yes 
101 No No No No No No No No No No No No No No   No .08 .08 2 Yes 
102 No No No No No No No Yes No No No No No No   No 1.4 .8 0 No 
103 No No No No No No No No No No No Yes No No   No .2 .5 47 No 
104 Yes 
Ye
s No No No No No Yes No No No No No 
Ye
s 1 No .3 .5 78 Yes 
105 No No No No No No No No No No No No No No   No 1.3 1.5 15 Yes 
106 No No No No No No No No No No No No No No   No .9 .5 23 No 
107 No 
Ye
s No No No No No No No No No No No No   No .9 .6 11 Yes 
108 No No No No No No No No No No Yes No No No   No .4 .4 27 Yes 
109 No No No Yes No No No No No No No No No No 0 Yes .3 .6 18 Yes 
110 No No No No No No No No No No No No No No   No 1 1 8 Yes 
111 No No No No No No No No No No No No No No   No .4 .6 0 No 
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112 No No No No No No No No No No No No No 
Ye
s 1 No .2 0 0 No 
113 No No No No No No No No No No No No Yes No   No 1.1 1 0 No 
114 No No No No Yes No No No No No No No No 
Ye
s   Yes     76 No 
115 Yes No No No No No No No No No No No No No 2 No 1.1 1 68 Yes 
116 No No No No No No No No No No Yes No No No 10 No .3 .2 18 Yes 
117 No No No No Yes No No No No No No No No No   No 1.5 1.8 35 Yes 
118 No No No No No No No Yes Yes No Yes No No No 1 Yes .3 .5 50 No 
119 No No No No No No No No No No Yes No No 
Ye
s   Yes 0 0 5 Yes 
120 No No No No No No No Yes No No No No No 
Ye
s   Yes .6 .8 38 Yes 
121 No No No No No No No No No Yes No No No 
Ye
s 2 No .2 .4 34 Yes 
122 No No No No No No No No No No No No No No 2 Yes 1 1.3 15 No 
123 No No No No No No No No No No No No No No   No .83 
1.3
3 16 No 
124 No 
Ye
s No No No No No No No No No No No No   Yes 1 .3 74 Yes 
125 No No No No No No No No No No No No No 
Ye
s 1 No 1.5 1.1 22 Yes 
126 No No No No No No No No No No Yes No No No 1 Yes 1 1 19 Yes 
127 No No No No Yes No No No No No Yes No No No 1 No .5 .5 1 Yes 
128 No 
Ye
s No No No Yes No No No No No No No 
Ye
s   No 1.2 1.3 57 Yes 
129 Yes 
Ye
s No No No No No No No No No No No No 4 No .5 .5 1 Yes 
130 No No No No No No No No No No No No Yes No   No .6 1 39 Yes 
131 No No No No No No No No No No No No Yes No 3 No .4 0 0 No 
132 Yes No No No No No No No No No No No Yes No 2 Yes .4 .5 27 Yes 
133 No No No No No No No No No No No No No No 1 Yes .5 .8 27 Yes 
134 Yes 
Ye
s No No No No No No No Yes No No No No 1 Yes .6 .6 61 Yes 
135 Yes No No No No No No Yes No No No No No No 1 Yes .7 1 13 No 
136 No 
Ye
s No No No No No No No No No No No 
Ye
s 10 Yes .7 .2 34 Yes 
137 No No No No No No No Yes No No No No No No   No .5 .3 26 No 
138 Yes 
Ye
s No Yes No No No No No No No No No No   Yes .8 1 10 Yes 
139 No No No No No No No Yes No No No No Yes No   Yes .5 .8 5 No 
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140 No 
Ye
s No No No No No No No Yes No No No No   Yes 
1.3
3 
1.0
8 32 Yes 
141 No No No No No No No No No No Yes No No No   Yes .1 .1 13 Yes 
142 No No No No No No No No No No No No No No   Yes .6 .6 4 No 
143 No 
Ye
s No No No No No No No No No No No 
Ye
s   No .2 .5 2 Yes 
144 No No No No No No No No No No No No No No 1 No .9 .5 51 Yes 
145 No No No No No No No No No No No No No No   No .8 .3 12 No 
146 Yes No No No Yes No No No No No No No No No   Yes 1.3 1 8 Yes 
147 No 
Ye
s No No No No No No No No No No No No   No 1.1 .3 45 No 
148 No 
Ye
s No No No No No Yes No No No No Yes No 1 Yes 
1.0
8 1 0 No 
149 No No No No No No No Yes No No No No No No   Yes .5 .3 39 Yes 
150 No No No No No No No Yes Yes No No Yes No No   No 1.1 .5 16 No 
152 No No No No No No No No No No No No No No   No .6 .3 6 No 
153 No No No No No No No No No No No No No No   No .7 .3 20 No 
154 No No No No No No No No No No No No No No 2 No .6 .1 8 No 
155 No No No No No No No No No No No No No No   Yes .4 .3 17 Yes 
156 Yes 
Ye
s No No No No No No No No No No No No 7 Yes .2 0 0 Yes 
157 No No No No No No No Yes No No No No No No   No       Yes 
158 No No No No No No No Yes No No No No No No 5 Yes       Yes 
159 No No No No No No No No No No No No No No 5 No 
.16
7 .33 0 No 
160 No No No No No No No No No No No No No No   Yes .67 .58 17 No 
161 No No No No   No No No No No No No No No 1 No 1 
1.0
8 29 No 
162 No No No No No No No No No No Yes No No No   No .92 2.2 22 Yes 
163 No No No No No No No Yes No No No No No No 1 No .25 .25 0 No 
164 No 
Ye
s No No No No No No No No No No No 
Ye
s   Yes .25 
.08
3 82 Yes 
165 No No No No No No No No No No No No Yes No   Yes 
.16
7 
.41
7 38 Yes 
166 No No No No No No No No No No No No No 
Ye
s 2 No 
.16
7 
.08
3 0 Yes 
167 No No No No   No No No No No No No No 
Ye
s   Yes 
.41
7 
.08
3 0 Yes 
168 No No No No No No No No No No Yes No No No   Yes 
1.1
7 1 39 Yes 
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169 No No No No No No No No Yes Yes No No No No   No .67 .5 23 Yes 
170 No No No No No No No No No No No No No No   Yes 1 .67 23 Yes 
172 No No No No No No No No No No No No No No   Yes .5 
.16
7 17 No 
173 No No No No No No No No No No Yes No No No   Yes .75 1 18 Yes 
174 No No No No No No No Yes No No No No No No   No .67 .75 16 No 
175 No No No No No No No No No No Yes No No 
Ye
s   No 
.58
3 
.41
7 0 Yes 
176 No No No No No No No No No No No No No No   Yes 
.58
3 .5 17 Yes 
177 No No No No No No No Yes No No No No No 
Ye
s   Yes .83 
1.7
5 30 No 
178 No No No No No No No No No No No No No 
Ye
s   No .5 .5 45 Yes 
179 No No No No No No No No No No No No No No   No .67 .75 0 Yes 
180 No No No No No No No No No No Yes No No No   No 
.16
7 .33 12 Yes 
181 No No No No No No No No No No No No No No   Yes .25 
.58
3 49 Yes 
182 No No No No No No No No No No No No No No   No .83 1 6 Yes 
183 No No No No No No No Yes No No No No No No   No .5 
.41
7 0 Yes 
184 No No No No No No No No No No Yes No No No   No .75 .66 10 No 
185 Yes 
Ye
s No No No No No No No No No No No No 1 No .33 .67 4 Yes 
186 No No No No No No No No Yes No No No No 
Ye
s   No .75 .75 40 Yes 
187 No No No No No No No Yes No No No No No No   No .25 
.16
7 13 Yes 
188 No No No No No No Yes Yes No No No No No No   No 
.41
7 .83 35 Yes 
189 Yes No No No No No No No No No No   No No   No .92 .5 12 No 
190 No No No No No No No Yes No No No No No No   No .5 .5 17 Yes 
191 No 
Ye
s No No No No No No Yes No No No No No   No .83 
.58
3 25 Yes 
192 No No No No No No No No No No No No No No   No .2 .5 0 No 
193 Yes No No No No No No No No No Yes No No No   Yes 1 .6 20 Yes 
194 No No No No No No No No No No No No No No   No .6 .7 32 No 
195 No No No No No No No Yes No No No No Yes No   No 1.1 .9 5 No 
196 No No No No No No No No No No No No No No   No .1 .3 28 Yes 
197 No No No No No No No Yes Yes No No No No No   No 
.58
3 
.08
3 28 Yes 
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198 No No No No No No No No No Yes Yes No Yes No 3 No .33 
.16
7 6 Yes 
199 No No No No No No No No No No No No No No   Yes 
.16
7 
.08
3 11 Yes 
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Table 9.3.3 Clinical factors and laboratory investigations in HIV positive women 
colonised with Candida 
ID On ARV 
Time since 
on ARV 
(months) Current ARV 
CD4 
cell/mm3 
Viral 
Load 
(copies/ml) Colonised 
Yeast  
Count 
(cfu/ml) YeastID YeastID2 
1 Yes 24 3TC,TDF,EFV 405 1698 Yes 20 C. famata   
2 Yes 84 3TC,TEN,Alluvia 546 40 Yes 560 C. albicans   
3 Yes 60 3TC,TDF,EFV 347 40 Yes 30 C. albicans   
4 Yes 72 DDI,AZT,Alluvia 580 40 No      
5 Yes 24 3TC,TDF,EFV 250   Yes 220 C. albicans C. tropicalis 
6 Yes 48 3TC,TDF,NVP 196 5 Yes 40 C. albicans   
7 Yes 36 TDF,AZT,Alluvia 346 351 Yes 1040 C. dubliniensis   
8 Yes 24   511 1191 No      
9 Yes 6 3TC,TDF,EFV 83   No      
10 Yes 36 3TC,d4t,EFV 418 13314 Yes 720 C. albicans   
11 Yes 24 3TC,TDF,EFV 567   Yes 20 C. albicans   
12 No   3TC,TDF,EFV 571   Yes 170 C. albicans   
13 Yes 60 3TC,d4t,EFV 444 40 No      
14 Yes 45       Yes 10 C. dubliniensis   
15 Yes 24 3TC,TDF,NVP 274 5 No      
16 Yes 5 3TC,TDF,EFV 104   Yes 470 C. albicans   
17 Yes 72 3TC,EFV,TEN 842 5 No      
18 Yes 5 3TC,TDF,NVP 101   No      
19 Yes 36 3TC,EFV,TEN     No      
20 Yes 84       No      
21 Yes 6   266   No      
22 Yes 28 3TC,TDF,EFV 419 40 No      
23 Yes 24 3TC,d4t,EFV 526 5 No      
24 Yes 96   1200 5 Yes 10 C. albicans   
25 No 0 HAART NAIVE 595   Yes 530 C. albicans   
26 No 0 HAART NAIVE 398   Yes 90 C. albicans   
27 Yes 60 Alluvia,EFV,TEN 370   Yes 10 C. albicans   
28 Yes 84   393 40 Yes 30 C. albicans   
29 Yes 12 3TC,TDF,EFV 650   No      
30 No   HAART NAIVE 646 40 Yes 200 C. dubliniensis   
31 Yes 24 3TC,TEN,Alluvia 409   No      
32 Yes 8 3TC,TDF,EFV 156 5 Yes 30 C. albicans   
33 Yes 84 3TC,TDF,EFV 324 2312 No      
34 Yes 12 3TC,d4t,EFV 27 183298 Yes 380 C. albicans   
35 Yes 36 3TC,TDF,EFV 821 5 Yes 130 C. albicans   
36 Yes 26 3TC,d4T,Alluvia 904 26 Yes 10 C. tropicalis   
37 Yes 84 3TC,TDF,NVP 626 5 Yes 130 C. albicans   
38 Yes 6 3TC,TDF,NVP 246 223 Yes 60 C. albicans   
39 Yes 6 3TC,TDF,EFV 178 451 No      
40 Yes 6 3TC,TDF,EFV 40   No      
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41 Yes 48 3TC,TDF,EFV 1023 5 Yes 70 C. albicans   
42 Yes 18 3TC,TDF,NVP 462 337 Yes 20 C. albicans   
43 Yes 72 3TC,d4t,EFV 239 400 No      
44 Yes 94 3TC,TDF,EFV 1172 5 No      
45 Yes 60 3TC,TDF,NVP 35 5 Yes 165 C. albicans   
46 Yes 72 3TC,TDF,NVP 166 40 Yes 60 C. albicans   
47 Yes 72 3TC,TDF,EFV 194 5 Yes 10 C. albicans   
48 Yes 12 3TC,TDF,EFV 180 40 No      
49 Yes 36 3TC,TDF,EFV 576 5 No      
50 Yes 6 3TC,TDF,NVP 267   No      
51 Yes 72 3TC,TDF,AZT 555 5 Yes 10 C. albicans   
52 Yes 84 3TC,TDF,EFV 145 14411 No      
53 Yes 96 3TC,d4T,Alluvia 482 5 No      
54 Yes 6 3TC,TDF,EFV 86   Yes 690 C. albicans   
55 Yes 12 3TC,TDF,EFV 302 5 Yes 1475 C. albicans   
56 Yes 36 3TC,AZT,Alluvia 134 5 No      
57 Yes 48 TDF,AZT,Alluvia 655 189 No      
58 Yes 6 3TC,TDF,NVP 292   Yes 570 C. tropicalis   
59 Yes 6 3TC,TDF,EFV 19   Yes 70 C. albicans   
60 Yes 24 3TC,TDF,EFV 684 1631 No      
61 Yes 36 3TC,TDF,EFV 386 40 Yes 230 C. tropicalis C. parapsilosis 
62 Yes 6 3TC,TDF,EFV 202   Yes 50 C. albicans   
63 Yes 48 3TC,TDF,EFV 716 5 No      
64 Yes 6 3TC,TDF,EFV 58   Yes 210 C. albicans   
65 Yes 6 3TC,TDF,EFV 40   No      
66 Yes 36 3TC,TEN,Alluvia 400 5 No      
67 Yes 12 3TC,TDF,EFV 418 5 No      
68 Yes 12 3TC,TEN,Alluvia 640 315002 Yes 370 C. albicans   
69 Yes 4 3TC,TDF,EFV 92   Yes 10 C. tropicalis   
70 Yes 24 3TC,TDF,NVP 778 40 No      
71 Yes 48 3TC,TDF,EFV 505 5 Yes 10 C. albicans   
72 Yes 120 3TC,TDF,EFV 621 5 No      
73 Yes 12 3TC,TDF,EFV 364 40 No      
74 Yes   3TC,TDF,EFV 699 5 Yes 10 C. albicans   
75 Yes 72 3TC,TDF,EFV 574 5 No      
76 Yes 60 3TC,TDF,EFV 141   No      
77 Yes 48 3TC,TDF,EFV 564 5 Yes 10 C. albicans   
78 Yes 108 3TC,TDF,EFV 307 5 Yes 240 C. albicans   
79 Yes 70 3TC,TDF,EFV 706 5 No      
80 Yes 60 3TC,TDF,EFV 321 110 Yes 80 C. albicans   
81 Yes 24 3TC,TDF,EFV 295   Yes 20 C. albicans   
82 Yes 12 3TC,TDF,EFV 34 46 Yes 180 C. albicans   
83 Yes 12 3TC,TDF,NVP 868   No      
84 Yes 60 3TC,TDF,EFV 701 5 Yes 20 C. albicans   
85 Yes 48 3TC,TDF,EFV 690   No      
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86 Yes 30 3TC,TDF,EFV 301 5 Yes 580 C. albicans   
87 Yes 24 3TC,AZT, Alluvia 194 63855 Yes 3750 C. famata   
88 Yes 60 3TC,TDF, EFV 151 40 No      
89 Yes 24 3TC,d4t,EFV 108 40 Yes 30 C. albicans   
90 Yes 30 3TC,AZT,Alluvia 508 5 Yes 100 C. dubliniensis   
91 Yes 15 3TC,TDF,EFV 273 5 Yes 350 C. albicans   
92 Yes 1 3TC,TDF,EFV 59   No      
93 Yes 60 3TC,TEN,Alluvia 277 1463 No      
94 Yes 84 TDF,AZT,Alluvia 264 40 No      
95 Yes 72 3TC,TDF,NVP     No      
96 Yes 24 3TC,TDF,EFV 467 5 No      
97 Yes 12 3TC,TDF,EFV 59 55 No      
98 Yes 24 3TC,TDF,EFV 167 20 Yes 20 C. albicans   
99 Yes 6 3TC,d4t,EFV 242 64000 Yes 110 C. albicans S. cerevisiae 
100 Yes 48 3TC,TEN,Alluvia 400 43 Yes 20 C. albicans   
101 Yes 36 3TC,TDF,AZT 102 5 Yes 40 C. dubliniensis   
102 Yes 13 3TC,d4t,EFV 619 5 No      
103 Yes 133 3TC,TDF,EFV 1000 20 No      
104 Yes 84   485   Yes 10 C. albicans   
105 Yes 48 3TC,TEN,Alluvia 400 2200 Yes 10 C. albicans   
106 Yes 48 3TC,TDF,EFV 508   No      
107 Yes 3 3TC,TDF,EFV 260   Yes 90 C. albicans   
108 Yes 36 AZT,EFV,TEN 255 5 Yes 30 C. dubliniensis   
109 No   HAART NAIVE     Yes 30 C. dubliniensis   
110 Yes 36 3TC,TDF,EFV 280 5 Yes 320 C. albicans   
111 Yes 16 3TC,d4t,EFV 500   No      
112 Yes 36 3TC,TEN,Alluvia 895 5 No      
113 Yes 56 3TC,d4t,EFV 279 40 No      
114 Yes 70 3TC,TDF,AZT 704   No      
115 No   HAART NAIVE 123   Yes 955 C. tropicalis   
116 Yes 1 3TC,TDF,EFV 114   Yes 275 C. krusei   
117 Yes 25 3TC,TDF,EFV 410 40 Yes 10 C. albicans   
118 Yes 36 3TC,TDF,EFV 389 40 No      
119 Yes 16 3TC,d4t,EFV 187 55 Yes 60 C. albicans   
120 Yes 22 3TC,TDF,EFV 355 40 Yes 20 C. albicans   
121 Yes 28 3TC,TEN,Alluvia 228 5 Yes 10 C. albicans   
122 Yes 36 3TC,TDF,EFV 573 5 No      
123 Yes 48   704   No      
124 Yes 84 3TC,TDF,EFV 1057 25 Yes 75 C. dubliniensis   
125 Yes 12 3TC,TEN,Alluvia 225 40 Yes 100 C. albicans   
126 Yes 48 AZT,EFV,TEN 750 5 Yes 565 C. tropicalis   
127 Yes 3 3TC,TDF,EFV 163 251345 Yes 265 C. dubliniensis   
128 Yes 48 3TC,TEN,Alluvia 298 40 Yes 1210 C. dubliniensis   
129 Yes 12 3TC,TDF,NVP 321 56 Yes 670 C. famata   
130 Yes 33 3TC,TDF,NVP 456 568 Yes 100 C. famata   
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131 Yes 1       No      
132 Yes 3 3TC,TDF,EFV 78   Yes 380 C. albicans   
133 Yes 12 3TC,TDF,EFV 562 5 Yes 30 C. dubliniensis   
134 Yes 48 AZT,EFV,TEN 748 5 Yes 10 C. albicans   
135 Yes 36 3TC,TDF,NVP 357 5 No      
136 Yes 3 3TC,TEN,Alluvia 7 131117 Yes 320 C. parapsilosis   
137 Yes 72 3TC,TDF,NVP 686 5 No      
138 No 0 HAART NAIVE 19   Yes 2470 C. albicans   
139 Yes 48 3TC,TDF,EFV 529 5 No      
140 Yes 72 3TC,TDF,NVP 584 25 Yes 50 C. albicans   
141 Yes 4 3TC,TDF,EFV 146   Yes 40 C. albicans   
142 Yes 3 3TC,TDF,EFV 286   No      
143 Yes 1 3TC,TDF,EFV 109 111000 Yes 230 C. albicans   
144 Yes 72 3TC,TDF,NVP 581 5 Yes 160 C. albicans   
145 Yes 24 3TC,TDF,NVP 332 5 No      
146 Yes 1 3TC,TDF,EFV 200   Yes 100 C. famata   
147 Yes 0 HAART NAIVE 158   No      
148 Yes 3 3TC,TDF,EFV 600 5 No      
149 Yes 60 3TC,TDF,EFV 388 5 Yes 10 C. albicans   
150 Yes 60 3TC,TDF,EFV 733   No      
152 Yes 48       No      
153 Yes 12       No      
154 Yes 3       No      
155 Yes 72 3TC,TDF,EFV 392   Yes 40 C. famata   
156 No 0 HAART NAIVE 398   Yes 570 C. albicans   
157 Yes 24 3TC,TDF,EFV 620 5 Yes 20 C glabrata   
158 Yes 72 3TC,TEN,Alluvia 513 5 Yes 490 C glabrata   
159 Yes 72 3TC,TDF,EFV 386 5 No      
160 Yes 48 3TC,TDF,NVP 418 5 No      
161 Yes 36 3TC,TDF,EFV 448   No      
162 Yes 1 3TC,TDF,EFV 349   Yes 20 S. cerevisiae   
163 Yes 72 3TC,TDF,NVP 835 5 No      
164 Yes 60 3TC,TEN,Alluvia 464 175 Yes 20 C. albicans   
165 Yes 2 3TC,TDF,EFV 163 139008 Yes 850 C. albicans   
166 Yes 12 3TC,TDF,EFV 350 40 Yes 290 C. albicans   
167 Yes 9 3TC,TDF,EFV 588 255 Yes 10 C. albicans   
168 Yes 84 3TC,AZT,Alluvia 926 664 Yes 330 C. albicans   
169 Yes 1 3TC,TDF,EFV 236 5 Yes 450 C. albicans   
170 Yes 120 3TC,TDF,EFV 400 5 Yes 150 C. albicans   
172 Yes 45 3TC,TDF,NVP 300 5 No      
173 Yes 12 3TC,TEN,Alluvia 469   Yes 50 C. albicans   
174 Yes 72 3TC,d4t,EFV 429 40 No      
175 Yes 15 3TC,TDF,EFV 357 5 Yes 10 C. dubliniensis   
176 No   HAART NAIVE 377   Yes 380 C. albicans   
177 Yes 72 TDF,AZT,Alluvia 262 261 No      
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178 Yes 1 3TC,TDF,EFV 396   Yes 20 C. albicans   
179 Yes 1 3TC,TDF,EFV 241   Yes 10 C. albicans   
180 Yes 4 3TC,TDF,EFV 193   Yes 50 C. albicans   
181 Yes 84 3TC,TDF,EFV 471 40 Yes 20 C. dubliniensis   
182 Yes 1 3TC,TDF,EFV 270   Yes 60 C. albicans   
183 Yes 1 3TC,TDF,EFV 141 119323 Yes 10 C. albicans   
184 Yes 60 AZT,d4T,EFV 414   No      
185 No 0 HAART NAIVE 9   Yes 1500 C. albicans   
186 Yes 36   770 5 Yes 130 C. albicans   
187 Yes 49 3TC,TDF,EFV 300 40 Yes 100 C. albicans   
188 Yes 24 3TC,TDF,EFV 190   Yes 50 C. albicans   
189 Yes 6 3TC,TDF,EFV 146   No      
190 No 6 3TC,TDF,NVP 253 40 Yes 20 C. albicans   
191 Yes 6 3TC,TDF,EFV 363   Yes 20 C. albicans   
192 Yes 9 3TC,TDF,NVP     No      
193 Yes 72 3TC,TDF,EFV 600   Yes 110 C. albicans   
194 Yes 6 3TC,TDF,EFV 200   No      
195 Yes 12 3TC,TDF,EFV     No      
196 Yes 6 3TC,TDF,EFV 380 5 Yes 20 C. albicans   
197 Yes 6 3TC,TDF,NVP 107   Yes 380 C. albicans   
198 Yes 14 3TC,TDF,EFV 291   Yes 160 C. dubliniensis   
199 Yes 36       Yes 320 C. tropicalis   
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9.4 Media and reagents 
API 20C Aux 
Suspension Medium (2 ml)  
Demineralized water 
NaCl 0.85 % Medium (2 ml) 
Sodium chloride 8.5 g 
Demineralized water 1000 ml 
C Medium (7 ml) 
Ammonium sulphate    5 g 
Monopotassium phosphate   0.31 g 
Dipotassium phosphate   0.45 g 
Disodium phosphate    0.92 g 
Sodium chloride    0.1 g 
Calcium chloride    0.05 g 
Magnesium sulphate    0.2 g 
Histidine     0.005 g 
Tryptophane     0.02 g 
Methionine     0.02 g 
Agar      0.5 g 
Vitamin solution    1 ml 
Trace elements    10 ml 
Water      qsp 1000 ml 
Final pH:     6.4-6.8 
 
CHROMagar Candida 
Composition in g/L 
Agar     15 
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Peptone    10.2 
Chloramphenicol   0.5 
Chromogenic mix   22 
pH     6.1 ±0.2  
Preparation 
Suspend in the proportion of 47.7 g/L in purified water. Heat and bring to boil 
(100°C) while swirling or stirring regularly until complete fusion of the agar. Cool to 
45-50°C and dispense. 
Coomassie Blue staining solution 
Coomassie Brilliant Blue R-250 2.5 g 
Ethanol    450 ml 
Acetic acid    100 ml 
Distilled water   400 ml 
  
The volume was adjusted to 1 litre with distilled water. The solution was stored at 
room temperature. 
 
Coomassie Blue destaining solution 
Methanol                                             450 ml 
Acetic acid                            100 ml 
Distilled water                                     400 ml 
 
The volume was adjusted to 1 litre with distilled water and the solution stored at room 
temperature. 
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0.5M EDTA        
Dissolve 186.1 g in 700mls distilled water. Adjust pH to 8.0 with 10M NaOH 
(approx. 50mls) 
Add distilled water to 1 liter 
 
Egg Yolk Media 
Sabouraud dextrose agar,   13 g  
NaCl      11.7 g 
CaCl2     0.11 g 
10% sterile egg yolk emulsion in 184 ml of distilled water 
20ml of egg yolk emulsion was centrifuged at 5000g for 10 minutes. The supernatant 
was added to cooled sterile medium containing NaCl and CaCl2 before the plates were 
poured. 
 
Sabouraud Dextrose Agar 
Composition 
Sabouraud Agar    60 g 
Distilled water    1 L 
Preparation 
The ingredients were boiled whilst stirring until completely dissolved. Thereafter, the 
solution was autoclaved at 121°C for 15 min. The solution was allowed to cool 
rapidly to 40-45°C and mixed well. It was aseptically poured into sterile petri dishes. 
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Sabouraud Dextrose Broth 
Sabouraud Broth   20 g   
Distilled water   1 L 
The ingredients were mixed well and the solution was autoclaved at 121°C for 15 
min. 
 
Sensititre YeastOne® 
Commercial agent, ingredients known to the manufacturers 
 
10x Tris borate EDTA (TBE) buffer 
Tris base    108g 
Boric acid    55g 
 
Yeast Carbon Base- Bovine Serum Albumin medium 
Agar     1.5 g 
Yeast Carbon Base powder  1.17 g 
Bovine Serum Albumin  0.2 g 
Glucose    0.2 g 
Water     100 mls 
The ingredients were boiled whilst stirring until completely dissolved. Thereafter, the 
solution was autoclaved at 121°C for 15 min. The solution was allowed to cool 
rapidly to 40-45°C and mixed well. It was aseptically poured into sterile petri dishes. 
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9.5 C. albicans isolates from South Africa on the MLST database
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Source: http://calbicans.mlst.net/earth/maps 
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9.6 Geographic distribution of C. albicans strains 
 
 
STUDYID 	DST Geography
3.1 2164 South	Africa
3.2 808 South	Africa,	Scotland
3.3 2177 South	Africa
6.1 2178 South	Africa
6.2 2179 South	Africa
6.3 2165 South	Africa
10.1 2182 South	Africa
10.2 2166 South	Africa
10.3 2166 South	Africa
12.1 2167 South	Africa
12.2 2180 South	Africa
12.3 2168 South	Africa
27.1 2183 South	Africa
27.2 124 South	Africa,	UK,	Israel,	France,	USA,	Morocco,	Austria
27.3 124 South	Africa,	UK,	Israel,	France,	USA,	Morocco,	Austria
35.1 210 South	Africa,	UK
35.2 2186 South	Africa
35.3 2187 South	Africa
41.1 95 South	Africa,	UK,	Switzerland,	Australia,	France,	Morocco,	Austria,	India,	Pakistan
41.2 1909 South	Africa
41.3 1909 South	Africa
42.1 2169 South	Africa
42.2 2181 South	Africa
42.3 2169 South	Africa
45.1 2170 South	Africa
45.2 2170 South	Africa
45.3 2171 South	Africa
78.1 2172 South	Africa
78.2 2173 South	Africa
78.3 2172 South	Africa
82.1 2185 South	Africa
82.2 646 South	Africa
82.3 2174 South	Africa
132.1 2188 South	Africa
132.2 1019 South	Africa,	UK
132.3 1019 South	Africa,	UK
140.1 915 South	Africa,	France
140.2 619 South	Africa,	China
140.3 619 South	Africa,	China
166.1 144 South	Africa,	USA,	Saudi	Arabia
166.2 661 South	Africa,	USA
166.3 2175 South	Africa
173.1 2189 South	Africa
173.2 656 South	Africa,	Mexico,	Scotland,	UK
173.3 124 UK,	Israel,	France,	USA,	Morocco,	Austria
185.1 392 South	Africa,	UK
185.2 392 South	Africa,	UK
185.3 2184 South	Africa
193.1 2176 South	Africa
193.2 2190 South	Africa
193.3 375 South	Africa,	Mexico,	Scotland,	UK
